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1Gen eral introduction
Parts of this chapter will be published in Clinical Investigation volume 1, Issue 
2 as the paper: Tyrosine kinase inhibitors in differentiated thyroid carcinoma: 
review of the clinical evidence
Hendrieke C. Hoftijzer, Ellen Kapiteijn, Tatiana Schneider, Guido C. Hovens, 
Hans Morreau, Hans Gelderblom, Johannes W.A. Smit
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I. Introduction
Thyroid cancer is the most common endocrine malignancy; however it is still a low 
prevalent disease with an incidence of 2-10/100.000 persons per year. The incidence 
has increased during the last decades, and this trend appears to be continuing (1-3). 
In the Netherlands this represents approximately 320 new patients per year, with a 3 
times higher incidence in women (4). However, the prevalence is higher because of 
a rather good prognosis (4).
Thyroid cancer is a heterogeneous disease which is classifi ed into differentiated 
thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC) and undifferentiated 
(anaplastic) thyroid carcinoma (ATC). Differentiated thyroid carcinoma is most com-
mon (95%) and includes papillary (80%), follicular (10-15%) and subtypes follicular 
variant of papillary thyroid carcinoma and Hürthle cell carcinoma. Mean age at 
diagnosis is between 45 and 50 year (5). The overall 10-year survival rates are about 
90-95% (6). This is because of a combination of favorable biological (i.e. indolent) 
behavior of the tumor as well as the availability of effective therapy consisting of 
near-total thyroidectomy followed by radioactive iodine-131 (RaI) ablative therapy.
Once distant metastases have occurred, the prognosis of DTC becomes worse. 
This is the result of dedifferentiation of thyroid cancer cells. The subsequent loss of 
the ability to accumulate RaI leads to unresponsiveness to the only curative treat-
ment option. Metastases are not immediately life threatening, but may impair quality 
of life considerably. In this situation, only palliative treatment options remain and 
include external beam radiation therapy or resection of symptomatic metastasis (7,8). 
Recently, increasing knowledge in tumor biology has led to the identifi cation of po-
tential targets and novel treatment options with tyrosine kinase inhibitors, including 
sorafenib and sunitinib (9,10). These multikinase inhibitors show promising results in 
patients with progressive metastatic DTC, refractory for RaI.
During routine follow-up for differentiated thyroid carcinoma patients are 
regularly withdrawn from thyroxine therapy to perform TSH stimulated whole body 
RaI scanning and measurement of thyroglobulin, a disease specifi c biomarker. This 
creates a state of controlled hypothyroidism. This and the fact that DTC patients are 
treated with TSH suppressive thyroxine replacement therapy makes DTC patients 
an interesting model to study the metabolic effects of thyroid hormone. There is no 
interference by endogenous thyroid hormone, because patients are treated with total 
thyroidectomy. Moreover there is no interfering effect from thyroid disease, like in 
patients treated with thyroxine for autoimmune thyroid disease.
In this introduction a general overview of DTC, the diagnosis, treatment and 
clinical consequences of therapy will be provided and the questions addressed in this 
thesis will be introduced.
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II. Differentiated thyroid carcinoma
1. Pathogenesis
Human thyroid tumors originate from epithelial follicular cells or from parafollicular 
C-cells. Follicular cell-derived tumors represent benign adenomas, differentiated 
(follicular and papillary) and undifferentiated (anaplastic) carcinomas. Genetic al-
terations are involved in the pathogenesis of thyroid carcinoma. The identifi cation of 
these alterations is important for the diagnosis of DTC and also for the understand-
ing of the pathophysiology of thyroid disorders (11-17). Recent developments have 
provided a detailed map of these genetic alterations (Figure 1).
In DTC, genetic alterations that have been identifi ed, and involve tyrosine kinase 
signaling pathways (12,15,16). In nearly all cases of papillary thyroid carcinoma 
(PTC), genetic defects involving the RET, RAS, and RAF protein kinase signaling 
cascade are identifi ed. The BRAFV600E mutation has been found in 29–69% of PTC 
and has been associated with aggressive features including extrathyroidal extension 
and advanced stage (18). Translocations of RET observed in PTC result in a chimeric 
protein consisting of an activated RET tyrosine kinase domain (12,17,19-30).
Follicular thyroid carcinomas (FTC) frequently harbor mutations in one of the 
three RAS genes. The RET–RAS–RAF pathway is interconnected with the epithelial 
Figure 1
Pathogenesis of differentiated thyroid tumors
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growth factor receptor (EFGR) activated cascade that among others leads to vascular 
endothelial growth factor (VEGF) and VEGF receptor (VEGFR) synthesis. Therefore, 
compounds targeting the activated RET–RAS–RAF pathway and beyond may be 
effective in non-RaI avid DTC. Other genetic alterations in FTC include PAX8-PPAR-
gamma rearrangement. This is a unique combination of genes that traditionally are 
associated with thyroid development (PAX-8) and cell differentiation and metabolism 
(PPAR-gamma) (13, 31). This chimeric protein acts as a dominant negative competitor 
for PPAR-gamma and is associated with more aggressive growth and propensity for 
invasion (31). The follicular variant of PTC (FVPTC) shares some of the molecular 
features of follicular tumors, but less common also BRAF mutations are reported (11). 
Anaplastic carcinomas are frequently associated with mutations of the p-53 tumor 
suppressor gene (32).
The genetic alterations involved in the pathogenesis of DTC result in loss of 
thyroid specifi c gene expression and loss of thyroid specifi c protein expression. Thy-
roid peroxidase (TPO), which liberates iodide for addition onto tyrosine residues on 
thyroglobulin for the production of thyroxine (T4) or triiodothyronine (T3) is thought 
to diminish in an early phase. The Sodium-Iodide-Symporter (NIS) expression is sub-
sequently lost. Herewith, the thyroid cell loses its ability to accumulate iodide, and 
thus becomes refractory for RaI therapy.
2. Diagnosis
Most differentiated thyroid carcinomas present as asymptomatic thyroid nodules. 
Carcinoma should be suspected if a hard irregular thyroid nodule is found, ipsilateral 
lymph nodes are enlarged and/or there is a history of progressive increase of the size 
of the nodule (5). Despite increasing standards of imaging techniques like ultrasound, 
fi ne needle aspiration (FNA) is still the procedure of choice in patients presenting 
with a thyroid nodule (33). The sensitivity of FNA for DTC is 90-95%. The specifi city 
is lower (60-80%) when all patients with a non-benign FNA are referred for surgery 
(34). It is diffi cult to make the distinction between benign and malignant follicular tu-
mors by FNA, since the essential criterion for FTC is capsular invasion, which cannot 
be determined by cytology. In addition, the distinction between a follicular adenoma 
and a follicular variant of a papillary thyroid carcinoma (FVPTC) is also diffi cult, 
because the crucial criterion here is the aspect of the nuclei. The consequence is that 
70-80% of the patients with suspicious results from FNA, who undergo a hemithy-
roidectomy, have a benign tumor (35). The use of molecular markers (e.g. BRAF, 
RAS, RET/PTC, PAX8-PPARgamma or galectin-3) may be considered for patients with 
indeterminate cytology on FNA to help guide management (35-42).
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After hemithyroidectomy the microscopical distinction between benign and 
malignant neoplastic thyroid nodules by conventional histology remains diffi cult 
as these lesions may share overlapping histological characteristics. Therefore, it 
is important to identify new markers to distinguish benign from malignant thyroid 
tumors. In recent years, several immunohistochemical markers have been studied to 
improve the differential diagnosis of thyroid lesions, using both candidate markers 
and unbiased approaches (43-54).
The expression of retinoid receptors may be interesting for the differentiation 
between benign and malignant thyroid tissues. Retinoids are important for growth, 
differentiation, and morphogenesis in vertebrates (55). Retinoids are derivatives of 
vitamin A (i.e. retinol). Retinoid receptors belong to the family of nuclear receptors 
and can be distinguished in retinoic acid receptors (RAR) and retinoid X receptors 
(RXR). According to the literature, retinoid receptors appear to be differentially ex-
pressed in benign and malignant thyroid tissues, the general picture being decreased 
expression of retinoid receptor subtypes in thyroid cancer (56-62), which may also 
have therapeutic implications (7,57,61,63-65) (Chapter 2).
After primary diagnosis, the Tumor-Node-Metastases classifi cation system (Table 
1 and Table 2) is used for staging of the disease. This system is based on pathologic 
fi ndings and divides patients into four stages (Table 3 and Table 4), with progressively 
poorer diagnosis and survival with increasing stage.
In studies in this thesis, the 5th edition of the TNM classifi cation system is used. 
Recently, the 6th edition has become available (66). The most important difference with 
the 5th edition is the fact that the dimension of T1 has been extended to 2 cm and that 
tumors with limited extrathyroidal extension are designated T3 instead of T4, which 
Table 1: TNM Classifi cation system 5th edition
T0 No evidence of primary tumor
T1 Tumor 1 cm or less in greatest dimension limited to the thyroid
T2 Tumor > 1 cm, but not more than 4 cm in greatest dimension, limited to the thyroid
T3 Tumor more than 4 cm in greatest dimension limited to the thyroid
T4 Tumor of any size extending beyond the thyroid capsule
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
N1a Metastasis in ipsilateral cervical lymph node(s)
N1b Metastasis in bilateral, midline, or contralateral cervical or mediastinal lymph node(s)
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
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has implications for the prognosis (67). Also the classifi cation of regional lymph node 
metastases has changed. Some experts propagate to continue the use of the 5th edition.
3. Initial therapy
a. Surgery
Recent guidelines of the European Thyroid Association (ETA) and the American 
Thyroid Association (ATA) give an up-to-date overview of the treatment strategies 
Table 2: TNM classifi cation 6th edition
T0 No evidence of primary tumor
T1a Tumor 1 cm or less
T1b Tumor more than 1 cm but not more than 2 cm
T2 Tumor > 2 cm, but not more than 4 cm, in greatest dimension limited to the thyroid
T3 Tumor > 4 cm in greatest dimension limited to the thyroid or any tumor with minimal 
extrathyroidal extension
T4a Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft 
tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. All 
anaplastic carcinomas are considered T4 tumors
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
N1a Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph 
nodes)
N1b Metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph 
nodes
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Table 3: TNM staging system 5th edition 
Under 45 years
 Stage I Any T Any N M0
 Stage II Any T Any N M1
45 years and older
 Stage I T1 N0 M0
 Stage II T2 N0 M0
T3 N0 M0
 Stage III T4 N0 M0
Any T N1 M0
 Stage IV Any T Any N M1
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for DTC (33,68). Initial therapy consists of near-total thyroidectomy, followed by RaI 
ablative therapy of thyroid remnants. Although there is still some controversy about 
the extent of thyroid surgery, there are strong arguments in favor of total or near-total 
thyroidectomy in all patients (69), this to permit accurate long-term surveillance for 
disease recurrence. Only very low risk patients (PTC, T1N0M0, unifocal, intrathyroi-
dal) may be treated with hemithyroidectomy. In tumor stages of T2 and higher a total 
thyroidectomy is indicated (70-72). In these patients near-total thyroidectomy results 
in lower recurrence rates because many papillary tumors are multifocal and bilateral 
(73,74). During follow-up both measurement of serum Tg as a tumor marker and RaI 
whole body scanning are explicitly affected by residual thyroid disease and warrant 
near-total or total thyroidectomy (33). The argument against total thyroidectomy is 
that it increases the risk of surgical complications such as recurrent laryngeal nerve 
injury (2%) and hypoparathyroidism. The latter occurs in 1/3 of the patients after 
total thyroidectomy, but persists only longer than 3 months in 2% of the patients 
(68). The experience of the surgeon plays an important role in determining the risk of 
complications (75-77).
b. Radioiodine-131 ablation therapy
Controversy also exists about the routine use of RaI ablative therapy for thyroid rem-
nants. There are three reasons for post-surgical RaI therapy. First, as already stated 
above, ablative therapy destroys remaining normal thyroid tissue, which increases 
the specifi city of detectable serum Tg and whole body scanning (72,78). Second, the 
use of high dose RaI permits post ablative scanning to detect persistent carcinoma 
or metastatic disease (79,80). The third reason is that RaI may destroy microscopic 
metastasis and carcinomas, thereby decreasing the risk of recurrence (72,81,82).
Table 4: TNM staging system 6th edition 
Under 45 years
 Stage I Any T Any N M0
 Stage II Any T Any N M1
45 years and older
 Stage I T1 N0 M0
 Stage II T2 N0 M0
 Stage III T3 N0 M0
T1, T2, T3 N1a M0
 Stage IVA T1, T2, T3 N1b M0  
T4a N0, N1 M0
 Stage IVB T4b Any N M0
 Stage IVC Any T Any N M1
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A number of large, retrospective studies show a signifi cant reduction in the 
rates of disease recurrence and cause specifi c-mortality after RaI ablative therapy 
(71,83,84-86). However, other studies show no benefi t, especially not in patients 
with small (<1.5 cm), intrathyroidal tumors (6,71,87-90). The benefi cial effect is 
probably only present in patients with high risk or irradical surgery (91). Moreover, 
various papers reported a relation between RaI therapy and non-thyroidal carcinoma, 
so the use of it should be applied carefully (92-97). Thus RaI ablation is not indicated 
in T1N0M0 disease, but still the treatment of choice in patients with high risk of 
recurrence/mortality, gross extrathyroidal extension of the tumor, documented lymph 
node metastases, incomplete tumor resection and distance metastases as proposed by 
recent ATA and ETA guidelines (33,68).
The effi cacy of RaI therapy depends on the radiation dose delivered to the thy-
roid remnant tumor or metastases and these are based on responsiveness of DTC to 
TSH. Therefore high TSH levels have to be established by either thyroid hormone 
withdrawal or by therapy with recombinant human TSH (rhTSH) (98,99). In addition, 
RaI uptake is increased by depletion of plasma inorganic iodide before RaI therapy 
through a low iodide diet (100-102). 
In addition, effi cacy of RaI ablative therapy of thyroid remnants is comparable 
between rhTSH and thyroxine withdrawal (68,103,104). In recent American Thyroid 
Association guidelines for the treatment of thyroid cancer it is recommended that 
ablation can be performed following either thyroxine withdrawal or rhTSH (33), and 
rhTSH is especially advised for patients unable to tolerate hypothyroidism.
c. TSH suppressive therapy
After initial therapy, all patients with DTC are treated with high doses of thyroxine 
aiming at suppressed TSH levels. The rationale for this approach is based on the 
potential harmful effects of TSH on tumor recurrence (83,105,106). Thyroid cancer 
cells express the TSH receptor on the cell membrane and respond to TSH stimulation 
by increasing the expression of thyroid cancer specifi c proteins and by increasing 
the rate of cell growth (107). A recent analysis by our institution indeed showed 
that TSH levels are positively associated with thyroid cancer associated death and 
relapse (108). Long-term TSH suppression however, may be associated with harmful 
effects on various systems including bone metabolism (109-111), glucose metabo-
lism (112,113), cardiac function including higher risk of ischemic heart disease and 
increased risk of atrial fi brillation (114,115) and quality of life (116-118).
The European Consensus on thyroid cancer (119,120) recommends that not all 
patients with DTC should be indiscriminately treated with TSH suppressive therapy, 
because of these negative effects of subclinical hyperthyroidism. Recent ATA thyroid 
cancer guidelines recommend initial TSH suppression below 0.1 mU/L for high risk 
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and intermediate risk thyroid cancer, while maintenance of TSH at or slightly below 
the lower limit of normal (0.1-0.5 mU/L) is appropriate for low-risk patients (33). In 
the future, TSH suppression may be achieved with thyroid hormone analogues that 
suppress pituitary TSH secretion with less effect on the cardiovascular system and the 
bone (121-123).
4. Follow-up
The purpose of follow-up protocols in DTC is the early detection of tumor recurrence 
or metastatic disease in order to optimize additional treatment. Most patients during 
follow-up have been cured defi nitely and have a low pre-test probability for recurrent 
disease. Therefore, the sensitivity of the diagnostic tests must be adequate to detect 
the few patients with evident remnant carcinoma whereas specifi city must also be 
high to avoid unnecessary treatment in patients without recurrent disease. Recur-
rence is usually detected during the early years of follow-up, but may be detected 
later. Therefore, in our center thyroid carcinoma patients are followed-up for 15 years 
after initial diagnosis, with tighter screening during the fi rst years.
a. Thyroglobulin
Thyroglobulin (Tg) is a glycoprotein that is produced only by normal or neoplastic 
thyroid follicular cells and is stimulated by TSH. In patients treated with total thy-
roidectomy and RaI ablative therapy, Tg should be undetectable. The type of analysis 
(RIA or immunometric assay) affects the interpretation of serum Tg values (124). The 
clinical interpretation of Tg is hampered by analytical problems. First, there is lack 
of universal standardization, leading to signifi cant inter-assay variability and a high 
intra-assay variability. Second, “hook” effects which primarily affect the immunomet-
ric assay method can lead to inappropriately low-or normal range Tg values (125). Di-
lution of the serum can detect this problem. Third, the presence of Tg auto-antibodies 
can lead to under- or overestimation of the serum total Tg concentration (126-129).
The Tg auto-antibody interference is the most serious diagnostic problem affect-
ing serum Tg measurements. The incidence of serum Tg auto-antibodies in DTC is 
approximately 15-30%. Despite these analytical problems, Tg measurements are still 
the basis in the follow-up in DTC, because in the absence of antibody interference, 
serum Tg has a high degree of sensitivity and specifi city to detect thyroid cancer, with 
highest degrees following thyroxine withdrawal or rhTSH stimulation (100). A single 
TSH stimulated serum Tg <0.5 ng/mL has an approximate 98-99.5% likelihood for 
the identifi cation of patients completely free of tumor (130,131).
Several studies have been performed to determine the diagnostic value of Tg 
measurements. The application of receiver operator (ROC) curves is essential, since 
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a chosen cut-off level is a subjective choice based on the balance between a desired 
percentage of missed recurrences versus unnecessary therapies. Therefore, in the 
European Consensus paper, it was recommended to defi ne institutional Tg cut-off 
levels (119). High sensitive Tg assays lead to a higher sensitivity at the cost of a lower 
specifi city (132). It is generally believed that high sensitive Tg assays cannot replace 
the need for TSH stimulated Tg measurements.
b. RaI whole body scanning, ultrasound and FDG-PET
The result of iodine-131 whole body scanning (WBS) depends upon the presence 
and the ability of thyroid-cancer tissue to take up iodine-131 in the presence of 
a high serum TSH, which is achieved by withdrawal of thyroxine supplementation 
for 4 weeks or by recombinant human TSH stimulation. WBS is most useful during 
follow-up when there is little or no remaining normal thyroid tissue. It may be of 
value in high or intermediate risk patients, but has no use in low-risk patients with an 
undetectable Tg and a negative ultrasound (120,133,134). Diagnostic RaI WBS has 
a much lower sensitivity than ultrasound and Tg measurement. Therefore the routine 
use of RaI scintigraphy in the diagnostic follow-up of low-risk DTC patients is no 
longer recommended (33,135). 
Ultrasound combined with FNA has the highest sensitivity (94%) for local recur-
rence and lymph node metastases (134,136) and thus, ultrasound has an important 
role in the follow-up of DTC.
Fluorodeoxyglucose-positron emission tomography (FDG-PET) may be indicated 
in patients with elevated serum Tg levels, in whom no RaI uptake is observed after 
diagnostic or therapeutic whole body scanning, especially in patients with invasive or 
metastatic Hürthle cell carcinoma (137-139). ATA guidelines recommend FDG-PET 
as a prognostic tool for staging in high risk patients with metastatic disease or at risk 
for rapid disease progression (33).
 The sensitivity of FDG-PET may be marginally increased with TSH stimulation, 
but the clinical benefi t of identifying additional small foci is yet to be proven (138). 
However, high FDG-PET uptake in large tumor masses may have an unfavorable 
prognostic signifi cance (140).
c. Thyroxine withdrawal and recombinant human TSH
Serum Tg measurements, RaI ablation and RaI diagnostic whole body scanning are 
based on the responsiveness of DTC to TSH. TSH stimulated Tg measurements have 
superior diagnostic value in DTC compared to Tg measurements on thyroxine re-
placement therapy (100). High serum TSH levels can be achieved either by thyroxine 
withdrawal or intramuscular injection of rhTSH. In the fi rst option, 4 weeks thyroxine 
withdrawal results in a controlled state of profound hypothyroidism with low FT4 and 
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high TSH. This is poorly tolerated by patients and has negative effects on multiple 
organs and systems: it exacerbates neuropsychiatric illness and cardiovascular dis-
ease, negatively infl uences lipid metabolism, increases atherosclerotic risks and thus 
negatively infl uences quality of life (141). There is also a theoretical disadvantage 
in thyroxine withdrawal, which states that high TSH levels may be unfavorable with 
respect to enhancement of tumor proliferation (105). High TSH level as a result of 
injections of rhTSH has less impact on quality of life (142). RhTSH is an adequate 
method to detect recurrence or metastases (98,99,143). Tg measurements during 
rhTSH have comparable accuracy with thyroxine withdrawal (144). The sensitivity 
and negative predictive value of Tg after rhTSH injections combined with ultrasound 
are 96.3% and 99.5% respectively (135). Also whole body scans performed after 
rhTSH injections have a similar sensitivity and negative predictive value compared to 
thyroxine withdrawal (98,99,143).
5. Therapeutic strategies for metastatic disease
a. Conventional treatment options
Distant metastases, usually in the bones and lungs, occur in approximately 10-15% 
of patients with DTC. Lung metastases are most frequent in young patients with papil-
lary carcinomas. In general, bone metastases are more common in older patients 
and in those with follicular carcinomas. Metastatic thyroid cancer that has become 
inoperable or refractory to RaI therapy is associated with a poor 10 year survival of 
5-10%. Because of the indolent character of DTC, metastases are not immediately life 
threatening, but may impair quality of life considerably (145).
In case of residual disease or metastases, surgery can be attempted when the 
lesion is accessible. In other cases high dose RaI therapy will be given in patients 
that accumulate RaI. The remission rate in pulmonary metastases treated with RaI 
is ~50%, varying from 90% in patients with microscopic metastases to only 10% 
in macronodular disease. The remission rates of bone metastases are worse, varying 
between 7 and 20% (5,146). The major problem in this category of patients is the 
dedifferentiation of thyroid cancer and with that the diminished or lost ability to 
accumulate RaI. Only palliative treatment options remain. These include external 
beam radiation therapy and chemotherapy, which have limited success (147).
External beam radiation can be used as palliative therapy in locally advanced 
disease and can reduce pain of bone metastases or dyspnea in case of airway obstruc-
tion. Many conventional chemotherapeutic protocols have been tried in progressive 
thyroid carcinoma, with overall disappointing results. The most frequently tested 
agent is doxorubicin. Doxorubicin alone or in combination with cisplatin and bleo-
mycin may induce temporary remissions or stationary disease in about 30-50% of the 
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patients (147,148). Furthermore, responses are typically short-lived and associated 
with a high degree of toxicity (149,150).
b. Experimental additional treatments
Lithium has been associated with increased trapping of iodine by the thyroid gland, 
without impairing iodine uptake, thus enhancing RaI retention. However, despite an 
increase in RaI uptake in tumor deposits, there are no data that demonstrate a better 
outcome of patients treated with lithium as an adjunct to RaI therapy (151-152).
PPAR-gamma agonists have been introduced as anti-diabetic agents. Their 
proposed mechanism is the differentiation of pre-adipocytes, thereby increasing the 
fatty-acid storing capacity of adipose tissue. Altered expression of PPAR-gamma and 
in-vitro benefi cial effects of PPAR-gamma agonists have been described in a number 
of malignancies. Although PPAR-gamma agonists showed promising results in pre-
clinical models for thyroid cancer, they do not result in clinically benifi cial response 
(153).
Retinoids are derivates of vitamin A, and are important for growth, differentia-
tion and morphogenesis in vertebrates (55). Benefi cial effects of retinoids have been 
reported in-vitro in thyroid carcinoma (63,154-156) including increased NIS mRNA 
expression and iodine uptake in some thyroid cancer cell lines (154). Interestingly, 
the promoter of the NIS gene has a retinoic acid responsive element (157). A limited 
number of human studies have been performed on the effects of retinoids on RaI-131 
uptake and reported variable results (64,65,158,159). The main conclusion however 
is that unfortunately retinoids are not able to restore susceptibility to RaI therapy (7).
c. Future treatment options
As a result of the increasing knowledge of the biologic mechanisms of thyroid cancer 
pathogenesis and progression, therapeutic agents that could target these mechanisms 
have been identifi ed. Table 5 gives an overview of the literature addressing the results 
of studies on tyrosine kinase inhibitors and DTC.
The anti-EGFR compound gefi tinib was not successful in 27 patients with DTC, 
medullary and anaplastic thyroid carcinoma (160). In a phase II study in 60 thyroid 
carcinoma patients with various histologies, the VEGFR inhibitor axitinib showed a 
partial response of 30% (median progression free survival (PFS) 18 months) (161). 
Recently, 3 phase II studies have been published, using multi-kinase inhibitors 
(9,10,162). Motesanib diphosphate induced a partial response in 14% of 93 DTC pa-
tients (median PFS 40 weeks) (162). Sunitinib, an inhibitor of RET, VEGFR and PDGFR 
induced a response rate of 13% and 32 % in DTC and MTC patients (163, 164).
Two studies have been published using sorafenib. Sorafenib (BAY 43-9006) is an 
inhibitor of RET, C-RAF, wild-type and mutant (V600E) BRAF, VEGFR1, -2, -3, Flt3, and 
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c-KIT. In the fi rst study, including DTC, anaplastic and medullary thyroid carcinoma 
patients, sorafenib induced a partial response in 23% (median PFS 79 weeks) (9). In 
the second study, including patients with DTC and anaplastic thyroid carcinoma, 
a partial response was observed in 11% (median PFS 4.5–16 weeks) (10). As bone 
metastases of DTC are poorly responsive to RaI, the response of bone metastases to 
the above-mentioned therapies is of interest. However, there are no separate analyses 
for patients with bone metastases in the above-mentioned studies. 
In DTC, a relationship has been identifi ed between genetic alterations in the RET, 
RAS, RAF cascade and loss of NIS expression (165,166). Interestingly, in an in-vitro 
study, sunitinib was able to reinduce NIS expression in RET/PTC transformed thyroid 
cells (168). In addition, sunitinib also increased RaI uptake in FRTL-5 cells. We there-
fore hypothesized that treatment with a multiple kinase inhibitor not only reduces 
tumor progression, but may also restore RaI uptake in non-RaI avid DTC. Therefore, 
we performed a single arm phase II trial to determine the effi cacy of sorafenib in 
patients with iodine refractory metastatic DTC, focusing on the reinduction of RaI 
uptake and the effi cacy in bone metastases (Chapter 3). 
Therapy with tyrosine kinase inhibitors is associated with alterations in thyroid 
hormone parameters. Sunitinib has been associated with hypothyroidism in 14–85% 
of the patients (169-174) and in some patients it induced hyperthyroidism (174-176). 
Both sunitinib induced hypothyroidism and hyperthyroidism may be caused by 
destructive thyroiditis, but other mechanisms, such as interference of sunitinib with 
thyroid peroxidase (177) or inhibition of thyroidal vascularization leading to thyroid 
Table 5: Literature on tyrosine kinase inhibitors in DTC
Drug Target Tumor 
type
Number 
of 
patients
Response 
Rate (%)
Stable 
Disease (%)
Progression 
free survival
Reference
Gefi tinib EGFR-RET DTC + 
MTC
18 + 4 0% 24% 
(>24 weeks)
16 weeks Pennell et al. 
(160) 
Axitinib VEGFR DTC 45 31 % 42 % 18 months Cohen et al. 
(161) 
Motesanib RET- PDGF 
-VEGFR-KIT
DTC 93 14 % 35% 
(>24 weeks)
40 weeks Sherman et al. 
(162) 
Sunitinib RET, VEGFR, 
PDGFR
DTC
DTC + 
MTC
37
26 + 7
13 %
32 % 
(7 CR)
68 %
-
-
-
Cohen et al. 
(163) 
Carr et al. 
(164) 
Pazopanib VEGFR, PDGFR DTC 26 32% 65 % 12 months Bible et al. 
(167) 
Sorafenib RET-RAS-RAF- 
VEGF-VEGFR- 
PDGF-cKIT
DTC 41
30
15 %
23 %
56% 
(>24 weeks)
53 %
15 months
79 weeks
Kloos et al. 
(10) 
Gupta et al. 
(9) 
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atrophy (178,179), have been proposed. Likewise, sorafenib was associated with TSH 
elevation in 18% of patients with metastatic renal cell carcinoma (180). 
All these studies are performed in patients with intact thyroid function. However, 
thyroid function abnormalities have also been observed during therapy with imatinib 
(181,182), motesanib (162), and sorafenib (9) in athyreotic patients treated for medul-
lary thyroid carcinoma and non-medullary thyroid carcinoma. Because an increased 
need of thyroxine is observed in athyreotic patients who are treated with tyrosine ki-
nase inhibitors, the mechanisms of hypothyroidism may include alterations in thyroid 
hormone metabolism. Stepwise deiodination is the major route of thyroid hormone 
degradation and is mediated by iodothyronine deiodinases (D1, D2, and D3) (183) 
and by hepatic conjugating enzymes (184). To address this subject, we studied the 
effect of sorafenib on peripheral thyroid hormone metabolism in athyreotic humans 
(Chapter 4).
III. Consequences of treatment of thyroid carcinoma
Patients with DTC who are treated with total thyroidectomy and RaI ablative therapy 
become completely dependent on exogenous thyroid replacement therapy. Because 
of the favorable effects on tumor recurrence, patients used to be treated with TSH 
suppressive doses of thyroxine (see TSH suppressive therapy) for approximately 15 
years. Whereas this long-term TSH suppression is associated with an overall better 
prognosis (108,185), this subclinical hyperthyroid state is associated with deleterious 
effects on the cardiovascular system (114,115,186,187), carbohydrate metabolism 
(112,188) and psychological well-being (116,118,189,190). 
During follow-up, DTC patients are regularly withdrawn from thyroxine therapy 
to evaluate recurrence and disease state with TSH stimulated whole body scintigra-
phy and Tg measurement. This creates a state of controlled hypothyroidism, which 
can exacerbate neuropsychiatric illness and cardiovascular disease, negatively infl u-
ences lipid metabolism, and increases atherosclerotic risks and also has an impact 
on quality of life. The long-term subclinical hyperthyroidism combined with episodes 
of short-term hypothyroidism make DTC patients an interesting model to study the 
metabolic effects of thyroid hormone. Also, there is no interference by endogenous 
thyroid hormone, because patients are treated with total thyroidectomy. Moreover 
there is no inference from thyroid disease, like in patients treated with thyroxine for 
autoimmune thyroid disease. 
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1. Thyroid physiology
The production of thyroid hormones is regulated by the hypothalamus-pituitary-
thyroid axis (Figure 2). Thyrotropin releasing hormone (TRH), which is produced 
by the hypothalamus, stimulates the secretion of thyrotropin (TSH) by the anterior 
pituitary. TSH promotes the thyroid to synthesize the prohormone thyroxine (T4). 
Iodine is actively taken up by the thyroid gland by the sodium-iodide-symporter 
NIS. The expression and activity of NIS is controlled by TSH. Thyroglobulin, which 
is synthesized by the follicular cells, is then iodinated with one or two iodides to 
form monoiodotyrosine (MIT) or diiodotyrosine (DIT). This process is catalyzed by the 
enzyme thyroid peroxidase (TPO). Two DIT molecules are then coupled to form T4 
and one DIT and one MIT are coupled to form T3. The thyroid secretes 90% T4 and 
10% T3. T3 is the active form of thyroid hormone. The majority of T3 is formed after 
conversion of T4 in T3 in peripheral tissues like liver, kidney and muscle. T4 and T3 
have a negative feedback mechanism on TRH secretion by the hypothalamus and the 
TSH production by the pituitary.
Peripheral thyroid metabolism is mainly regulated by the iodothyronin deiodin-
ases D1, D2, and D3 (183,191) (Figure 2). D1 is present in the thyroid, liver and 
kidneys. It converts T4 to T3, and is involved in the serum T3 production. In addition, 
it plays a role in the breakdown of rT3 (192,193). D2 catalyzes local T3 production 
Figure 2 
Thyroid hormone production and homeostasis in thyroidectomized patients
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in various tissues. It is present in brain, skeletal muscle, thyroid, pituitary, brown 
adipose tissue, aortic smooth muscle cells, osteoblasts and the heart (194-196). In 
the brain, D2 is expressed mainly in astrocytes in the cerebral cortex, hippocampus 
and amygdala (197). D2 in skeletal muscle may also contribute to plasma T3 produc-
tion. D3 inactivates T3 and T4 and thus regulates the clearance of T3 and T4. It is 
present in the brain, skin, placenta and fetal tissues. It is thought that it contributes 
to thyroid hormone metabolism by protecting tissues from excess thyroid hormone. 
The deiodinases adjust the thyroid hormone levels of individual tissues in response 
to various conditions.
Several polymorphisms in D1 and D2 have been described, of which some are 
associated with circulating levels of T4, T3 and TSH (198-200), with most studies 
investigating the consequences of the D2-Thr92Ala polymorphism (rs225014). 
Two polymorphisms in the D1 gene, D1-C785T (rs11206244) and D1-A1814G 
(rs12095080), have been associated with changes in the balance of thyroid hormones 
in the serum, with raised T3, low T4 and low rT3 levels, but these changes have not 
been associated with differences in TSH. This implies that the net effect is perceived 
by the hypothalamus and pituitary as “neutral” (192,201,220). 
Controversy exists about the functional implications of the D2-Thr92Ala poly-
morphism, which has been associated with a decreased D2 activity in some in-vitro 
experiments (198) but not in others (199,200). So far no associations are found be-
tween the D2-Thr92Ala polymorphism and serum thyroid hormone levels in studies 
in healthy subjects (192,198-200). 
Torlontano et al. reported in thyroidectomized differentiated thyroid carcinoma 
patients that homozygous carriers of the D2-Ala92 allele need higher dosages of 
T4 (202). This difference was most prominently observed in the group with near-
suppressed TSH (TSH values between 0.1 and 0.5 mU/l). This study has various 
limitations, because actual values of serum TSH levels for wild type and homozygous 
groups within the near-suppressed TSH group are not given. It is, therefore unclear 
whether TSH levels in both groups are indeed identical, which would be a key fi nding 
to ascribe the slight differences in thyroxine dose to the polymorphism. We therefore 
performed a study to reconfi rm the fi ndings of Torlontano et al. We studied the as-
sociation between the D2-Thr92Ala polymorphism and thyroid hormone levels and 
T4 dosage in 154 patients treated for DTC and 141 patients substituted with T4 for 
Hashimoto thyroiditis (Chapter 5). 
In healthy blood donors the D2-ORFa-Asp variant (rs12885300) was associated 
with lower levels of serum T4, fT4 and rT3, but not with plasma T3 and TSH levels 
(203). This suggests that the D2-ORFa-Asp polymorphism leads to higher activity of 
D2 at the pituitary level. However, this association was not seen in elderly men (203). 
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Intraindividual variation in serum T4, T3 and TSH is narrow; however there is a 
considerable interindividual variability (204). A large body of evidence suggests that 
every individual has a unique thyroid function setpoint, compatible with a genetic 
infl uence on the regulation of the pituitary-thyroid axis (204-206). We hypothesized 
that polymorphisms in D1 and D2 could infl uence the setpoint of the hypothalamus-
pituitary-thyroid axis. We tested this hypothesis in 151 patients treated for differenti-
ated thyroid carcinoma (DTC). During follow-up of DTC, patients are treated with 
thyroxine substitution therapy in a dose intended to suppress TSH level, which results 
in a constant and precisely measurable supply of T4. During this period they regularly 
come for routine measurements of TSH and FT4, moreover they are regularly with-
drawn from thyroxine to perform TSH stimulated radioactive iodine-131 whole body 
imaging, which leads to a wide individual range of combined measurements of TSH 
and FT4. These patients are therefore an ideal group to assess the relationship between 
polymorphisms in deiodinases and the setpoint of the hypothalamus-pituitary-thyroid 
axis (Chapter 6). 
2. Bone metabolism
The involvement of thyroid hormone in bone metabolism has been well documented 
clinically, ranging from decreased skeletal development in childhood hypothyroidism 
(207-209), accelerated growth in childhood hyperthyroidism (210) to an increased 
risk for osteoporosis in overt and subclinical hyperthyroidism (109,211-213). 
Although clinical observations suggest a clear involvement of thyroid hormone 
in bone metabolism, the molecular mechanisms by which thyroid hormone acts on 
bone is so far only been partially uncovered. T3 promotes osteoblastic proliferation, 
differentiation and apoptosis and, by induction of interleukin 6 (IL-6), prostaglandins, 
and RANKL, probably also promotes osteoclast formation and activation. This sug-
gests that osteoblasts are the primary target cells for T3 in the regulation of bone 
remodeling (208,209,213-217). A functional role of TSH on skeletal development 
and metabolism has been proposed on the basis of data obtained in animal studies 
(218-220) and in humans as well (221). This was however disputed by data obtained 
in thyroid hormone receptor (TR) defi cient mice, which indicated that bone remod-
eling was predominantly mediated by T3 via TRalpha (222,223). It has also been 
reported recently that in humans there is a signifi cant association between bone min-
eral density (BMD) and serum thyroid hormone concentrations rather than TSH (224). 
Designing a study to address the potential role of deiodinases, including D2 on 
skeletal metabolism is diffi cult in humans. The study of the effects of functional D2 
polymorphisms on BMD and bone turnover in humans may shed light on this role. 
Interestingly, a study by Canani et al. reported (198) that the maximal velocity of D2 
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was decreased by 3 to 10-fold in thyroid and skeletal muscle of carriers of the D2-
Thr92Ala polymorphism. This effect was observed in the absence of differences in D2 
mRNA level or in the biochemical protein properties of the 92Ala allele. Therefore, 
it was suggested that either a functionally relevant single nucleotide polymorphism 
occurs in linkage disequilibrium with the Thr92Ala polymorphism or the 92Ala allele 
affects protein translation or stability. 
We therefore performed a study in an attempt to elucidate a potential role for 
D2 in skeletal metabolism and BMD by evaluating the relationship between the D2 
Thr92Ala polymorphism, BMD and bone turnover markers in cured thyroidectomized 
differentiated thyroid carcinoma patients receiving thyroid hormone substitution. This 
human model has the advantage of having strictly regulated serum thyroid hormone 
levels which are kept in a relatively narrow range (Chapter 7).
We have also designed a study in an attempt to discriminate between potential 
effects mediated by decreased thyroid hormone levels from those mediated by in-
creased TSH levels in a human model in which the reciprocal relationship between 
thyroid hormones and TSH was interrupted. To this effect, we studied parameters of 
bone metabolism after parenteral administration of recombinant human TSH (rhTSH) 
resulting in exogenously increased TSH levels while preserving normal thyroid hor-
mone levels by uninterrupted thyroid hormone substitution in athyroid differentiated 
thyroid carcinoma (DTC) patients. We studied the same parameters in age-, gender- 
and BMI matched athyroid DTC patients during short-term thyroxine withdrawal, 
resulting in decreased thyroid hormone levels and endogenously increased TSH 
levels, and after reestablishment of thyroid hormone substitution (Chapter 8).
3. Cardiac function 
Thyroid hormone has profound effects on the cardiovascular system. Hyperthyroidism 
induces cardiac arrhythmias, left ventricular (LV) hypertrophy and diastolic dysfunc-
tion, and enhances systolic function (225-227). Subclinical hyperthyroidism resulting 
from TSH suppressive thyroxine therapy, is associated with increased heart rate and 
supraventricular arrhythmias, including atrial fi brillation, increased LV mass (LVM) 
with a slightly enhanced systolic function, and diastolic dysfunction. Diastolic dys-
function is at least partly reversible after restoration of euthyroidism and is associated 
with an increase in mortality (114,228-230). Conversely, hypothyroidism is associated 
with bradycardia, mild hypertension, increased peripheral cardiovascular resistance, 
heart failure (225,227,231), decreased cardiac output and diastolic dysfunction 
(225,227,232-234). Long-standing hypothyroidism can even result in asymmetrical 
septal hypertrophy (235) and pericardial effusion (230). Hypothyroidism is also 
associated with coronary artery disease, presumably because of associated hyper-
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cholesterolaemia, hypertriglyceridaemia and hypertension (225,227,236). Thyroxine 
substitution reverses most cardiovascular alterations associated with hypothyroidism 
(227,230,231,237). 
The consequences of acute hypothyroidism during thyroxine withdrawal on cardiac 
function have been investigated in only a few studies. The results of those studies have 
been inconclusive, varying from mainly decreased diastolic function to mainly altered 
systolic function (238-246). In these studies, without control groups, these parameters 
are measured by different techniques (echocardiography, radionuclide imaging), 
without blinding the observers with regards to treatment modalities. Therefore, we 
performed a prospective study in a homogeneous group of athyreotic DTC patients to 
assess the impact of overt hypothyroidism induced by short-term thyroxine withdrawal 
on cardiac function measured by a new sophisticated echocardiography technique: 
tissue Doppler imaging (TDI). Cardiac parameters of the patients are compared to a 
matched group of controls without cardiovascular co-morbidities (Chapter 9).
4. Quality of life
Differentiated thyroid carcinoma is associated with an excellent medical prognosis, 
with 10-year survival rates reaching 90-95 %. The excellent prognosis and the mod-
erate invasiveness of the initial therapy may implicate that quality of life in cured 
DTC patients may be relatively normal. On the other hand, the awareness of having 
a malignant disease and the TSH suppressive thyroxine replacement therapy may 
lead to a decreased quality of life (114,228,247). Only a few studies have evaluated 
quality of life in cured DTC patients (117,118,189,190,248). These studies are limited 
by small patient numbers (118,189), a limited number of quality of life parameters 
(117,248), and/or the absence of a healthy control group (117,189,190). Studies 
that focused on the relation between the level of TSH suppression and quality of 
life in DTC patients are inconclusive because of small patient numbers, selection 
of patients with symptoms of hyperthyroidism or selection of patients with a long 
duration of cure (100,228). For that reason, we investigated quality of life in a large 
cohort of cured DTC patients, compared to healthy controls matched for age, gender 
and socioeconomic status. In addition, determinants of quality of life, including TSH 
level were investigated (Chapter 10).
IV. Outline of this thesis
In Chapter 2 we evaluate the diagnostic value of the expression of retinoic acid re-
ceptors (RAR) and retinoid X receptors (RXR) expression for the differential diagnosis 
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of thyroid neoplasms. To improve especially the differentiation between benign and 
malignant thyroid tissues we defi ned optimal semi quantitative cut-off levels using 
ROC analysis and hierarchical cluster analysis.
In Chapter 3 we describe a single arm phase II trial to determine the effi cacy of 
sorafenib treatment in patients with iodine refractory metastatic DTC, focusing on the 
reinduction of RaI uptake and the effi cacy in bone metastases.
Chapter 4 focuses on the observation of changes in thyroid hormone levels during 
treatment with sorafenib (described in chapter 3). We did this, in order to elucidate 
the mechanism behind the tyrosine kinase induced thyroid function alterations.
The remainder of this thesis describes the clinical consequences of exogenous 
subclinical hyperthyroidism during TSH suppressive therapy and of short term hy-
pothyroidism during thyroxine withdrawal in order to study the metabolic effects of 
thyroid hormone.
Deiodinase type 2 catalyzes local T3 production in various tissues. Controversy ex-
ists about the functional implications of the D2-Thr92Ala polymorphism. In Chapter 
5, we studied the association between the D2-Thr92Ala polymorphism and thyroid 
hormone levels and thyroxine dose in 154 patients treated for DTC and 141 patients 
substituted with T4 for Hashimoto thyroiditis.
It is suggested that every individual has a unique thyroid function setpoint, compat-
ible with a genetic infl uence on the regulation of the pituitary-thyroid axis. Chapter 
6 studies the infl uence of polymorphisms in D1 and D2 on the setpoint of the 
hypothalamus-pituitary-thyroid axis. 
Chapter 7 investigates the relationship between the D2-Thr92Ala polymorphism and 
bone mineral density and bone turnover parameters. 
Controversy exists about whether high TSH or low FT4 infl uences bone metabolism 
in hypothyroidism. In Chapter 8, we describe a prospective study which investigates 
the effects of high TSH levels, either achieved by hypothyroidism or by recombinant 
human TSH on bone metabolism. Therefore we will be able to discriminate between 
potential effects mediated by decreased thyroid hormone levels versus those medi-
ated by increased TSH.
In Chapter 9, we show the effects of short term overt hypothyroidism, 4 weeks after 
thyroxine withdrawal on cardiac function.
Chapter 10 describes quality of life in a large cohort of cured DTC patients compared 
to age, gender and socioeconomic status. 
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Abstract
Background
Although differential expression of retinoic acid receptor (RAR) subtypes between 
benign and malignant thyroid tissues has been described, their diagnostic value has 
not been reported. 
Aim
To investigate the diagnostic accuracy of RAR and retinoid X receptor (RXR) subtype 
protein expression for the differential diagnosis of thyroid neoplasms. 
Methods
We used a tissue array containing 93 benign thyroid tissues (normal thyroid, multi-
nodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (papillary 
thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of 
PTC (FVPTC)). Immunostaining was done for RAR and RXR subtypes. Staining was 
analyzed semi quantitatively based on receiver operating curve analyses and using 
hierarchical cluster analysis. 
Results
We found increased expression of cytoplasmic (c) RARalpha, cRARgamma, cRXRbeta 
and decreased expression of nuclear (n) RARbeta, nRARgamma, and nRXRalpha in 
thyroid carcinomas compared with benign tissues. We found three proteins differently 
expressed between FA and FTC and fi ve proteins differentially expressed between FA 
and FVPTC, with high diagnostic accuracies. Using cluster analysis, the combina-
tion of negative staining of membranous RXRbeta and positive staining for cRXRbeta 
had a high positive predictive value (98%) for malignant thyroid disease, whereas 
the combination of positive nRXRalpha and negative cRXRbeta staining had a high 
predictive value (91%) for benign thyroid lesions. 
Conclusion
We conclude that differences in RAR and RXR subtype protein expression may be 
valuable for the differential diagnosis of thyroid neoplasms. The results of this study 
and especially the value of cluster analysis have to be confi rmed in subsequent studies.
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Introduction
The microscopical distinction between benign and malignant neoplastic thyroid 
nodules by conventional histology is often diffi cult as these lesions may share overlap-
ping histological characteristics. Therefore, it is important to identify new markers to 
distinguish benign from malignant thyroid tumors. In recent years, several immunohis-
tochemical markers have been studied to improve the differential diagnosis of thyroid 
lesions, using both candidate markers and unbiased approaches (1–12).
The expression of retinoid receptors may be interesting for the differentiation between 
benign and malignant thyroid tissues. Retinoids are important for growth, differentiation, 
and morphogenesis in vertebrates (13). Retinoids are derivatives of vitamin A (i.e. retinol). 
Retinoid receptors belong to the family of nuclear receptors and can be distinguished in 
retinoic acid receptors (RAR) and retinoid X receptors (RXR). According to the literature, 
retinoid receptors appear to be differentially expressed in benign and malignant thyroid 
tissues, the general picture being decreased expression of retinoid receptor subtypes in thy-
roid cancer (Table 1) (14–20), which may also have therapeutic implications (17,18,21–23). 
However, in these publications on retinoid receptor expression in thyroid lesions, the question 
whether retinoid receptor expression could be used for the differential diagnosis of thyroid 
neoplasms was not addressed, probably because most studies included relatively small 
number of patient samples or the studies included only a subset of retinoid receptors (Table 1).
We therefore, decided to study the diagnostic value of RAR and RXR subtype ex-
pression in benign and malignant thyroid tissues, using receiver operating curve (ROC) 
analyses as well as hierarchical cluster analysis (12).
Materials and methods
Thyroid tissues
We obtained one hundred and seventy histological samples from surgically removed 
thyroid lesions representing fi ve different histological thyroid disorders and adjacent 
thyroid normal tissue from the archive of the Department of Pathology of the Leiden 
University Medical Center. We selected 93 benign thyroid tissues (normal n=64, mul-
tinodular goiter n=16, follicular adenoma (FA) n=13), and 77 non-medullary thyroid 
carcinomas (papillary thyroid carcinoma (PTC) n=53, follicular thyroid carcinoma (FTC) 
n=13 and follicular variant of PTC (FVPTC) n=11). All original histological diagnoses 
were reviewed by two independent observers. Given the variability in phenotype of 
follicular lesions, only micro follicular FA and widely invasive FTC’s were included on 
which both observers agreed. Likewise, we only included encapsulated FVPTC tumors 
with a typical PTC nuclear pattern on which both observers agreed.
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Tissue microarray
Formalin-fi xed, paraffi n-embedded blocks routinely prepared from surgical speci-
mens of thyroid tumors were selected for this study. Representative areas containing 
tumor or adjacent normal tissue were identifi ed by a pathologist. Triplicate tissue 
cores with a diameter of 0.6 mm were taken from each specimen (Beecher Instru-
ments, Silver Springs, MD, USA) and arrayed on a recipient paraffi n block, using 
standard procedures (24).
Immunohistochemistry methods
Four micrometer consecutive tissue sections were cut from each arrayed paraffi n block 
and prepared on pathological slides. The sections were deparaffi nized in xylene followed 
by 0.3% hydrogen peroxide in methanol at room temperature for 20 min to block en-
dogenous peroxidase. After rehydration, antigen retrieval was performed by microwave 
treatment in 0.001 M citrate buffer (pH 6.0). The sections were incubated with the fol-
lowing primary antibodies against RAR and RXR subtypes: anti-RARalpha monoclonal 
antibody 9A9A6, dilution 1:3000; anti- RARbeta monoclonal antibody 8B10B2, dilution 
1:200; anti-RARgamma monoclonal antibody. 4G-7A11, dilution 1:350; anti-RXRalpha 
monoclonal antibody 4RX3A2, dilution 1:1000 (all gifts of Dr C Rochette-Egly, IGBMC, 
Illkirch, France), anti-RXRbeta polyclonal antibody sc-831, dilution 1:650 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); anti-RXRgamma polyclonal antibody sc-555, dilu-
tion 1:500 (Santa Cruz). Sections were incubated overnight at room temperature with 
the primary antibodies, dissolved in PBS with 1% bovine serum albumin. Subsequently, 
the sections were incubated for 30 min with either the biotinylated rabbit-anti-mouse 
conjugate, dilution 1:200 or goat-anti-rabbit, dilution 1:400 (DakoCytomation, Glostrup, 
Denmark), followed by incubation for 30 min with the streptavidin-biotin-peroxidase 
conjugate. This step was performed by 10-min incubation with 3,3’- diaminobenzidine-
tetrachloride substrate in a buffered 0.05-M Tris/HCl (pH 7.6) solution containing 0.002% 
hydrogen peroxide. Negative controls were stained with the primary antibody omitted. 
The sections were counterstained with hematoxylin.
Immunohistochemical scoring
A semi quantitative assessment of immunohistochemical scoring was performed 
including both the intensity of staining and the percentage of positive cells. The per-
centage of cells with positive staining was scored as follows: >0–20%: ‘1’, >20–50%: 
‘2’, >50–70%: ‘3’, and >70–100% ‘4’. The staining intensity was scored as faint: ‘1’, 
intermediate: ‘2’, and intense: ‘3’. Scores for proportion of positive cells and intensity 
were multiplied. Nuclear, cytoplasmic, and membranous staining was scored inde-
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pendently. The total score per sample therefore ranged from 0 to 12. Score results for 
triplicate samples were averaged.
Statistical analyses
Statistical analyses were performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). 
Initially, staining scores for every individual antibody were expressed as mean ± SD 
per histological category (Table 2). The next step was the analysis of differences in 
staining scores for each antibody between malignant versus benign tissues, malignant 
versus normal tissues, FA versus FTC and FA versus FVPTC using the Mann-Whitney 
test. For each differentially expressed antibody between two histological categories, 
the optimal cut-off value for the distinction between the two categories was deter-
mined by receiver operating characteristic (ROC) analysis. In theory, this could give 
different cut-off values for one antibody for different comparisons. Only antibodies 
with sensitivities and specifi cities above 70% were included in further analyses. In 
addition to the individual protein markers, the analysis of the diagnostic accuracy of 
panels of antibodies was performed using hierarchical clustering analysis of tissue 
microarray data using Cluster and TreeView (Cluster and TreeView 2.11; Eisen Lab, 
University of California at Berkeley, CA, USA) (12,25). Input for these analyses was 
the individual staining score per sample for each antibody. A P-value of <0.05 was 
considered signifi cant.
Table 2: Results of retinoid receptor staining
Normal
n=64
Multi 
nodular 
goiter
n=16
Follicular 
adenoma
n=13
FTC
n=13
FVPTC
n=11
PTC
n=53
Nuclear RARα 4.47 ± 1.98 4.06 ± 1.46 4.88 ± 1.67 6.02 ± 3.71 1.12 ± 2.39 2.56 ± 2.43
Cytoplasmic RARα 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 2.43 ± 4.47 1.67 ± 2.42 1.21 ± 2.47
Nuclear RARβ 8.53 ± 2.20 8.62 ± 1.42 8.63 ± 2.21 5.62 ± 3.37 5.78 ± 3.12 6.21 ± 3.18
Nuclear RARγ 4.56 ± 2.59 3.17 ± 1.40 3.17 ± 2.26 1.61 ± 1.58 0.85 ± 1.92 2.00 ± 2.63
Cytoplasmic RARγ 0.00 ± 0.00 0.00 ± 0.00 0.55 ± 1.81 1.78 ± 3.54 0.54 ± 1.80 0.93 ± 2.58
Nuclear RXRα 2.29 ± 2.00 2.27 ± 2.03 2.64 ± 2.60 0.44 ± 0.12 0.00 ± 0.00 0.37 ± 1.10
Nuclear RXRβ 0.71 ± 1.62 0.36 ± 1.21 0.00 ± 0.00 0.00 ± 0.00 0.30 ± 0.95 0.32 ± 1.33
Cytoplasmic RXRβ 0.07 ± 0.53 0.00 ± 0.00 2.18 ± 4.85 5.99 ± 4.89 2.68 ± 4.54 6.80 ± 4.55
Membranous RXRβ 1.66 ± 2.06 3.34 ± 2.05 4.53 ± 2.69 1.88 ± 1.88 1.41 ± 2.84 0.92 ± 2.20
Scoring method: The percentage of cells with positive staining was scored: >0–20%: ‘1’, >20–50%: ‘2’, 
>50–70%: ‘3’, and >70–100% ‘4’. The intensity was scored as faint: ‘1’, intermediate: ‘2’, and intense: 
‘3’. These scores were multiplied by each other for a combination score. Score results for triplicate 
samples were averaged. Distinctive scores were categorized according to nuclear, cytoplasm and 
membranous staining patterns. Data are mean ± SD. RAR= Retinoic Acid Receptor RXR= Retinoid X 
Receptor
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Results
RAR and RXR expression in thyroid lesions: benign versus malignant
The scores for expression of RAR and RXR receptor subclasses are shown in Table 2. 
Benign tissue samples had an overall lower expression of cytoplasmic RARalpha (cR-
ARalpha), cytoplasmic RARgamma (cRARgamma), and cytoplasmic RXRbeta (cRXR-
beta) and a higher expression of nuclear RARalpha (nRARalpha), nuclear RARbeta 
(nRARbeta), nuclear RARgamma (nRARgamma) and nuclear RXRalpha (nRXRalpha) 
compared with malignant tissues. FA scored particularly high for nuclear RXRalpha 
(nRXRalpha) and low for nuclear RXRbeta (nRXRbeta) expression. FVPTC also had a 
very low expression of nRXRbeta. RXRgamma staining did not reveal a positive result 
in all thyroid tissues, and was excluded from further analyses. 
*
*
*
*
*
*
*
malignant malignant
*
*
*
*
*
*
*
*
* *
*
#
#
# #
# #
D
BA
C
*
Figure 1 
Immunostaining of RAR and RXR subtype antibodies in normal, benign, and malignant thyroid 
lesions. Immunohistochemistry scores were expressed semi-quantitatively (for explanation, see text). 
Data are expressed as mean ± S.D. Comparisons between (A) benign and malignant, (B) normal and 
malignant, follicular adenoma (FA) and follicular thyroid carcinoma (FTC), and (D) FA and follicular 
variant of papillary carcinoma (FVPTC) were performed with the Mann–Whitney test.
*P<0.005; # P<0.05; n= nuclear; c= cytoplasmic; m= membranous; RAR= Retinoic Acid Receptor; 
RXR= Retinoid X Receptor
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Figure 1 shows the differences in expression patterns for different categories of 
thyroid tissues. All RAR and RXR subtypes appeared to be differentially expressed 
between malignant thyroid lesions and normal thyroid tissue.
RAR and RXR expression in thyroid lesions: follicular lesions
The differentiation between follicular lesions (FA, FTC, and FVPTC) is diffi cult. 
Therefore, we compared these subgroups separately. FTC had a signifi cantly lower 
expression of nRARbeta, nRXRalpha, and mRXRbeta compared with FA. FVPTC had 
a signifi cantly lower expression of nRARalpha, nRARbeta, nRARgamma, nRXRalpha, 
and mRXRbeta compared with FA (Figure 1).
ROC analyses
For each differentially expressed antibody between two categories, the optimal cut-
off values for the distinction between the two histological classes were determined 
by ROC analysis. Only antibodies with sensitivities and specifi cities above 70% were 
used for further analyses (Table 3). Comparison of the expression between benign and 
malignant thyroid tissues revealed sensitivities and specifi cities >70% for nRXRalpha, 
cRXRbeta, and mRXRbeta, the highest sensitivity (89%) and specifi city (96%) for 
nuclear RXRalpha (Table 3). NRXRalpha and cRXRbeta also discriminated reasonably 
between malignant and normal thyroid tissues. 
In the comparison between FA and FTC, nRARbeta, nRARalpha, cRXRbeta, and 
mRXRbeta had sensitivities and specifi cities above 70%, the highest sensitivity for FTC 
found for nRARalpha (85%) and the highest specifi city for nRARbeta (91%; Table 3).
In the comparison between FA and FVPTC, nRARbeta, nRARgamma, nRARalpha, 
nRXRalpha and mRXRbeta had sensitivities and specifi cities above 70%. The highest 
sensitivity for FVPTC was found for nRXRalpha (100%) and the highest specifi cities 
for both nuclear nRARalpha (91%) and nRARgamma (91%; Table 3).
Hierarchical cluster analysis
To identify the optimal combinations of RAR and RXR subtype expression for the dif-
ferential diagnosis of thyroid neoplasms, we performed an unsupervised hierarchical 
cluster analysis, the results of which are shown in Table 4 and Figure 2. We found 
that 98% of thyroid lesions in cluster 2 (negative staining of mRXRbeta and positive 
staining for cRXRbeta) were malignant; whereas 91% of the lesions in cluster 4 (posi-
tive staining for nRXRalpha and a negative staining for cRXRbeta) were benign. The 
diagnostic parameters are summarized in Table 4. In general, the follicular lesions 
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did not cluster separately, but we found that only one FA was present in cluster 2 
(high positive predictive value for malignancy), whereas in cluster 4 (high positive 
predictive value for benign lesions) only one FTC was present (Figure 2).
Discussion
The present study was performed to evaluate the diagnostic value of the expression 
of RAR and RXR subtypes in a large panel of thyroid neoplasms. To our knowledge, 
the diagnostic value of RAR and RXR receptor expression for the differential diagnosis 
of thyroid neoplasms has not been published before (14–20). Our study also differed 
from earlier ones with regard to the identifi cation of optimal semi quantitative cut-off 
levels using ROC analyses and hierarchical cluster analysis.
Table 3: Diagnostic value of RAR and RXR differentially expressed in thyroid tissues with sensitivity 
and specifi city above 70%. 
Malignant versus benign Malignant versus normal
Cut-off 
level a 
Sensitivity 
for 
malignancy 
(%)
Specifi city 
for 
malignancy 
(%)
Cut-off 
level a 
Sensitivity 
for 
malignancy 
(%)
Specifi city 
for 
malignancy 
(%)
Nuclear RAR β <8.5 72 80
Nuclear RXR α <1 89 96 <1 89 75
Cytoplasmic 
RXR β
>1 71 96 >1 71 89
Membranous 
RXR β
<1 74 72
FTC versus FA FVPTC versus FA
Cut-off 
level a
Sensitivity 
for FTC (%)
Specifi city for 
FTC (%)
Cut-off 
level a
Sensitivity 
for FVPTC 
(%) 
Specifi city 
for FVPTC 
(%)
Nuclear RAR α <1 85 80 <3 92 91
Nuclear RAR β <8 73 91 <8 91 82
Nuclear RAR γ >1 82 91
Nuclear RXR α <1 100 73
Cytoplasmic 
RXR β 
>2 71 82
Membranous 
RXR β 
<4 82 75 <1 82 82
Benign thyroid tissues= multinodular goiter, follicular adenoma and normal 
RAR= retinoic acid receptor, RXR= retinoid X receptor. a Obtained by ROC analyses of semi-
quantitative immunohistochemistry scores.
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In general, we found an increased expression of cRARalpha, cRARgamma, 
cRXRbeta, and a decreased expression of nRARbeta, nRARgamma, and nRARalpha 
in thyroid carcinomas compared with benign thyroid tissue. The most challenging 
pathological differential diagnosis is between FA, FTC, and FVPTC. We found three 
proteins differentially expressed between FA and FTC and fi ve proteins differentially 
expressed between FA and FVPTC. In the comparison between FA and FTC the highest 
sensitivity for FTC was found for nRARalpha and the highest specifi city for nRARbeta. 
In the comparison between FA and FVPTC, the highest sensitivity for FVPTC was 
found for nRXRalpha and the highest specifi cities for nRARalpha and nRARgamma. 
Some of these observations are in line with other studies that investigated RAR and/
or RXR expression in thyroid tissue samples (Table 1). Rochaix et al. (14) (Immu-
nohistochemistry), Haugen et al. (18) (RT-PCR), and Elisei et al. (19) (RT-PCR) also 
found reduced RARbeta expression in PTC, compared with normal tissue. Rochaix 
et al. (14) only investigated two FTC samples of which one sample showed moderate 
RARbeta expression and the other did not. Our fi nding of higher nuclear and lower 
cytoplasm expression of RARgamma in malignant thyroid tissues was not reported 
before. Nuclear RXRalpha expression was low or absent in thyroid carcinomas in our 
study. This fi nding is confi rmed by a paper by Takiyama et al. (16). We did not fi nd 
positive RXRgamma staining in thyroid tissues, which is unexpected, given the results 
of Haugen et al. by western blot (18).
Table 4: Diagnostic value of combinations of retinoid receptor staining for benign vs. malignant 
thyroid lesions, based on hierarchical cluster analysis.
Combination mRXRβ- and 
cRXRβ+
Combination not present Total
(a) Diagnostic value of combinations of retinoid receptor staining for benign versus malignant thyroid 
lesions, based on cluster 2 in hierarchical cluster analysis
Malignant 44 35 79
Benign 1 (FA) 96 98
Total 45 131 176
PPV malignancy = 98% NPV malignancy = 72% LR malignant 56
Combination nRXRα+ and 
cRXRβ -
Combination not present Total 
(b) Diagnostic value of nRXRα and cRXRβ staining for benign versus malignant thyroid lesions, based on 
cluster 4 in hierarchical cluster analysis
Benign 41 56 97
Malignant 4 (3 PTC and 1 FTC) 75 79
Total 45 130 175
PPV benign = 91% NPV benign = 57% LR benign 8.6
RAR= retinoic acid receptor, RXR= retinoid X receptor, PPV= positive predicting value, NPV= negative 
predicting value, LR= likelihood ratio
Dieke Hoftijzer BW.indd   57 23-02-11   15:19
58 Chapter 2
Figure 2 
Hierarchical cluster analyses using RAR and RXR subtype antibodies in thyroid tissues. Nuclear 
RXRalpha, cytoplasmic RXRbeta, and membranous RXRbeta were identifi ed as the best predictors 
of benign or malignant thyroid lesions. The absence of membranous (m) RXRbeta and the presence 
of cytoplasmic (c) RXRbeta had a high positive predictive value for malignancy (98%, cluster 2). The 
presence of nuclear (n) RXRalpha and absence of cytoplasmic RXRbeta had a high positive predictive 
value for benign lesions (91%, cluster 4). CTL= normal thyroid, FA= follicular adenoma, FTC= 
follicular thyroid carcinoma, PTC= papillary thyroid carcinoma, FVPTC= follicular variant PTC.
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There are two studies on RXRbeta expression in thyroid neoplasms (15,16). They 
both found decreased or absent expression of RXRbeta in carcinomas. One of these 
studies, however, (15) used RT-PCR and contained only 12 human thyroid carcinoma 
samples. In our study, we differentiated between nuclear, cytoplasmic, and membra-
nous staining. The only study that also differentiated between nuclear and cytoplasm 
staining pattern, only investigated RXR isoform expression (16).
We performed a cluster analysis including all studied tissues and antibodies. 
Our fi ndings showed that the combination of negative staining of mRXRbeta and a 
positive staining for cRXRbeta had a high accuracy for the detection of malignant 
thyroid tissues, whereas the combination of a positive staining for nRXRalpha and a 
negative staining for cRXRbeta was present in most benign tissues.
There are some limitations to our study. Although we were able to distinguish 
between follicular lesions, the number of follicular lesions was relatively small. 
Therefore, additional studies should be performed with larger numbers of follicular 
lesions, also including histological subtypes of follicular lesions. Moreover, the fi nd-
ings of our study and the clinical usefulness of hierarchical cluster analysis have to 
be validated in subsequent studies and most importantly in cytological preparations. 
Also, other diffi cult-to-classify thyroid neoplasms such as minimally invasive follicu-
lar carcinomas as well as FA subclasses should be included in subsequent studies. 
The biological mechanisms responsible for the differential expression of RAR and 
RXR between thyroid tissues also remain to be elucidated. In conclusion, differences 
in RAR and RXR subtype protein expression as studied by immunohistochemistry may 
be of additional value in the differential diagnosis of thyroid neoplasms.
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Abstract
Objective
Treatment options for patients with radioactive iodine (RaI) refractory metastases 
of differentiated thyroid carcinoma (DTC) are limited. We studied the effects of the 
multitarget tyrosine kinase inhibitor sorafenib on the reinduction of RaI uptake and 
tumor progression.
Design
Open, single center, single arm 26-week prospective phase II study with open-ended 
extension.
Methods
We treated 31 patients with progressive metastatic or locally advanced RaI refrac-
tory DTC with sorafenib 400 mg b.i.d.. The primary endpoint was reinduction of RaI 
uptake at 26 weeks. Additional endpoints were the radiological response and the 
infl uence on bone metastases.
Results
At 26 weeks of sorafenib therapy, no reinduction of RaI uptake at metastatic sites 
was observed, but 19 patients (59%) had a clinical benefi cial response, eight of 
whom had a partial response (25%) and 11 had stable disease (34%). Seven patients 
had progressive disease (22%). Sorafenib was signifi cantly less effective in patients 
with bone metastases. The estimated median progression free survival was 58 weeks 
(95% confi dence interval, CI, 47–68). In general, thyroglobulin (Tg) response (both 
unstimulated and TSH stimulated) refl ected radiological responses. The median time 
of the nadir of Tg levels was 3 months. Responses were not infl uenced by histological 
subtype, mutational status or other variables. No unusual side effects were observed.
Conclusions
Sorafenib has a benefi cial effect on tumor progression in patients with metastatic 
DTC, but was less effective in patients with bone metastases. Diagnostic whole body 
scintigraphy did not reveal an effect of sorafenib on the reinduction of RaI uptake.
Dieke Hoftijzer BW.indd   64 23-02-11   15:19
Sorafenib in DTC 65
Introduction
The prognosis of differentiated thyroid carcinoma (DTC) in general is favorable due 
to the effi cacy of the combined treatment of surgery and radioactive iodine (RaI) 
and the biological behavior of the tumor (1, 2). However, approximately 50% of 
patients with distant metastases of DTC die within 10 years of diagnosis (3). Al-
though the role of RaI in recurrent or metastatic thyroid cancer is beyond dispute 
(4–6), the effi cacy of this therapy is hampered by the decreased expression of the 
Sodium-Iodide-Symporter (NIS) in DTC during the process of dedifferentiation (7–9). 
Predictive factors for responsiveness to RaI treatment include a younger age, small 
metastases, well-differentiated thyroid tumor histology and the absence of uptake of 
18-fl uoro deoxyglucose (FDG) at FDG-positron emission tomography (PET) scanning. 
Especially in patients with bone metastases, the effi cacy of RaI is limited to 7–20% of 
the patients (4,6,10,11). At present, there are no effective therapies available for RaI 
non-avid DTC. Conventional chemotherapy is hardly effective in DTC, and no longer 
recommended in international guidelines (12,13). 
In DTC, many genetic alterations have been identifi ed, involving tyrosine kinase 
signaling pathways (14–16). In nearly all cases of papillary thyroid carcinoma (PTC), 
genetic defects involving the RET, RAS, and RAF protein kinase signaling cascade 
are identifi ed. The BRAFV600E mutation has been found in 29–69% of PTC and has 
been associated with aggressive features including extrathyroidal extension and ad-
vanced stage (17). Translocations of RET observed in PTC result in a chimeric protein 
consisting of an activated RET tyrosine kinase domain (15,18–32). Follicular thyroid 
carcinomas (FTC) frequently harbor mutations in one of the three RAS genes. The 
RET–RAS–RAF pathway is interconnected with the epithelial growth factor receptor 
(EFGR) activated cascade that among others leads to vascular endothelial growth 
factor (VEGF) and VEGF receptor (VEGFR) synthesis. Therefore, compounds targeting 
the activated RET–RAS–RAF pathway and beyond may be effective in non-RaI avid 
DTC. The anti-EGFR compound gefi tinib was not successful in 27 patients with DTC, 
medullary or anaplastic thyroid carcinoma (33). In a phase II study in 60 thyroid 
carcinoma patients with various histologies, the VEGFR inhibitor axitinib showed a 
partial response of 30% (median progression free survival (PFS) 18 months) (34). Re-
cently, 3 phase II studies have been published, using multi-kinase inhibitors (35–37). 
Motesanib diphosphate induced a partial response in 14% of 93 DTC patients (me-
dian PFS 40 weeks) (36). Two studies have been published using sorafenib. Sorafenib 
(BAY 43-9006) is an inhibitor of RET, CRAF, wild-type and mutant (V600E) BRAF, 
VEGFR1, -2, -3, Flt3, and c-KIT.
In the fi rst study, including DTC, anaplastic and medullary thyroid carcinoma 
patients, sorafenib induced a partial response in 23% (median PFS 79 weeks). In 
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the second study, including patients with DTC and anaplastic thyroid carcinoma, 
a partial response was observed in 11% (median PFS 4.5–16 weeks) (37). As bone 
metastases of DTC are poorly responsive to RaI, the response of bone metastases 
to the above-mentioned therapies is of interest. However, there were no separate 
analyses for patients with bone metastases in the above-mentioned studies. 
In DTC, a relationship has been identifi ed between genetic alterations in the 
RET, RAS, RAF cascade and loss of NIS expression (17,38). Interestingly, in an in-vitro 
study, sunitinib was able to reinduce NIS expression in RET/PTC transformed thyroid 
cells (39). In addition, sunitinib also increased RaI uptake in FRTL-5 cells. We there-
fore hypothesized that treatment with a multiple kinase inhibitor not only reduces 
tumor progression, but may also restore RaI uptake in non-RaI avid DTC. Therefore, 
we performed a single arm phase II trial to determine the effi cacy of sorafenib in 
patients with iodine refractory metastatic DTC, focusing on the reinduction of RaI 
uptake and the effi cacy in bone metastases.
Patients and methods
Patients
Eligibility criteria for the present study were the presence of progressive metastases 
or unresectable local recurrence of DTC for which RaI therapy was no longer effec-
tive, as indicated by prior negative post-therapeutic whole body scintigraphy (WBS). 
Progressive disease was defi ned according to response evaluation criteria in solid 
tumors (RECIST) criteria in the year before initiation of treatment. Patients who were 
selected had to have undergone total thyroidectomy and RaI ablative therapy. Exclu-
sion criteria were pregnancy, contraindications for the application of recombinant 
human thyrotropin (rhTSH) and contraindications for the use of sorafenib. In addition, 
no patients with poorly responsive DTC were included as it was hypothesized that 
the likelihood of reinduction of RaI uptake in this category of tumors would be very 
small. Other eligibility criteria included Eastern Cooperative Oncology Group perfor-
mance status 0–2 and life expectancy more than 3 months. Patients were ineligible 
if they had previous exposure to biological therapies. All patients provided written 
informed consent before enrollment onto the trial. The study protocol was approved 
by the Institutional Review Board of the Leiden University Medical Center. This study 
has been registered at ClinicalTrials.gov (# NCT00887107). 
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Study design
The study was a 26-week open-label, single-arm, phase II study of oral sorafenib 
in patients with metastatic DTC. The primary objective was to study the effect of 
sorafenib treatment on reinduction of radioiodine uptake. Secondary objectives were 
radiological tumor response according to RECIST and the relation between the pres-
ence of bone metastases and therapy success. Sorafenib was initially administered 
at a dose of 400 mg orally twice a day. Eligibility assessments, including a review 
of medical history and prior treatments, physical examination and laboratory as-
sessments were completed within 2 weeks before initiation of the sorafenib therapy. 
Baseline radiological evaluation by computed tomography (CT) of target lesions was 
performed 4 weeks prior to initiation of therapy. From all patients, tumor samples 
from the primary tumors were obtained for review by the institutional pathologist 
(H.M.). After inclusion, the patients underwent a diagnostic scintigraphy 3 days after 
i.v. administration of 185 MBq I-131 (Mallinckrodt BV, Petten, The Netherlands). 
Single photon emission computed tomography (SPECT) of the head and neck and 
chest was performed. Two experienced observers visually analyzed all images. An 
I-131 standard was used to quantify the uptake in the area of interest at WBS. Patients 
were prescribed a low iodide diet from 7 days prior to the administration of I-131 
(40). The patients received i.m. injections with 0.9 mg rhTSH (Thyrogen, Genzyme, 
Naarden, The Netherlands) on two consecutive days before the RaI administration. 
The day after the fi rst WBS, patients started treatment with sorafenib 400 mg bid. 
Twenty-six weeks after initiation of sorafenib therapy, CT scanning and RaI imaging 
studies were repeated. All target lesions were imaged using CT. According to RECIST 
criteria, bone lesions were not evaluated as target lesions. It was carefully planned 
that CT scans using i.v. contrast were performed after diagnostic RaI scintigraphies. 
Procedures to exclude the occurrence of new bone metastases included bone and 
FDG-PET scintigraphy. Patients visited the hospital every 4 weeks for physical ex-
amination and assessment of laboratory safety parameters. Patients were assessed for 
new symptoms, compliance with study medications, and concomitant medications. 
Dose adjustments were made as needed for toxicity. The target serum TSH levels were 
below 0.1 mU/l. After completion of 26-week treatment, patients were allowed to 
continue sorafenib treatment, when a favorable response (complete or partial remis-
sion, or stable disease) had been achieved, until progression according to RECIST 
criteria. Adverse events were graded with the use of Common Terminology Criteria 
for Adverse Events (version 3). 
To study the relation between effi cacy and tumor mutational state, tumor DNA 
from patients was isolated from the paraffi n-embedded material by taking tissue 
punches (diameter, 0.6 mm) with a tissue microarrayer (Beecher Instruments, Silver 
Springs, MD, USA) from tumor and normal areas selected on the basis of a hematoxylin 
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eosin (HE)-stained slide. Mutational analysis was performed using PCR amplifi cation 
followed by sequencing on an ABI 3730 automated sequencer (Applied Biosystems, 
Foster City, CA, USA) ABI 3700. Codons investigated were: B-type Raf kinase (BRAF, 
V600E and exon 11), HRAS (codon 12/13 and 61), KRAS (codon 12/13 and 61), 
NRAS (codon 61), and phosphatidylinositol-3-kinase, catalytic, alpha polypeptide 
(PIK3CA, exons 9 and 20). Primer sequences are available on request. 
Laboratory parameters
The following laboratory parameters were assessed: serum TSH, free-thyroxine (FT4), 
thyroglobulin (Tg), and Tg antibody levels were measured at all visits. TSH and Tg 
were also measured 1 and 3 days after the last rhTSH injection. Safety parameters 
were assessed at every visit and included a hematological profi le as well as serum 
levels of sodium, potassium, creatinine, renal and liver function. Serum TSH was 
determined with a Modular Analytics E-170 system ((Roche Diagnostic Systems), 
intra-assay variability: 0.9–10.7%, interassay variability: 0.9–12.1%). Serum Tg was 
determined with IRMA ((Tg kit, Brahms, Berlin, Germany) on a Wallac (Wallac, Turku, 
Finland), intra-assay variability: 0.1–13.9%, interassay variability: 12.3–17.4%). Se-
rum Tg antibodies were determined with IRMA (Sorin Biomedica, Amsterdam, The 
Netherlands) on a Wallac (Wallac, Turku, Finland, intra-assay variability: 3.6–4.1%, 
interassay variability: 11.6%).
Statistical methods 
Using a Simon two-stage design, the study required 24 subjects to decide whether 
the proportion responding, P, is ≤10% or ≥40%. If the number of responses was six 
or more, the hypothesis that P ≤ 10% is rejected with a target error rate of 5% and an 
actual error rate of 2.8%. If the number of responses was fi ve or less, the hypothesis 
that P ≥ 40% is rejected with a target error rate of 5% and an actual error rate of 
4%. All enrolled patients were included in an intention-to-treat analysis. Data are 
reported as mean ± S.D., median (range) or proportions. Estimates of PFS (time from 
starting study drug to progression) with associated 95% CI’s were obtained using the 
Kaplan–Meier method. Analyses of variables infl uencing response to sorafenib were 
analyzed with binomial logistic regression (26-week data). The calculations were 
performed using SPSS 16.0 for Windows (SPSS, Chicago, IL, USA).
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Results
Patient characteristics
Between 13 October 2007 and 7 October 2008, a total of 31 patients started sorafenib 
treatment (Figure 1). One patient chose not to start sorafenib therapy after giving 
signed informed consent. Therefore, 32 patients were included in the intention-to-
treat analysis. A total of 22 patients completed 26 weeks of treatment. The remaining 
patients discontinued treatment earlier because of disease progression (four patients, 
see effi cacy section for details), drug-related adverse events (two patients, see ad-
verse events section for details), non-drug related adverse events (two patients) or the 
patient’s request (one patient). Eight of the 22 patients who completed the 26-week 
trial and continued sorafenib treatment, discontinued treatment later on, two because 
of adverse events and six because of disease progression. The median duration of 
sorafenib treatment for all patients was 32 weeks (range 3 days to 79 weeks). Median 
duration of follow-up was 63 weeks (range 28–80 weeks).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 patients started 26-week therapy
Four patients discontinued for adverse events 
 
One patient discontinued at own wish 
 
Four patients discontinued for tumor progression 
22 patients completed 26-week therapy
11 patients continued therapy 
32 patients signed informed consent
One patient did not start treatment 
Two patients discontinued for adverse events 
 
Six patients discontinued for tumor progression  
 
Three patients discontinued for 
tumor progression 
Figure 1
Study fl owchart.
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Baseline characteristics are given in Table 1. All patients had undergone prior 
RaI treatments with a median activity of 15.2 (range 3.7–30.0) GBq. The number 
of RaI treatments ranged from 1 to 4. None of the patients had RAI uptake before 
inclusion as indicated by post-therapeutic WBSs and at baseline. Fifteen patients had 
undergone external beam irradiation. In all patients, external beam irradiation was 
aimed at one or more bone metastases. As no bone metastases were target lesions 
this treatment did not interfere with the assessment of effi cacy. Interestingly, the most 
common histologic carcinoma subtype was Hürthle cell carcinoma. In follicular 
thyroid with Hürthle cell metaplasia, the majority of cells were Hürthle cells. At study 
entry, almost all patients had lung metastases (n=30), whereas 14 patients had bone 
metastases. Most patients had metastases at multiple sites. In 10/13 patients with 
PTC, BRAFV600E mutations were identifi ed, one of which (the tall cell variant) also 
Table 1: Baseline Characteristics
All patients
(n=32)
Gender (No. ;%)
 Female 13 (39)
 Male 19 (61)
Time from diagnosis (year) (median, range) 3 (0 – 18)
Age (year) (median, range) 65 (53 – 82)
Histology (no. ;%)
 Papillary 13 (41)
 Tall cell 1 (3)
 Hürthle cell metaplasia 2 (6)
 Follicular variant papillary 3 (9)
 Follicular 15 (47)
 Hürthle cell metaplasia 11 (34)
 Mixed papillary 1 (3)
Initial TNM stage (no. ;%) (5 unknown)
 T1-3 N 0-1 M0 12 (44)
 T4 N 0-1 M0 6 (23)
 M1 9 (33)
Tumor extent at study entry (no. ; %) 
 Thyroid bed only 1 (3)
 Lungs only 8 (25)
 Lungs and bone only 7 (22)
 Locally advanced * and distant metastasis 9 (33)
 Other 7 (22)
Radioiodine dose (GBq) (median, range) 15.2 (3.7 – 30.0)
External beam radiation (no. ; %) 15 (47)
*Including both thyroid bed (n= 5) and neck lymph nodes (n= 4)
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showed a PIK3CA mutation. Few additional mutations were identifi ed: one KRAS in 
FVPTC; two NRAS mutations were found (one in a PTC without a BRAF mutation and 
one in a FTC); and one additional PIK3CA mutation was found in a FTC with Hürthle 
cell metaplasia.
Effi cacy
Data on responses are given in Table 2 and Figure 2. Disease progression led to 
treatment discontinuation of patients at 6 weeks (one patient with new bone metas-
tases), 18 weeks (one patient with a new abdominal metastasis, one patient with new 
pulmonary metastases), 25 weeks (one patient with cerebral metastases), 26 weeks 
(end of 26-week trial: two patients with new bone metastases, one patient with a new 
pulmonary metastasis), 32 weeks (two patients with new bone metastases, one pa-
tient with progression of a hip lesion, one patient with new liver metastases and one 
patient with new lung lesions) and 40 weeks (one patient with a new neck lesion). 
At 26 weeks, 19 patients (59%) had achieved a clinical benefi cial response, eight 
of whom had a partial response (25%) and 11 had stable disease (34%; Table 2). 
There were no complete responses. At 26 weeks, the cumulative number of patients 
with progressive disease was seven. Interestingly, four patients with progressive 
disease based on new lesions had no progression or a considerable decrease in the 
sum of the longest diameter of target lesions. Radiological response at 26 weeks was 
not infl uenced by gender (P = 0.593), age (P = 0.172), initial tumor lymph nodes 
metastases (TNM) stage (P = 0.488), histology (P = 0.614), or the presence of the 
BRAFV600E mutation (P = 0.760). The prevalence of other mutations was too low to 
allow statistical analysis. However, when bone metastases were present, the response 
to sorafenib was signifi cantly worse than in the absence of bone metastases (P = 
0.004, Table 2). 
Although this study was not formally designed for the establishment of PFS, esti-
mation of median PFS was 58 weeks (95% CI, 47–68). Likewise, PFS was infl uenced 
by the presence of bone metastases. PFS was 69 weeks (CI: 58–80) in patients without 
bone metastases and 47 weeks (CI: 32–62) in patients with bone metastases (P = 
0.046). 
In general, Tg response refl ected radiological response and there were no dif-
ferences between the responses of unstimulated versus TSH stimulated Tg measure-
ments (Table 2, Figure 2). The median time of the nadir of Tg levels was 3 months. 
The median change in Tg at 26 weeks versus baseline was -16 mg/l (range -2746 
to 17.836). Remarkably, one patient with progression in a non-target lesion had a 
decrease in unstimulated Tg, but an increase in TSH stimulated Tg. In one 54-year-old 
woman with pulmonary metastases of a Hürthle cell FTC, a remarkable rise in serum 
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Tg from 1664 to 99 900 mg/l was observed 8 weeks after initiation of therapy. A 
chest CT scan revealed an impressive decrease in the number, size, and density of all 
pulmonary metastases. 
Reinduction of radioiodine uptake could be evaluated in 21 patients who had 
completed 26-week treatment with sorafenib. In one patient, WBS could not be 
performed for technical reasons. In three patients with extensive metastases, both at 
baseline and at 26 weeks, RaI WBS revealed uptake at the thyroid bed, but not at the 
sites of metastases. In 20 patients, there was no RaI uptake at metastatic sites after 26 
weeks of sorafenib therapy. In one patient with an occipital skeletal metastasis that 
did not accumulate RaI at baseline, very slight RaI uptake was observed at 26 weeks. 
However, a post-therapeutic WBS performed after subsequent 7600 MBq RaI therapy 
did not reveal any uptake, and consequently it was concluded that no clinically 
relevant reinduction of RaI therapy had occurred in this patient.
Table 2: Tumor response
All patients 
(n=32)
Bone metastases Histology (a)
Absent Present PTC FVPTC FTC
Reinduction of iodine 
uptake at 26 weeks
0 Total
Hürthle 
cell
Total
Hürthle 
cell
Radiological response (n; % of total patients)
(b) (c)
Complete response 0 (0) 0 (0) 0 (0) 0 (0) 0 0 (0) 0 (0) 0
Partial response 8 (25) 5 (16) 3 (9) 2 (22) 0 2 (67) 4 (49) 4
Stable disease 11 (34) 7 (22) 4 (13) 6 (67) 1 0 (0) 5 (36) 3
Clinical benefi t 19 (59) 12 (38) 7 (22) 8 (89) 1 2 (67) 9 (64) 7
Progressive disease 7 (22) 0 (0) 7 (22)* 1 (11) 0 1 (33) 5 (36) 3
Serum Thyroglobulin levels (μg/l)
Baseline (median; range) 77 (4.4-8570)
26-weeks (n=22) 46 (0.9-19500)
Delta Tg (versus 
baseline, median; range)
-16 (-2746-17836)
Nadir 29 (0.5-7634)
Time to nadir 
(months, median; range)
3 (0-5)
Progression free survival
PFS (weeks, median; CI) 58 (47-68)
* P= 0.005 versus no bone metastases
(a) One patient with mixed PTC and FTC left the study because of an adverse event and could not be 
evaluated
(b) Percentage of total (n= 32) patients
(c) Percentage of evaluable patients per histology class
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Adverse events
Adverse events led to discontinuation of the study in six patients at respectively 3 
weeks (angioedema), 5 weeks (myocardial infarction), 7 weeks (hematuria), 12 weeks 
(concomitant small cell lung carcinoma), 38 weeks (dyspnea, not related to tumor 
progression), and 50 weeks (congestive heart disease). Doses were reduced in 18 
(56%) patients to control toxicities. The median dose at 26 weeks was 400 mg/day. 
The most prevalent adverse events are mentioned in Table 3. The hand–foot syndrome 
occurred in the fi rst few weeks of treatment and subsided in most patients after dose 
reduction and topical treatment. Most patients received nutritional support for weight 
loss. In three patients with considerable weight loss, a percutaneous gastric feeding 
catheter had to be inserted. Mineral defi ciencies were treated with supplementation. 
Hypertension was treated with antihypertensive drugs. Hematological abnormalities 
were mild and did not require treatment. In order to maintain serum-free T4 levels 
and TSH levels at the required values, fi ve patients required a thyroxine dose reduc-
tion, whereas in six patients, the dose needed to be increased. No relationship was 
observed between toxicity and performance state and age.
Discussion
We studied the effi cacy of the multiple target tyrosine kinase inhibitor sorafenib in 
patients with iodine-refractory metastatic DTC, focusing on the reinduction of RaI 
uptake and the effi cacy in patients with bone metastases. After 26 weeks of treatment, 
we found a partial response rate of 25% and a clinical benefi cial response in 59% of 
Figure 2 (page 73)
(A) The change from baseline in tumor dimensions (sum of longest diameters (SLD)) is shown for 22 
patients who completed 26 weeks of treatment with sorafenib and one patient who discontinued 
treatment at 18 weeks for disease progression (new soft-tissue lesion (#)). Not shown are data for 
three patients with progressive disease due to new lesions. Four patients with progressive disease 
based on new lesions had no progression or a considerable decrease in SLD (*). Target and non-target 
lesions are defi ned according to the response evaluation criteria in solid tumors (RECIST). (B) The 
natural logarithm of the change at 26 weeks from baseline in unstimulated and TSH stimulated serum 
thyroglobulin (Tg) levels is shown for 22 patients who completed 26 weeks of treatment with sorafenib 
and one patient who discontinued treatment at 25 weeks for disease progression (new cerebral 
metastasis (#)). One patient with progression in a non-target lesion had a decrease in unstimulated 
Tg but an increase in TSH stimulated Tg (*). TSH stimulated Tg measurements were performed 3 days 
after the last injection of 0.9 mg rhTSH. (C) Medians of unstimulated serum thyroglobulin (Tg) levels of 
25 evaluable patients during 26 weeks of treatment with sorafenib stratifi ed according to radiological 
response. Three of these patients with progressive disease discontinued treatment before 26 weeks. 
From one other patient, who also discontinued treatment before 26 weeks for disease progression, no 
Tg levels were obtained.
Dieke Hoftijzer BW.indd   74 23-02-11   15:19
Sorafenib in DTC 75
the patients. Patients with bone metastases responded signifi cantly worse. Reinduc-
tion of RaI uptake as studied by diagnostic WBS was not observed in any patient. 
RaI therapy is the only available conventional therapy for patients with metastases 
of DTC. Hürthle cell carcinomas respond less favorably to RaI, which is compat-
ible with the fact that the most prevalent histology was Hürthle cell metaplasia. The 
fact that 10/13 PTC harbored BRAFV600E mutations also illustrates the unfavorable 
prognostic characteristic of our patient group (41). The extensive characterization 
in recent years of the molecular pathways involved in the pathogenesis of DTC has 
revealed potential targets for new therapies. The identifi cation of tyrosine kinase ac-
tivated pathways in DTC together with the advent of novel classes of tyrosine kinase 
inhibitors has provided new therapeutic perspectives for patients with non-RaI avid 
DTC. The results of our study with respect to radiological response are comparable 
with those observed in another study with sorafenib by Gupta et al. (35) and better 
than observed in the study of Kloos et al. (37). The latter study, however, included 
patients with anaplastic carcinoma. Comparison of the results of phase II studies 
with different tyrosine kinase inhibitors in DTC is hampered by differences in pa-
tient categories (including histologies, tumor stages, sites of metastases, and tumor 
extent), study design, and analytical methods. Nonetheless, the results obtained with 
sorafenib in different studies, including our own suggest that sorafenib is among the 
most successful and promising compounds for metastatic DTC. We found a signifi -
Table 3: Adverse events
Event
All 
Number of 
patients (% of 
total n=32)
Grades (% of category)
1 2 3 4
Hand foot syndrome 21 (66) 33 33 33 0
Weight loss 18 (56) 35 50 15 0
Diarrhea 16 (50) 31 69 0 0
Alopecia 15 (47) 87 13 0 0
Rash 15 (47) 60 40 0 0
Mucositis 14 (44) 100 0 0 0
Hypertension 13 (41) 31 31 38 0
Hypocalcaemia 13 (41) 100 0 0 0
Thrombopenia 9 (28) 100 0 0 0
Hypophosphatemia 9 (28) 100 0 0 0
Anemia 8 (25) 100 0 0 0
Myocardial infarction 1 (3) 0 0 0 100
Congestive heart disease 1 (3) 0 0 100 0
Hematuria 1 (3) 0 100 0 0
According to Common Terminology Criteria for Adverse Events (version 3).
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cant difference in the response to sorafenib between patients with or without bone 
metastases, the latter category responding worse. Nevertheless, 23% of patients with 
bone metastases had a favorable response. Those patients had metastases at multiple 
sites, mostly pulmonary that regressed under sorafenib, whereas the bone metastases 
were stable. 
The explanation for a less favorable response of bone metastases is not clear. It 
can be hypothesized that both pharmacokinetic factors (lower tissue levels in bone) 
and tumor-related factors are involved. As it is hardly possible to obtain tissue from 
bone metastases, the relationship between the genetic profi le of bone metastases and 
responsiveness to sorafenib is not easy to study. Another explanation may be that 
it has been observed that the role of VEGFR signal transduction in tumor propaga-
tion in conscript vascular systems such as soft-tissue metastases may differ from less 
well-defi ned vascular beds as the bone marrow. As a consequence, VEGFR targeted 
therapies may have less prominent benefi cial effects in bone metastases. In addition 
it is also conceivable that the presence of bone metastases infl uences the response of 
soft-tissue metastases to sorafenib. Although the mechanism is not clear it could be 
hypothesized that the systemic release of proteins or cytokines, such as interleukin 6 
or TGF beta from the bone microenvironment plays a role in this phenomenon. 
The fact that there was a mixed response in some subjects (both regression and 
progression) is explained by the heterogeneous nature of metastases in thyroid car-
cinoma, which can be caused by tumor-related factors and the microenvironment 
of the metastatic site. This may lead to differences in tumor dependence on tyrosine 
kinase activated pathways, which may consequently lead to differences in response 
to sorafenib. RECIST does not take into account these phenomena, which are very 
important for the selection of lesions that may or may not respond to tyrosine kinase 
inhibitors. 
Another purpose of our study was to assess the effects of sorafenib on RaI up-
take. We did not fi nd reinduction of RaI uptake in any patient. Although a clear 
relation has been found in-vitro between genetic alterations in DTC and decreased 
NIS gene expression (17,38), multiple mechanisms may be involved in decreased 
NIS functionality, including impaired NIS membrane traffi cking (42,43), epigenetic 
changes in NIS and/or NIS promoter genes (44). Although in-vitro studies have shown 
that multiple target tyrosine kinase inhibitors may lead to reinduction of RaI uptake 
(39,45), it may well be that these additional mechanisms have prevented a benefi cial 
effect of sorafenib on RaI uptake in our study. Another explanation for the lack of an 
effect of sorafenib on RaI uptake may be the lower sensitivity of diagnostic WBS as 
compared to post therapeutic scintigraphy. For this reason, we used SPECT acquisi-
tion in our diagnostic scintigraphies, which has a higher sensitivity than conventional 
WBS. Nevertheless, we cannot exclude that a limited sensitivity may indeed have 
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contributed to our observation of a failure of sorafenib to reinduce RaI uptake. As 
baseline CT scans were performed 4 weeks prior to radioiodine scintigraphies, i.v. 
contrast could have interfered with the diagnostic scintigraphy at baseline. As no 
urinary iodine measurements were performed, this cannot be entirely ruled out. 
However, the fact that all patients had negative post-therapeutic WBSs previously 
ascertains the true radioiodine non-avid nature of the lesions. 
Although uptake of RaI is an important determinant of tumor response, another 
important factor is radio sensitivity. Indeed, a subgroup of thyroid carcinomas does not 
respond to RaI therapy, despite RaI uptake. Genetic alterations in radiation-induced 
apoptotic pathways, including p-53 or cdk-21 may be involved. Therefore, in the 
design of redifferentiation studies in thyroid carcinoma, this aspect should always be 
taken into account, ideally involving genetic studies in these pathways. 
Serum Tg levels in general paralleled radiological changes. However, tumor lysis 
during sorafenib or comparable compounds can lead to elevated Tg levels as was 
observed in one patient. This could be due to tumor lysis, but it could in theory also 
be caused by increased Tg synthesis as a result of enhanced differentiated behavior 
of thyroid carcinoma cells. 
Although sorafenib therapy had considerable adverse effects, no unexpected or 
new adverse effects were observed. Most of the adverse effects were temporary and 
could be managed with dose reduction or therapeutic measures. Weight loss was 
considerable, especially in patients with low weight at baseline, requiring dietary 
support or even catheter feeding. 
In conclusion, the results of our study confi rm the potential role of sorafenib in 
patients with non-RaI avid metastases of DTC. In addition, we found that patients 
with bone metastases respond less favorably, and that diagnostic WBS did not reveal 
an effect of sorafenib on the reinduction of RaI uptake in these patients. Future phase 
III studies should confi rm the effi cacy of sorafenib for DTC.
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Abstract
Background
Therapy with tyrosine kinase inhibitors is associated with thyroid dysfunction. 
Decreased serum thyroid hormone levels during tyrosine kinase inhibitors are also 
observed in athyreotic patients with thyroid carcinoma. We therefore hypothesized 
that tyrosine kinase inhibitors may infl uence thyroid hormone metabolism.
Aim
The aim was to study the effects of sorafenib therapy on serum thyroid hormone 
concentrations and iodothyronine deiodination in athyreotic patients.
Design
The design included a prospective open, single-center, single-arm 26-wk study. 
Methods
We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, re-
verse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with 
progressive non-medullary thyroid carcinoma treated with sorafenib. Ratios of T3/T4 
and T3/rT3, which are independent of substrate availability and refl ect iodothyronine 
deiodination, were calculated.
Results
Serum free T4 and T3 levels, adjusted for levothyroxine dose per kilogram body 
weight, decreased by 11 and 18%, respectively, whereas TSH levels increased. The 
serum T3/T4 and T3/rT3 ratios decreased by 18 and 22%, respectively, which is com-
patible with increased type 3 deiodination.
Conclusions
Sorafenib enhances T4 and T3 metabolism, which is probably caused by increased 
type 3 deiodination.
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Introduction
Therapy with tyrosine kinase inhibitors in patients with malignancies is associated 
with alterations in thyroid hormone parameters. Sunitinib has been associated with 
hypothyroidism in 14–85% of the patients, ranging from transient increases in 
TSH to persistent hypothyroidism, requiring thyroxine substitution (1–6). In some 
patients, sunitinib induced hyperthyroidism as well (7–9). Both sunitinib induced 
hypothyroidism and hyperthyroidism may be caused by destructive thyroiditis, but 
other mechanisms, such as interference of sunitinib with thyroid peroxidase (4) or 
inhibition of thyroidal vascularization leading to thyroid atrophy (10, 11), have been 
proposed. Likewise, sorafenib was associated with TSH elevations in 18% of patients 
with metastatic renal cell carcinoma (12). All of the above mentioned studies were 
performed in patients with intact thyroid glands. However, thyroid function abnor-
malities have also been observed during therapy with imatinib (13, 14), motesanib 
(15), and sorafenib (16) in athyreotic patients with medullary thyroid carcinoma and 
non-medullary thyroid carcinoma. Imatinib increased TSH levels in all patients with 
medullary thyroid carcinoma (13, 14). Therapy with motesanib caused TSH eleva-
tions in 22% of 93 patients with non-medullary thyroid carcinoma. Sorafenib was 
associated with increased TSH levels in 33% of thyroid carcinoma patients (16). 
Because an increased need of thyroxine is observed in athyreotic patients who are 
treated with tyrosine kinase inhibitors, the mechanisms of hypothyroidism may in-
clude alterations in thyroid hormone metabolism. Stepwise deiodination is the major 
route of thyroid hormone degradation and is mediated by iodothyronine deiodinases 
(D1, D2, and D3) (17) and by hepatic conjugating enzymes (18). No human studies 
have been published to address the effect of sorafenib on peripheral thyroid hormone 
metabolism. We therefore studied the effects of sorafenib, administered for 26 weeks, 
on peripheral thyroid hormone metabolism in athyreotic humans.
Patients and Methods
Design
The effects of sorafenib on peripheral thyroid hormone metabolism were analysed in 
an open, single center, single arm 26-week prospective phase II study, intended to 
achieve reinduction of RaI uptake in athyreotic patients with progressive metastatic 
or locally advanced non-medullary thyroid carcinoma. Results of this study have 
been published recently (19). Sorafenib was initially administered at a dose of 400 
mg orally twice daily. Exclusion criteria were pregnancy, contraindications for the 
application of recombinant human TSH (rhTSH), and contraindications for the use of 
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sorafenib. The institutional review board approved the study and all patients provided 
written informed consent.
Before initiation of sorafenib therapy and at 26 weeks, the patients underwent 
computed tomography scans for analysis of tumor dimensions and rhTSH (Thyro-
gen®, Genzyme, Naarden, The Netherlands) assisted 4 mCi diagnostic scintigraphies. 
During the study patients visited the hospital every month for assessment of thyroid 
function parameters, biochemical safety parameters and a physical examination. 
Fasting morning blood samples were stored at -80°C until analysis. All patients were 
treated with levothyroxine, which was adjusted if needed to maintain a target TSH 
concentration below 0.1 mU/L. Only patients who completed 26 weeks of treatment 
with sorafenib were included in the present analysis (per protocol analysis).
Study aims
The objective of this study was to evaluate the effects of sorafenib on thyroid hormone 
serum levels and to evaluate the effects of sorafenib on iodothyronine deiodinase activity. 
Study parameters
The following thyroid function parameters were measured: serum TSH, free thyroxine 
(FT4), total thyroxine (T4), free 3,5,3- triiodothyronine (FT3), total 3,5,3-triiodothyro-
nine (T3), and reverse 3,5,3-triiodothyronine (rT3). Because levothyroxine dosages 
were adjusted during the study according to serum TSH levels, serum thyroid hor-
mone levels were corrected for the daily levothyroxine dose and body weight. Dose-
adjusted FT4 was calculated as follows: (FT4 (pmol/liter) * weight (kg))/levothyroxine 
dose (μg).
To assess effects of sorafenib on iodothyronine deiodination, ratios of serum 
levels of T3/T4 and T3/rT3 were calculated. The T3/rT3 ratio is considered to be a 
sensitive indicator of the peripheral metabolism of thyroid hormone, being positively 
infl uenced by D1 and D2 deiodinase and negatively by D3 deiodinase. Serum thy-
roxine-binding globulin (TBG) levels and FT4/T4 and FT3/T3 ratios were calculated 
to exclude effects of sorafenib on thyroid hormone binding proteins.
Assays
Fasting blood samples were collected before daily levothyroxine ingestion at both 
baseline and 26 wk and stored at -80°C. TSH, FT4, T4, T3, and TBG were measured 
by chemiluminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical 
Diagnostics via GE Healthcare, Rochester, NY). FT3 was measured with a RIA (Trinity 
Dieke Hoftijzer BW.indd   86 23-02-11   15:19
Sorafenib and thyroid hormone metabolism 87
Biotech, Bray, Ireland). rT3 was measured with an in-house RIA (20). The detection 
limit of the TSH assay was 0.005 mU/liter. Within-assay coeffi cients of variation 
amounted to 4% for TSH, 2% for T4, 2% for T3, and 3–4% for rT3.
Statistics
Data are reported as mean ± SD, median (range) or proportions. Differences in thyroid 
hormone parameters were analyzed using the two tailed Student’s t-test for paired data, 
comparing measurements between baseline and after 26 weeks sorafenib therapy for 
normally distributed data or with a Wilcoxon test for non-normally distributed data. 
Differences were considered statistically signifi cant at P < 0.05. All calculations were 
performed using SPSS 16.0 for windows (SPSS, Chicago, IL)
Results
Between October 2007 and October 2008, a total of 32 patients were included in the 
study. Twenty-two patients completed the 26 weeks because one patient chose not to 
start therapy and nine patients discontinued treatment during the 26 wk for disease 
progression (four patients), adverse events (four patients), and the patient’s request 
(one patient) as reported previously (19). Because the thyroid hormone profi le of one 
patient was not recorded, 21 patients were included in the present analysis: seven 
females, 14 males, with a median age of 65 yr (range, 53–82 yr), all with distant 
metastases of nonmedullary thyroid carcinoma (local, 4%; lungs only, 29%; lungs 
and bones, 24%; lungs and local, 14%; other, 29%). The effi cacy of sorafenib with 
respect to tumor progression and the presence of adverse effects has been reported 
previously (19). Effects of sorafenib on study parameters are given in Table 1.
We observed a profound decrease in mean body weight of 6 kg. During the study, 
the levothyroxine dose per kilogram body weight was signifi cantly increased (2.48 
μg/kg before vs. 2.71 μg /kg after sorafenib; P=0.008) (Table 1, Figure 1). Neverthe-
less, TSH increased signifi cantly from 0.051 to 0.545 mU/liter (P=0.023). Despite the 
increase in thyroxine dose, signifi cant decreases in serum T3 (1.90 vs. 1.60 nmol/
liter) and dose-adjusted free T3 levels (1.59 vs. 1.35 pmol*kg/μg) were observed. 
Absolute rT3 levels tended to increase after sorafenib therapy, and T3/T4, T3/rT3, and 
T4/rT3 ratios decreased signifi cantly by 18, 22, and 7%, respectively, refl ecting an 
increased conversion of T4 into rT3. Potential effects of sorafenib on thyroid hormone 
binding proteins were assessed by measuring TBG levels, which were not infl uenced 
by sorafenib, and by calculating ratios of free over total T4 and T3 concentrations, 
which did not differ before and after sorafenib.
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Discussion
In this study, we assessed the relationship between treatment with the multiple 
target kinase inhibitor sorafenib and alterations in thyroid hormone parameters. 
Therapy with tyrosine kinase inhibitors is associated with hypothyroidism. Proposed 
mechanisms include direct effects of these drugs on the thyroid, including destructive 
thyroiditis (4,10,11). Because thyroid function abnormalities have also been observed 
in athyreotic patients on thyroxine substitution, the mechanisms of hypothyroidism 
may include alterations in thyroid hormone metabolism as well. We hypothesized 
that sorafenib may infl uence the activities of iodothyronine deiodinases (D1, D2, and 
D3) (17), which has not been studied in humans so far. We found that a higher sub-
stitution dose of thyroxine was needed to maintain serum FT4 levels. These fi ndings 
are consistent with a previous report in which eight imatinib treated patients that had 
undergone thyroidectomy required substantial increases in levothyroxine replace-
ment dose (13). Indeed, the increased need of levothyroxine may be underestimated 
because some patients may have been overtreated before initiation of the trial. In 
addition, we found a clear decrease in serum T3/T4, T3/rT3, and T4/rT3 ratios. These 
Table 1: Thyroid hormone parameters
N Baseline 26-weeks sorafenib P –value 
Weight (kg) 21 77.3 ± 13.5 71.0 ± 14.2 <0.001
Sorafenib dose (mg/kg/day) 21 10.4 ± 2.4 8.4 ± 2.7 0.003 
Levothyroxine dose (μg/kg/day) 21 2.48 ± 0.67 2.71 ± 0.61 0.008
T4 (nmol/L) 21 149.4 ± 31.9 152.9 ± 37.7 0.664
T3 (nmol/L) 20 1.90 ± 0.33 1.60 ± 0.34 0.007
FT4 (pmol/L) 21 27.3 ± 5.9 26.6 ± 6.9 0.587
FT4 (pmol/L)*weight (kg) / 
levothyroxine dose (μg)
21 11.7 ± 3.6 10.4 ± 3.6 0.034
FT3 (pmol/L) 13 5.43 ± 0.71 4.80 ± 1.09 0.075
FT3 (pmol/L)*weight (kg) / 
levothyroxine dose (μg)
13 1.59 ± 1.38 1.35 ± 1.15 0.005
rT3 (nmol/L) 20 0.68 (0.50-1.02) 0.79 (0.63-1.12) 0.091 *
TSH (mU/L) 21 0.01 (0.005-0.33) 0.100 (0.005-4.670) 0.023 *
TBG (mg/L) 21 19.8 ± 4.3 19.5 ± 4.0 0.620
FT3/T3 * 103 13 2.73 ± 0.33 2.93 ± 0.31 0.279
FT4/T4 * 103 21 5.55 ± 0.94 5.84 ± 0.95 0.124
T3/T4 * 100 20 1.28 ± 0.00 1.05 ± 0.00 <0.001 
T3/rT3 20 2.74 ± 0.50 2.16 ± 0.53 <0.001
T4/rT3 20 220 ± 27 205 ± 32 0.036
Data expressed as mean ± SD or median (range)
* Wilcoxon -test
Dieke Hoftijzer BW.indd   88 23-02-11   15:19
Sorafenib and thyroid hormone metabolism 89
1,50
2,00
2,50
3,00
3,50
4,00
1 2 3 4 5 6
Time[Months]
D
os
eT
hy
ro
xi
ne
[u
g/
K
g]
10
15
20
25
30
35
FT
4[
pm
ol
/
L]
Dose/Kg
FT4
1,0
1,5
2,0
2,5
3,0
3,5
4,0
Baseline 6Months
Ra
ti
o
T3
/
rT
3
Figure 1
(A) Relation between levothyroxine dose adjusted for body weight (Dose Thyroxine) and serum FT4 
concentrations during 6 months of treatment with sorafenib. (B) Individual T3/rT3 ratios before and 6 
months after treatment with sorafenib.
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ratios refl ect alterations in the peripheral metabolism of thyroid hormone, being posi-
tively infl uenced by deiodinases D1 and D2 and negatively by D3 (17). Moreover, 
they are independent of levothyroxine administration. The decreased T3/T4 and T3/
rT3 ratios may be caused by a decrease in D1 and/or D2 activity. However, this would 
be associated with a decreased rather than an increased T4 metabolism. Therefore, 
the decreased T3/T4 and T3/rT3 ratios are best explained by an increased D3 activity. 
The fact that, 2 months after the start of sorafenib, a signifi cantly higher T4 dose 
per kilogram body weight was necessary to maintain FT4 concentrations strongly 
suggests that the phenomenon is already present early after initiation of sorafenib 
therapy. It is worthwhile to further elucidate the effects of sorafenib on D3 in in-vitro 
studies. It is unlikely that the increased D3 activity refl ects a state of non thyroidal 
illness because serum TSH increased during sorafenib, whereas in non thyroidal ill-
ness, decreased rather than increased TSH levels would be expected. Although it can 
be hypothesized that decreased absorption of T4 could also have played a role, the 
interval between sorafenib and thyroxine intake was approximately 12 h. In addition, 
decreased T4 absorption would not affect T3/T4 and T3/rT3 ratios. No changes in TBG 
levels and the ratios between free and bound thyroid hormones were observed, ruling 
out effects of sorafenib on thyroid hormone binding proteins, which again, even if 
present, would not have affected the T3/rT3 ratio. It may hypothesized that sorafenib 
may also infl uence conjugation of thyroid hormone with glucuronates and sulfates 
by hepatic microsomal enzymes. However, altered conjugation would not infl uence 
T3/rT3 ratios. The fact that the increase in overall rT3 levels was non signifi cant may 
suggest that rT3 degradation may be enhanced as well. It is likely that, because rT3 
is the preferred substrate for type 1 deiodinase (in the absence of hyperthyroidism), 
increased rT3 may lead to enhanced type 1 deiodinase-mediated rT3 degradation. 
In conclusion, this study shows that, in addition to direct effects of tyrosine kinase 
inhibitors on the thyroid gland, enhanced peripheral metabolism of thyroid hormone, 
likely by activity of type 3 deiodinase, may contribute to hypothyroidism during 
therapy with these drugs.
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Abstract
Objective
The type 2 deiodinase (D2)-Thr92Ala polymorphism has been associated with de-
creased D2 activity in some in-vitro experiments but not in others. So far no associa-
tion between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has 
been observed in humans, but in a recent study in athyroid patients, it was suggested 
that patients homozygous for the 92Ala allele needed higher T4 doses to achieve TSH 
suppression. We studied the association between the D2-Thr92Ala polymorphism 
with thyroid hormone levels and T4 dosage, in patients treated for differentiated 
thyroid carcinoma (DTC) and in a group of patients treated for Hashimoto thyroiditis. 
Patients 
We studied 154 patients with DTC treated with TSH suppressive thyroid hormone 
replacement therapy for longer than 3 years and 141 patients with Hashimoto thy-
roiditis treated for at least 6 months with T4.
Measurements
In all patients, serum levels of TSH, free T4, T3 and reverse T3 were measured and 
genotypes of the D2-Thr92Ala polymorphism were determined by Taqman assay. 
Univariate regression analysis was performed to determine the relation between T4 
dosages and the D2-Thr92Ala polymorphism corrected for age, gender, BMI and 
serum TSH levels.
Results
Both in DTC patients and Hashimoto patients, no association was observed between 
serum thyroid hormone levels or T4 dosages in presence of the D2-Thr92Ala poly-
morphism. Categorization of DTC patients according to degree of TSH suppression 
did not change these results.
Conclusion
The D2-Thr92Ala polymorphism is not associated with thyroid hormone levels or T4 
dose in patients treated for DTC or Hashimoto thyroiditis.
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Introduction
Most actions of thyroid hormone are mediated by the active form of thyroid hormone, 
T3. Serum and local T3 concentrations are mainly regulated by the iodothyronine 
deiodinases D1, D2 and D3 (1). D2 is essential for the local production of T3 through 
deiodination of T4. D2 is thus essential for the negative feedback regulation of thyroid 
hormone on TSH production in the pituitary. Several polymorphisms in D2 have 
been described (2–5). Controversy exists about the functional implications of the 
D2-Thr92Ala polymorphism, which has been associated with a decreased D2 activity 
in some in-vitro experiments (2) but not in others (5). So far no associations were 
found between the D2-Thr92Ala polymorphism and serum thyroid hormone levels 
in studies in healthy subjects (4,6,7). Torlontano et al. reported in thyroidectomized 
differentiated thyroid carcinoma (DTC) patients that homozygous carriers of the D2-
Ala92 allele needed higher dosages of T4 (8). This difference was most prominently 
observed in the group with near-suppressed TSH (TSH values between 0.1 and 0.5 
mU/l). Limitations of this study were that actual values of serum TSH levels for wild-
type and homozygous groups within the near-suppressed TSH group were not given. 
It is therefore unclear whether TSH levels in both groups were indeed identical, 
which would be a key fi nding to ascribe the slight differences in T4 dose indeed to 
the polymorphism. The fact that serum T4 and T3 levels did not differ between the 
wild-type group and D2-Thr92Ala homozygotes is also remarkable. Moreover, as 
TSH is a continuous variable, we believe that the optimal analytic strategy would be 
by regression analysis, rather than a categorized approach. We therefore performed 
this study to reconfi rm the fi ndings of Torlontano et al. For this reason, we studied the 
association between the D2-Thr92Ala polymorphism and thyroid hormone levels and 
T4 dosage in 154 patients treated for DTC and 141 patients substituted with T4 for 
Hashimoto thyroiditis, using a linear regression model. In addition, we performed a 
categorized analysis to allow maximal comparability with the Torlontano study.
Patients and methods
Patients
Patients treated for DTC were recruited from the outpatient clinic of the Department 
of Endocrinology of the Leiden University Medical Center. All patients had been 
treated by near-total thyroidectomy followed by radioiodine ablation. After initial 
treatment, T4 therapy was started in a dose intended to suppress TSH levels below 0.4 
mU/l for 15 years. All patients were cured as defi ned by the absence of 131-Iodine 
accumulation at diagnostic scintigraphy, serum thyroglobulin (Tg) concentrations 
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below 2 μg/l after TSH stimulation in the absence of Tg antibodies, a normal neck 
ultrasound and no other indication for disease. Patients with tumor relapse were only 
included if they had been subsequently cured. The Local Ethics Committee of the 
Leiden University Medical Center approved the study, and written informed consent 
was obtained from all subjects.
We also included 141 patients treated for at least 6 months with T4 therapy for 
Hashimoto thyroiditis. Serum TSH levels were between 0.11 and 4.0 mU/l. These 
patients were described earlier by Appelhof et al. (9).
Study design
After an overnight fast, patients had a physical examination, including, height (me-
ters [m]) and weight (kilograms [kg]). Blood was collected for determination of TSH, 
free T4 (FT4), T3 and reverse T3 (rT3). Serum samples were handled immediately 
and stored at –80 ° C in Sarstedt tubes. DNA was collected for genotyping of the 
D2-Thr92Ala polymorphism. To be able to compare our study with the study of 
Torlontano et al. (8) patients were categorized in groups with a suppressed TSH (< 
0.1 mU/l), near-suppressed TSH (0.1–0.5 mU/l) or non-suppressed TSH (> 0.5 mU/l). 
Serum biochemistry
In the patients treated for DTC, serum FT4 and TSH were measured using a chemo-
luminescence immunoassay with a Modular Analytics E-170 system (intra-assay CV 
of 1.6–2.2% and 1.3–5.0%, respectively (Roche, Almere, the Netherlands). Serum 
T3 was measured with a fl uorescence polarization immunoassay, CV 2.5–9.0%, on 
an ImX system (Abbott, Abbott Park, IL). Reverse T3 was measured using a RIA as 
described previously (10). In the patients treated for Hashimoto thyroiditis, serum 
TSH and FT4 were measured by time-resolved fl uoroimmunoassay and serum T4 and 
T3 by in-house RIA methods (6). 
Genotyping
DNA was isolated from peripheral leucocytes by the salting out procedure (11). 
Genotypes of the D2-Thr92Ala polymorphism (rs225014) were determined using 5 
ng genomic DNA in a 5′ fl uoregenic Taqman assay and reactions were performed in 
384-wells format on ABI9700 2 × 384-well PCR machines with end-point reading 
on the ABI 7900HT TaqMan® machine (Applied Biosystems, Nieuwerkerk aan den 
IJssel, the Netherlands). Primer and probe sequences were optimized using the single 
nucleotide polymorphism assay-by design service of Applied Biosystems.
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Statistical analysis
Values are presented as mean ± standard deviation (SD), median (range) or as num-
bers or proportions of patients. Deviation from Hardy–Weinberg Equilibrium was 
analyzed using a χ 2 -test. Dominant (Thr/Thr vs. Ala/X) and recessive (Thr/X vs. 
Ala/Ala) effects of the polymorphism were analyzed. The association between D2-
Thr92Ala genotypes and T4 dosages or thyroid hormone levels was analyzed using 
multivariate regression analyses. This was corrected for age, gender, BMI and the 
natural logarithm of TSH levels. In addition, differences between the different D2 
genotype groups were analyzed using unpaired t -test or ANCOVA. All calculations 
were performed using SPSS 12.0 for windows (SPSS, Inc., Chicago, IL). Differences 
were considered statistically signifi cant at P < 0.05.
Results
Patient characteristics
We studied 154 DTC patients. Mean duration of TSH suppressive therapy was 9.2 
years (range 0.5–42.6 years). Median duration of cure was 8.9 years (range 1.0–41.8 
years). The mean dose of T4 was 183 ± 51 μg/day. Mean T4 dose was 2.2 ± 1.0 μg/kg 
body weight. We also studied 141 patients with Hashimoto thyroiditis on T4 replace-
ment therapy. Genotyping of the D2-Thr92Ala polymorphism failed in two subjects. 
The remaining 139 patients were treated with T4 for a mean duration of 7.3 ± 5.8 
years. Mean T4 dose was 125 ± 46 μg/day. 
Thyroid hormone parameters and D2-Thr92Ala
Allele frequencies of the D2-Thr92Ala polymorphism in the DTC patients and Hashi-
moto thyroiditis patients were 39.6% and 40.3%, respectively. The genotype distribu-
tions did not deviate from Hardy–Weinberg equilibrium. Thyroid hormone levels and 
T4 dose for patients with DTC and Hashimoto thyroiditis are presented in Table 1. No 
differences were observed in thyroid hormone levels and T4 dose, corrected for BMI 
and TSH levels between wild-type, heterozygous and homozygous carriers of the D2-
Thr92Ala polymorphism. Analyses were comparable when T4 dose was corrected for 
BMI. No differences were observed in the correlation between lnTSH and T4 dose/kg 
or FT4 level for the different carriers of the D2-thr92ala polymorphism (Figure 1a–d).
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Discussion
We studied the association between the D2-Thr92Ala polymorphism and thyroid hor-
mone levels and T4 dose in two separate groups of patients, treated for DTC or Hashi-
moto thyroiditis. Frequencies of the alleles of D2-Thr92Ala are in agreement with 
previous studies varying between 30.0% and 38.8% in patient with normal thyroid 
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Figure 1 
(A) Correlation between the natural logarithm of TSH and T4 dosage/kg for the different alleles of D2-
Thr92Ala polymorphism in 154 patients with differentiated thyroid carcinoma. Lines: regression lines; 
bars: 95% confi dence intervals of regression lines. (B) Correlation between the natural logarithm of 
TSH and FT4 for the different alleles of D2-Thr92Ala polymorphism in 154 patients with differentiated 
thyroid carcinoma. Lines: regression lines; bars: 95% confi dence intervals of regression lines. (C) 
Correlation between the natural logarithm of TSH and T4 dosage/kg for the different alleles of D2-
Thr92Ala polymorphism in 139 patients treated for Hashimoto thyroiditis. (D) Correlation between 
the natural logarithm of TSH and FT4 for the different alleles of D2-Thr92Ala polymorphism in 139 
patients treated for Hashimoto thyroiditis.
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function or not taking thyroid replacement or thyreostatic medication (3,4,6,7). The 
D2-Thr92Ala polymorphism was not associated with thyroid hormone parameters or 
T4 dosages in the two separate groups of patients included in our analyses. This is 
in accordance with previous studies (4–7). Torlontano et al. found that homozygous 
DTC carriers of the D2-Ala92 allele need higher T4 dosages (8). This association 
was observed in the near-suppressed TSH group, but not in the suppressed group. 
The study of Torlontano et al. has however, several limitations. TSH levels in the 
near-suppressed group of the different alleles were not given, which would have been 
useful to investigate whether the differences in T4 dose are not caused by alterations 
in TSH levels. In our study, no differences were observed in TSH levels or T4 dose for 
the different alleles with and without categorization according to the degree of TSH 
suppression in the DTC patients or Hashimoto patients. In addition, we believe that 
the analysis strategy should be primarily based on regression analysis rather than TSH 
categories, because for alterations in TSH levels should be corrected.
Remarkably, they did not fi nd any differences in thyroid hormone levels suggest-
ing that patients with D2-Ala92 alleles need a higher T4 dose to reach the same serum 
FT4 level. By inference, the Ala allele would not affect T4 feedback but rather T4 
resorption. Torlontano et al. explain the discrepancies of their fi ndings with previous 
studies by two arguments. First, they state that in previous studies thyroid hormone 
levels were within the wide reference range, which makes is diffi cult to detect subtle 
differences in thyroid hormone levels for different carriers of the D2-Thr92Ala poly-
morphism. However, they found this difference only in the near-suppressed group, 
which is an ill-defi ned group with a wide plasma TSH range including patients with 
normal TSH levels. Second, Torlontano et al. argue that the difference between their 
fi nding and earlier studies may be explained by the absence of a thyroid gland in 
their patients. However, in our analysis with athyroid DTC and Hashimoto patients, 
we could not confi rm this. A post hoc power analysis for T4 dose and T4/kg showed 
a suffi cient power of 100%. Therefore, it seems unlikely that underpowering of our 
study plays a major role in the negative fi ndings.
In summary, we found no association between the D2- Thr92Ala polymorphism 
and thyroid hormone levels and T4 dose in two separate groups of patients treated for 
DTC or Hashimoto thyroiditis.
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Abstract
Context
Iodothyronine deiodinases D1, D2 and D3 play an important role in synthesis and 
degradation of T3. The relationship between serum TSH and T3 levels is determined 
by an individual setpoint of the hypothalamus-pituitary-thyroid axis. 
Objective
Several polymorphisms have been described in D1 and D2 of which some are associ-
ated with serum TSH and iodothyronine levels. In this study we investigate whether 
polymorphisms of D1 and D2 infl uence the setpoint of the hypothalamus-pituitary-
thyroid-axis.
Design
We collected 1905 serum FT4 and TSH measurements during 11.5±8.8 years of 
follow-up in patients treated for differentiated thyroid carcinoma (DTC). We deter-
mined these polymorphisms: D1-rs11206244, D1-rs12095080, D2-rs225014 and 
D2-rs12885300. Effects of these polymorphisms on the setpoints of the hypothalamus-
pituitary-thyroid-axis were analysed with a linear mixed model.
Patients
151 consecutive patients treated and cured for DTC were included 
Results
DTC patients homozygous for the D2-rs12885300 T allele have an altered setpoint 
of the hypothalamus-pituitary-thyroid axis. The slope of the regression line (corrected 
for age, BMI and gender) for wild-type patients was -0.32±0.028 (ln[TSH mU/l]/[FT4 
pmol/l]), the intercept 4.95. For heterozygous patients the slope was -0.30±0.028 
(ln[TSH mU/l]/[FT4 pmol/l]), the intercept 4.23. The slope of homozygous patients 
was -0.35±0.026 (ln[TSH mU/l]/[FT4 pmol/l]) and the intercept 6.07 (P =0.036 com-
pared to wild-type and heterozygous patients).
Conclusion
Our data suggest that the negative feedback of FT4 on TSH is weaker in patients 
homozygous for the D2-ORFa-Gly3Asp than in wild-type and heterozygous subjects. 
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Background
Thyroid hormone has an important role in a wide range of physiological processes: 
from growth and development in children to energy homeostasis in the adult (1). Most 
actions of thyroid hormone are mediated by the active form of thyroid hormone, triio-
dothyronine (T3). Serum T3 levels are relatively constant in healthy subjects. Serum and 
local T3 concentrations are mainly regulated by the iodothyronine deiodinases D1, D2 
and D3 (2). D1 is mainly involved in serum T3 production. In addition, it plays a role in 
the breakdown of rT3 (3,4). D2 catalyzes local T3 production through deiodination of 
T4 production in various tissues and is necessary for the negative feedback regulation 
of thyroid hormone on thyrotropin (TSH) production in the pituitary (5). Approximately 
80% of T3 is produced by extrathyroidal pathways (2). D3 inactivates T3 and T4 and 
thus regulates the clearance of T3 and T4. It is thought to contribute to thyroid hormone 
metabolism by protecting tissues from excess thyroid hormone. The deiodinases adjust 
the thyroid hormone levels of individual tissues in response to various conditions (6,7).
Several polymorphisms have been described in D1 and D2 of which some are 
associated with circulating levels of T4, T3 and TSH (8,9,10,11). Two polymorphisms in 
the D1 gene, D1-rs11206244 (previously D1-C785T) and D1-rs12095080 (previously 
D1-A1814G), have been associated with changes in the balance of thyroid hormones in 
the serum, with raised T3, low T4 and low rT3 levels, but these changes have not been 
associated with differences in TSH. This implies that the net effect is perceived by the 
hypothalamus and pituitary as “neutral” (1,12,13,14). However, the D1-rs11206244 
is in linkage disequilibrium with another single-nucleotide polymorphism (SNP) 
rs2235544 which did show a distinct association with circulating FT3/FT4 ratio (11).
Controversy exists about the functional implications of the D2-rs225014 (previ-
ously D2-Thr92Ala) polymorphism, which has been associated with a decreased D2 
activity in some in-vitro experiments (9), but not in others (13). So far only one study 
found an association between the D2-rs225014 polymorphism and serum thyroid 
hormone levels (15), however a previous study performed by our department could 
not confi rm these data (16). A recent study by Butler et al. performed a prospective 
intervention study which aimed at demonstrating in-vivo effects of the Thr92Ala D2 
variant. They found subtle differences in the serum changes of total T3 in the Ala/Ala 
subjects 60 minutes after TRH injection. However, there were no signifi cant differences 
in the response of FT4 and TSH after TRH injection (17).
In healthy blood donors the D2-ORFa-Asp variant (rs12885300) was associated 
with lower levels of serum T4, fT4 and rT3, but not with plasma T3 and TSH levels (8). 
This suggests that the D2-rs1288530 polymorphism leads to higher activity of D2 at the 
pituitary level. However, this association was not seen in elderly men (8).
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Intraindividual variation in serum T4, T3 and TSH is narrow; however there is a 
considerable interindividual variability (18). A large body of evidence suggests that 
every individual has a unique thyroid function setpoint, compatible with a genetic 
infl uence on the regulation of the pituitary-thyroid axis (18,19,20). We hypothesized 
that polymorphisms in D1 and D2 could infl uence the setpoint of the hypothalamus-
pituitary-thyroid axis. We tested this hypothesis in 151 patients treated for differentiated 
thyroid carcinoma (DTC). These individuals have no endogenous thyroid hormone 
production and thus no interference of the intrinsic T3 production of the thyroid. Dur-
ing follow-up of DTC, patients are treated with thyroxine substitution therapy in a dose 
intended to suppress TSH level, which results in a constant and precisely measurable 
supply of T4. During this period they regularly come for routine measurements of TSH 
and FT4, moreover they are regularly withdrawn from thyroxine to perform TSH stimu-
lated radioactive iodine-131 whole body imaging, which leads to a wide individual 
range of combined measurements of TSH and FT4. These patients are therefore an 
ideal group to assess the relationship between polymorphisms in deiodinases and the 
setpoint of the hypothalamus-pituitary-thyroid axis.
Patients and Methods
Patients
One hundred and fi fty-one consecutive patients treated for DTC were recruited from the 
outpatient clinic of the Department of Endocrinology of the Leiden University Medical 
Center, a tertiary referral center for thyroid carcinoma. All patients had been treated by 
near-total thyroidectomy followed by radioiodine ablation between 1992 and 2007. After 
initial treatment, thyroxine therapy was started in a dose intended to suppress TSH levels 
below 0.4 mU/l for 15 years. All patients were cured as defi ned by the absence of I-131 
accumulation at diagnostic scintigraphy, serum thyroglobulin (Tg) concentrations below 
2 μg/l after TSH stimulation in the absence of Tg antibodies, a normal neck ultrasound 
and no other indication for disease. Patients with tumor relapse were only included if they 
had been subsequently cured. Patients that used corticosteroids or psychopharmaca that 
could alter serum TSH or FT4 levels (amiodarone, dopamine, phenytoin, lithium) were 
excluded from the study. The Local Ethics Committee of the Leiden University Medical 
Centre approved the study, and written informed consent was obtained from all subjects.
Study design
We collected all FT4 and TSH measurements since the initial diagnosis of the patients 
with the exception of recombinant human (Thyrogen) stimulated TSH levels. Blood 
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was collected for regular outpatient clinic appointments from 1992 till 2007. In 2007, 
blood was collected for DNA isolation for genotyping of the deiodinase type 1 and 
2 polymorphisms, and for measurements of T3 and rT3 in addition to TSH and FT4. 
Serum biochemistry
Serum free T4 concentrations were measured throughout the study period on an IMx 
system (Abbott, Abbott Park, IL) (intra-assay variability of 2.5–7.6% and interassay 
variability of 5.6–12.4% at different levels). Serum TSH concentrations were deter-
mined throughout the study period with Elecsys E-170 on a Modular Analytics E-170 
system (Roche Diagnostic Systems, Basel, Switzerland; reference range 0.4–4.5 mU/
liter, detection limit 0.005 mU/liter, intraassay variability 0.9–10.7%, and interassay 
variability 0.9–12.1%). Serum T3 was measured with a fl uorescence polarization im-
munoassay, CV 2·5–9·0%, on an ImX system (Abbott, Abbott Park, IL). Reverse T3 was 
measured using a RIA as described previously (20).
Genotyping
DNA was isolated from peripheral leucocytes by the salting out procedure (21). 
Genotypes of the D1 and D2 polymorphisms were determined using 5 ng genomic 
DNA in a 5’ fl uoregenic Taqman assay and reactions were performed in 384-wells 
format on ABI9700 2x384well PCR machines with endpoint reading on the ABI 
7900HT TaqManÒ machine (Applied Biosystems, Nieuwerkerk aan den IJssel, The 
Netherlands). Primer and probe sequences were optimized using the single nucleo-
tide polymorphism assay-by-design service of Applied Biosystems.
Statistical Analysis
Values are presented as mean ± standard deviation (SD), median (range) or as 
numbers or proportions of patients. Deviation from the Hardy-Weinberg Equilibrium 
was analysed using a X2-test. For the comparison of setpoints of the hypothalamus-
pituitary-thyroid axis, we used a regression analysis with a general mixed model with 
a random intercept and random slope to assess the correlation between the natural 
logarithm of TSH (lnTSH) and FT4 for the different alleles of the polymorphisms. 
Herewith, we tested if the regression lines (with the equation lnTSH= β ∙FT4+α, where 
β is the slope and α is the intercept) were similar in slopes given a random intercept. 
We had different numbers of combined TSH/FT4 measurements for each individual. 
With our model the regression lines of patients were compared independently of the 
number of blood samples (combined TSH/FT4 measurements) available. However, 
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regression lines are expected to be more accurate if an individual patient had more 
TSH/FT4 measurements. In our model, we corrected for sex, BMI and age at time of 
the blood sampling, since these parameters can infl uence the lnTSH/FT4 relationship.
All calculations were performed using SPSS 17.0 for windows (SPSS, Inc., Chi-
cago, IL). Differences were considered statistically signifi cant at P<0.05.
Results
Patient characteristics
Patient characteristics are summarized in Table 1. We studied 151 DTC patients, 28 
males and 123 females. At the timepoint of the blood sampling for the determination 
of the different alleles of the deiodinase type 1 and 2 polymorphisms, mean age was 
49.1 ± 12.9, mean dose of thyroxine 183 ± 51 μg/day and mean duration of follow-up 
11.5 ± 8.8 years.
We identifi ed a total of 3121 blood samples routinely obtained during follow up 
between 1992 and 2007. In 1905 of these samples both TSH and FT4 were measured 
and these values were used for this study. Mean number of measurements per patient 
was 12.53 ± 5.49 (range 4-32).
During this period, patients were regularly withdrawn from thyroxine for routine 
TSH stimulated radioiodine-131 whole body scanning. Therefore, the TSH (and FT4) 
values have a very wide range (see Table 2).
Genotyping failed in 3 patients for the D1-rs11206244 polymorphism, in 4 
patients for the D1-rs12095080 polymorphism, in 3 patients for the D2-rs225014 
polymorphism and in 4 patients for the D2-rs12885300 polymorphism.
Polymorphisms in deiodinases and values of TSH and FT4
Detailed information on genotype frequencies of the two deiodinases is given in Table 2.
For the D1-rs11206244 (D2-C785T) polymorphism 66 patients were wild type 
(C/C), 58 patients were heterozygous (C/T) and 24 patients were homozygous variant 
carriers (T/T). For the D1-rs12095080 (D1-A1814G) polymorphism, 125 patients were 
wild type (A/A), 19 patients were heterozygous (A/G) and only 3 were homozygous 
(G/G). The D2-rs225014 polymorphism (D2-Thr92Ala) was more equally distributed: 
56 patients were wild type (Thr/Thr), 64 heterozygous (Thr/Ala) and 28 homozygous 
(Ala/Ala). For the D2-rs12885300 (D2-ORFa-Gly3Asp) polymorphism, 70 patients 
were wild type (Gly/Gly), 64 patients were heterozygous (Gly/Asp) and 13 patients 
were homozygous (Asp/Asp). The genotype distributions did not deviate from the 
Hardy-Weinberg equilibrium.
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Correlation between TSH and FT4 for the different alleles of the D1 and the 
D2 polymorphisms
We used a linear mixed model analysis to compare the slopes of the regression lines 
between lnTSH and FT4 for the different alleles of the D1 and D2 polymorphisms. 
Interestingly, the regression lines of the D2-rs12885300 (D2-ORFa-Gly3Asp) poly-
morphism for wild type and heterozygous patients were signifi cantly different from 
the regression line of homozygous subjects (Table 2, Figure 1). The slopes were com-
parable; however the intercept for homozygous patient was signifi cantly higher. The 
slope of the regression line for wild type patients was -0.322 ± 0.028 (ln[TSH mU/l]/
[FT4 pmol/l]) with an intercept of 4.95. For heterozygous patients the slope was also 
-0.299 ± 0.028 (ln[TSH mU/l]/[FT4 pmol/l]) with an intercept of 4.23. The slope of the 
homozygous patients was -0.347 ± 0.026 (ln[TSH mU/l]/[FT4 pmol/l]), whereas the 
intercept was 6.07 (p = 0.036 vs. wild-type and heterozygous subjects).
Table 1: Patient characteristics
Patients
(n=151)
Age (yr, mean ± SD) 49.10 ± 12.93
Sex (M/F) 28/123
Tumor stage
Unknown 6
T0 N1 M0 1
T0 N1 M1 1
IA T1 N0 M0 8
IB T2 N0 M0 72
IIA T1 N1 M0 7
IIB T2-3 N0-1 M0 28
IIIA T1-3 N1-2 M0 6
IIIB T1-3 N3 M0, T4, any N M0 18
IV Any T, any N, M1 4
Histology Tumor
Papillary (n) 104
Papillary-follicular variant (n) 21
Follicular (n) 25
Follicular-Hurtle cell (n) 1
Duration of follow-up (yr) (mean ± SD) 11.45 ± 8.86
Total number of blood samples 3121
Number of blood samples with both TSH and FT4 1905
Number of measurements per patient 12.53 ± 5.49 (range 4-32)
L-thyroxin dose (μg/day) (mean±SD) 182.87 ± 50.84
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Table 2: Distribution of sample size, thyroid hormone parameters
Deiodinase type 1 C785T polymorphism
Setpoint analysis 1992-2007 Wild type Heterozygous Homozygous
N (3 missing polymorphisms) 66 58 24
Number of blood samples 885 739 245
FT4 (pmol/l) (mean ± SD) 21.17 ± 5.63 21.27 ± 6.26 22.08 ± 5.219
TSH (mU/l) (median(range)) 0.13 (0.004-289) 0.14 (0.005-365) 0.07 (0.005-256)
LnTSH (median(range)) -2.04 (-5.52-5.67) -1.96 (-5.3-5.9) -2.66 (-5.3-5.55)
β (slope) (ln[TSH mU/l]/[FT4 pmol/l]) 
(mean ± SD)
-0.269 ± 0.023 -0.275 ± 0.024 -0.296 ± 0.021
Intercept (mean ± SD) 5.82 ± 0.58 5.53 ± 0.58 5.08 ± 0.82
Cross-sectional data 2007
TSH (mU/l) 0.63 ± 1.36 0.28 ± 0.64 0.41 ± 1.01
T4 (nmol/l) 138.33 ± 33.67 141.78 ± 45.07 133.04 ± 41.51
T3 (nmol/l) 1.47 ± 0.31 1.50 ± 0.36 1.37 ± 0.33
T3/T4 ratio 0.011 ± 0.002 0.011 ± 0.002 0.011 ± 0.004
rT3 (nmol/l) 0.57 ± 0.24 0.51 ± 0.19 0.54 ± 0.20
Deiodinase type 1 A1814G polymorphism
Setpoint analysis 1992-2007 Wild type Heterozygous Homozygous
N (4 missing polymorphisms) 125 19 3
Number of blood samples 1570 260 33
FT4 (pmol/l) (mean ± SD) 21.61 ± 5.83 21.27 ± 5.73 22.96 ± 6.57
TSH (mU/l) (median(range)) 0.12(0.04-364) 0.17 (0.05-324) 0.10 (0.05-93)
LnTSH (median(range)) -2.12 (-5.52-5.90) -1.77 (-5.30-5.78) -2.32 (-5.30-4.53)
β (slope) (ln[TSH mU/l]/[FT4 pmol/l]) 
(mean ± SD)
-0.338 ± 0.061 -0.323 ± 0.023 -0.317 ± 0.008
Intercept (mean ± SD) 4.96 ± 1.48 5.70 ± 0.55 5.52 ± 0.67
Cross-sectional data 2007
TSH (mU/l) 0.44 ± 1.01 0.63 ± 1.23 0.09 ± 0.13
T4 (nmol/l) 137 ± 37.64 151.70 ± 50.05 115.37 ± 19.09
T3 (nmol/l) 1.46 ± 0.33 1.46 ± 0.40 1.55 ± 0.43
T3/T4 ratio 0.011 ± 0.003 0.010 ± 0.002 0.013 ± 0.003
rT3 (nmol/l) 0.56 ± 0.23 0.52 ± 0.14 0.41 ± 0.05
Deiodinase type 2 Thr92Ala polymorphism
Setpoint analysis 1992-2007 Wild type Heterozygous Homozygous
N (3 missing polymorphisms) 56 64 28
Number of blood samples 781 777 311
FT4 (pmol/l) (mean ± SD) 21.73 ± 5.93 21.63 ± 5.79 21.10 ± 5.73
TSH (mU/l) (median(range)) 0.12 (0.05-364) 0.10 (0.04-365) 0.14 (0.05-324)
LnTSH (median(range)) -1.85 (-5.30-5.67) -2.30 (-5.50-5.90) -1.96 (-5.30-5.78)
β (slope) (ln[TSH mU/l]/[FT4 pmol/l]) 
(mean ± SD)
-0.313 ± 0.022 -0.319 ± 0.022 -0.315 ± 0.018
Intercept (mean ± SD) 5.64 ± 0.54 5.47 ±0.53 5.29 ± 0.77
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Cross-sectional data 2007
TSH (mU/l) 0.44 ± 0.99 0.37 ± 0.87 0.66 ± 1.60
T4 (nmol/l) 144.80 ± 34.96 135.30 ± 44.38 133.26 ± 34.29
T3 (nmol/l) 1.49 ± 0.28 1.46 ± 0.38 1.40 ± 0.33
T3/T4 ratio 0.011 ± 0.001 0.011 ± 0.003 0.011 ± 0.002
rT3 (nmol/l) 0.58 ± 0.23 0.52 ± 0.21 0.55 ± 0.19
Deiodinase type 2 ORFa-Gly3Asp polymorphism
Setpoint analysis 1992-2007 Wild type Heterozygous Homozygous
N (3 missing polymorphisms) 70 64 13
Number of blood samples 865 818 199
FT4 (pmol/l) (mean ± SD) 21.90 ± 5.95 21.44 ± 5.68 21.02 ± 5.71
TSH (mU/l) (median(range)) 0.12 (0.05-364) 0.11(0.05-218) 0.24 (0.05-131)
LnTSH (median(range)) -2.12 (-5.30-5.90) -2.21 (-5.52-5.39) -1.42 (-5.30-4.88)
β (slope) (ln[TSH mU/l]/[FT4 pmol/l]) 
(mean ± SD)
-0.322 ± 0.028 -0.299 ± 0.028 -0.347 ± 0.026
Intercept (mean ± SD) 4.95 ± 0.66 4.23 ± 0.66 6.07 ± 0.86
Cross-sectional data 2007
TSH (mU/l) 0.51 ± 1.15 0.39 ± 1.05 0.52 ± 0.90
T4 (nmol/l) 138.03 ± 42.98 136.68 ± 37.29 152.67 ± 20.13
T3 (nmol/l) 1.45 ± 0.33 1.45 ± 0.36 1.58 ± 0.23
T3/T4 ratio 0.011 ± 0.003 0.011 ± 0.002 0.010 ± 0.001
rT3 (nmol/l) 0.56 ± 0.21 0.50 ± 0.19 0.71 ± 0.33 
Table 2: Continued
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Figure 1 
Correlation between the natural logarithm of serum levels of TSH and serum levels of FT4 for the D2-
ORFa-Gly3Asp polymorphism in 151 patients with differentiated thyroid carcinoma.
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Discussion
This study demonstrates that thyroidectomised DTC patients on thyroxine substitution 
who are homozygous for the D2-rs12885300 (D2-ORFa-Gly3Asp) polymorphism 
have an altered setpoint of the hypothalamus-pituitary-thyroid axis. This study com-
prises a unique series of 1905 combined TSH and FT4 measurements. The mixed 
model analysis of the TSH/FT4 ratios is a precise approach to determine differences 
in individual setpoints. Our data suggest that the negative feedback of T4 on TSH is 
weaker in patients homozygous for the D2-rs12885300 (D2-ORFa-Gly3Asp) than 
in wild-type and heterozygous subjects. This is demonstrated by a higher lnTSH in 
combination with equal FT4 levels for homozygous patients. 
Patients treated for DTC are ideal to investigate thyroid hormone metabolism, 
because they have been treated with total thyroidectomy and radioiodine ablation 
therapy. Because of this treatment they have no intrinsic T3 production. Therefore T3 
levels are dependent on production at the tissue level through deiodination of exog-
enous T4 by D1 and D2. The negative feedback regulation of pituitary TSH secretion 
by T3, which in our patients is completely produced outside the thyroid, is mainly 
dependent on pituitary D2.
Although we have found a clear difference in the setpoint of the hypothalamus-
pituitary-thyroid axis for the different D2-rs12885300 (D2-ORFa-Gly3Asp) polymor-
phisms, there are some unknown factors that could have also infl uenced TSH/FT4 
ratios. We will discuss these factors briefl y. First, unfortunately, because samples 
were collected as routine clinical follow-up, only TSH and FT4 levels were available, 
hence T3 and rT3 are only measured at one time point in 2007. Therefore we are 
not able to speculate about the serum values of T3 and rT3, and with that not the 
complete metabolic cycle of thyroid hormones during the entire period of the sample 
collection. 
Second, we did not correct for a possible seasonal infl uence on setpoints. Two 
studies showed higher serum T3 and T4 values during the winter and lower values 
of TSH and total T3 during spring in healthy volunteers (23,24). However, given the 
huge number of random samples we assume that the seasons in which blood samples 
were collected will probably be equally distributed. Moreover, a previous study 
suggests a very limited effect of seasonal variation in thyroid function tests (20). In 
addition to this, we think that healthy volunteers in these studies and our thyroid-
ectomized patients are not easily compared, since healthy persons have intrinsic 
thyroid hormone production possibly dependent on the seasonal feedback variation, 
whereas our patient population is treated with a fi xed dose of thyroxine substitution. 
We therefore think that the potential contribution of seasonal infl uence is limited.
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Our observations are however in contrast to the fi ndings of Coppotelli et al. (25) 
who found an increased D2 activity of the D2-rs12885300 polymorphism in an in-
vitro study and with the results of the study by Peeters et al. (8), who found that healthy 
blood donors with a D2-rs12885300 mutation needed less T4 to produce local T3 
for the negative feedback action on the pituitary. These results were not confi rmed 
in a group of healthy elderly men (8). However their observations in healthy blood 
donors with intrinsic thyroid function cannot be easily compared to DTC patients on 
TSH-suppressive thyroxine therapy. 
Our patients are treated with a TSH suppressive dose of thyroxine (26,27). An-
other factor could be that long term subclinical hyperthyroidism may result in down-
regulation of D1 and D2 and/or upregulation of D3 (2). However, we did not fi nd 
a signifi cant contribution of follow-up time and age at presentation to the observed 
effects of the D2-rs12885300 polymorphism on the setpoint of the hypothalamus-
pituitary-thyroid axis.
In conclusion, we have found an altered setpoint of the hypothalamus-pituitary-
thyroid axis for patients homozygous for the D2-rs12885300 polymorphism. How-
ever, it is unknown what the clinical signifi cance of this altered setpoint will be. In 
the future, it would be interesting to investigate the proof of functionality of this D2 
polymorphism and differences in biological variability in cell lines containing the 
different alleles of the D2-rs12885300 polymorphism.
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Abstract
The role of type 2 deiodinase (D2) in the human skeleton remains unclear. The D2 
polymorphism Thr92Ala has been associated with lower enzymatic activity, which 
could result in lower local triiodothyronine (T3) availability in bone. We therefore hy-
pothesized that the D2-Thr92Ala polymorphism may infl uence bone mineral density 
(BMD) and bone turnover. We studied 154 patients (29 men, 125 women: 79 estro-
gen-replete, 46 estrogen-defi cient) with cured differentiated thyroid carcinoma. BMD 
and bone turnover markers [bone-specifi c alkaline phosphatase (BAP), cross-linking 
terminal C-telopeptide of type I collagen (CTX), procollagen type 1 aminoterminal 
propeptide (P1NP), and cross-linked N-telopeptide of type I collagen (NTX)] were 
measured. Effects of the D2-Thr92Ala polymorphism on BMD and bone turnover 
markers were assessed by a linear regression model, with age, gender, estrogen state, 
body mass index (BMI), serum calcium, 25-hydroxyvitamin D, parathyroid hormone 
(PTH), thyroid-stimulating hormone (TSH), and free thyroxine (T4) as covariables. 
Sixty patients were wild type (Thr/Thr), 66 were heterozygous (Thr/Ala), and 28 were 
homozygous (Ala/Ala) for the D2 polymorphism. There were no signifi cant differences 
in any covariables between the three genotypes. Subjects carrying the D2-Thr92Ala 
polymorphism had consistently lower femoral neck and total hip densities than wild-
type subjects (p = 0.028), and this was accompanied by signifi cantly higher serum 
P1NP and CTX and urinary NTX/creatinine levels. We conclude that in patients with 
cured differentiated thyroid carcinoma, the D2-Thr92Ala polymorphism is associated 
with a decreased femoral neck BMD and higher bone turnover independent of serum 
thyroid hormone levels, which points to a potential functional role for D2 in bone.
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Introduction
The involvement of thyroid hormone in bone metabolism has been well documented 
clinically, ranging from decreased skeletal development in childhood hypothyroidism 
(1–3), to accelerated growth in childhood hyperthyroidism (4), to an increased risk 
for osteoporosis in overt and subclinical hyperthyroidism (5–8). Although clinical 
observations suggest a clear involvement of thyroid hormone in bone metabolism, 
the molecular mechanisms by which thyroid hormone acts on bone so far have been 
only partially uncovered. Triiodothyronine (T3) promotes osteoblastic proliferation, 
differentiation, and apoptosis and, by induction of interleukin 6 (IL-6), prostaglan-
dins, and RANKL, probably also promotes osteoclast formation and activation. This 
suggests that osteoblasts are the primary target cells for T3 in the regulation of bone 
remodeling (1,2,9–12). A functional role of thyroid stimulating hormone (TSH) on 
skeletal development and metabolism has been proposed on the basis of data ob-
tained in animal studies (13–15) and in humans (16,17). This was disputed, however, 
by data obtained in thyroid hormone receptor (TR)–defi cient mice, which indicated 
that bone remodeling was predominantly mediated by T3 via TRalpha (18,19). It also 
has been reported recently that in humans there is a signifi cant association between 
bone mineral density (BMD) and serum thyroid hormone concentrations rather than 
TSH (20).
Most actions of thyroid hormone are mediated by the active form of thyroid hor-
mone, T3. Circulating and local T3 concentrations are regulated mainly by the iodo-
thyronine deiodinases D1, D2, and D3 (21). D2 is essential for the local production 
of T3 through deiodination of triiodothyroxine (T4). Although earlier studies on the 
role and functional expression of iodothyronine deiodinase enzymes in the skeleton 
have been equivocal (12,14,22–25), a recent study reported normal growth in mice 
with defi ciencies in D1 and D2, indicating that D2 may not be critical in skeletal 
development (26). This notion was supported in a recent study that demonstrated 
that D2 activity is restricted to mature osteoblasts, suggesting a possible role for D2 
in mature osteoblast function (27). Devising a study to address the potential role of 
deiodinases, including D2, on skeletal metabolism is diffi cult in humans, but study 
of the effects of functional D2 polymorphisms on BMD and bone turnover in humans 
may shed light on this role. 
Several polymorphisms in D2 have been described (28–30). The single-nucleotide 
polymorphism (SNP) in D2-Thr92Ala has been associated with body mass index (BMI) 
and insulin resistance in subjects with obesity and type 2 diabetes mellitus (28,29), 
although this was not confi rmed in the Framingham Offspring Study (31). In a study 
by Canani and colleagues (28), the maximal velocity of D2 was decreased by 3- to 
10-fold in thyroid and skeletal muscle of carriers of the D2-Thr92Ala polymorphism. 
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This effect was observed in the absence of differences in D2 mRNA level or in the 
biochemical protein properties of the 92Ala allele. It was therefore suggested that 
either a functionally relevant SNP occurs in linkage disequilibrium in the Thr92Ala 
polymorphism or the 92Ala allele affects protein translation or stability. 
The objective of this study was to try to elucidate a potential role for D2 in skel-
etal metabolism and BMD by evaluating the relationship between the D2-Thr92Ala 
polymorphism, BMD, and bone turnover markers in cured thyroidectomized differen-
tiated thyroid carcinoma patients receiving thyroid hormone substitution. This human 
model has the advantage of strictly regulated serum thyroid hormone levels that are 
kept in a relatively narrow range.
Patients and Methods
Patients
Patients included in the study were all under control of the outpatient clinic of the 
Department of Endocrinology of the Leiden University Medical Center. All patients 
had a diagnosis of differentiated thyroid carcinoma, for which they had been treated 
by near-total thyroidectomy followed by standard postoperative [131I] radioiodine 
ablation therapy. All patients were cured as defi ned by the absence of 131-Iodine 
accumulation at diagnostic scintigraphy, serum thyroglobulin (Tg) concentrations 
below 2 mg/L after TSH stimulation, in the absence of Tg antibodies, a normal neck 
ultrasound, and no other indication for disease (32). Patients with tumor relapse were 
included only if they were subsequently cured. None of the patients used any drug or 
had a disease known to infl uence bone metabolism. The Leiden University Medical 
Center Local Ethics Committees approved the study, and written informed consent 
was obtained from all subjects.
Study design
On the day of the study, patients underwent a full clinical examination, including 
height (meters) and weight (kilograms). Blood was collected after an overnight fast 
and measured for TSH, serum free T4 (FT4), T3, calcium, parathyroid hormone 
(PTH), 25-hydroxyvitamin D [25(OH)D], bone-specifi c alkaline phosphatase (BAP), 
cross-linking terminal C-telopeptide of type I collagen (CTX), and procollagen type 1 
amino-terminal propeptide (P1NP). A second-morning-void urine was measured for 
excretion of cross-linked N-telopeptide of type I collagen (NTX). Plasma, serum, and 
urine samples were handled immediately and stored at -80˚C in Sarstedt tubes. BMD 
(expressed in grams per square centimeter) was measured at the femoral neck and 
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lumbar spine (vertebrae L2–L4) by dual-energy X-ray absorptiometry (DXA, NHANES 
III–adjusted; Hologic 4500, Hologic, Inc., Bedford, MA, USA). Following World 
Health Organization (WHO) criteria, osteopenia was defi ned as a T-score between 
-1 and -2.5 and osteoporosis as a T-score below -2.5. The following data also were 
recorded: smoking habits, alcohol use, physical activity, calcium intake, medications 
(including self-prescription drugs) or vitamin or mineral supplements, and daily 
calcium intake and for females: date of fi rst menstruation (menarche), date of last 
menstruation, cycle regularity, and estrogen substitution if applicable.
Biochemical parameters 
Serum free T4 (FT4) and TSH were measured using a chemoluminescence immu-
noassay with a Modular Analytics E-170 system (intra-assay CV of 1.6-2.2 % and 
1.3-5.0 % respectively (Roche, Almere, The Netherlands). Serum T3 was measured 
with a fl uorescence polarization immunoassay, CV 2.5-9.0 %, on an ImX system (Ab-
bott, Abbott Park, IL, USA). Thyroglobulin was measured by Dynotest TG-s (Brahms 
Diagnostica GmbH, Germany). Plasma PTH was measured using an immunoradio-
metric assay (Nichols Diagnostic Institutes, Wijchen, The Netherlands). Calcium was 
measured by colorimetry and 25(OH)-vitamin D by RIA (Incstar/DiaSorin, Stillwater, 
MN, USA). Serum BAP was measured by RIA (Hybritech Europe, Liege, Belgium). 
Serum CTX and P1NP were measured by chemoluminescence immunoassay using 
the Modular Analytics E-170 system (Roche Diagnostics, Almere, The Netherlands). 
NTX was measured by ELISA (Ostex International Inc., Seattle, WA, USA). NTX was 
expressed as the ratio between NTX and urine creatinine excretion (NTX/creatinine) 
to correct for differences in creatinine excretion. Insulin sensitivity was estimated by 
homeostasis model assessment [HOMA: fasting insulin (milliunits per milliliter) - fast-
ing glucose (millimoles per liter)/22.5]. 
Genetic analyses
DNA was isolated from peripheral leukocytes by the salting-out procedure. Geno-
types were determined using 5 ng of genomic DNA by a 5’ fl uoregenic TaqMan assay, 
and reactions were performed in 384-well format on an ABI9700 2x384-well PCR 
machine with endpoint reading on the ABI 7900HT TaqMan machine (Applied Bio-
systems, Nieuwerkerk aan den IJssel, The Netherlands). Primer and probe sequences 
were optimized using the SNP assay-by-design service of Applied Biosystems.
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Statistical Analyses
Values are presented as mean ± SE, median (range), or as numbers or proportions of 
patients. Nonnormally distributed data (TSH and PTH) were log-transformed before 
analyses. Comparisons between groups were analyzed by ANOVA or chi-square 
tests. The relation between the three D2-Thr92Ala genotypes [Thr/Thr (wild type), Thr/
Ala (heterozygote), and Ala/Ala (homozygote)], BMD, and markers of bone turnover 
were studied by a stepwise univariate regression analysis. After correction for age, 
gender, and estrogen status (ie, estrogen deplete or replete), the following covariables 
were entered: BMI, serum levels of calcium (corrected for an albumin concentration 
of 42 g/L), 25(OH)-vitamin D, lnPTH, FT4, T3, and lnTSH. We calculated that to 
detect an effect size of 0.15 (corresponding to an r2 of 0.13), adopting an alpha value 
of 0.05 and a beta value of 0.80, the number of subjects needed is 108. Because it 
has been documented that the D2-Thr92Ala polymorphism is associated with insulin 
resistance (28), we also compared insulin sensitivity (HOMA) in the three genotypes. 
Deviation from Hardy-Weinberg equilibrium was analyzed using a chi-square test. 
All calculations were performed using SPSS 12.0 for windows (SPSS, Inc., Chicago, 
IL, USA). Differences were considered statistically signifi cant at p<0.05.
Results
Patient characteristics
Of a potential of 330 patients with cured differentiated thyroid carcinoma, 105 were 
excluded for various reasons (Figure 1). Sixty-nine patients were not willing or able to 
participate in the study for different reasons. A total of 156 patients thus were included 
in the study. Two patients were left out from the analyses because of incomplete 
data. Thirteen patients had postoperative hypoparathyroidism for which they were 
adequately supplemented with active vitamin D metabolites and calcium as required. 
Additional analyses were performed leaving out these patients (see below and Table 
2). In addition, serum PTH levels were included as a covariable in the analyses (see 
below) to correct for the potentially confounding effects of hypoparathyroidism. The 
basal characteristics of the 154 patients included in the study are shown in Table 1. 
All patients were receiving L-thyroxine treatment at a mean dose of 183 ± 4 μg/day.
The D2 Thr92Ala polymorphism, BMD and biochemical parameters of 
skeletal metabolism 
Genotype frequencies of the D2-Thr92Ala polymorphism [Thr/Thr = 60 (39%), Thr/
Ala = 66 (43%), and Ala/Ala = 28 (18%)] did not deviate from Hardy-Weinberg 
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330 patients were treated for DTC 
105 patients were excluded: 
 
x N = 26 <18 years or >75 years 
x N = 22 medication influencing bone metabolism 
x N = 15 not fulfilling criteria for cure 
x N = 9 diseases influencing bone metabolism 
x N = 5 hyperparathyroidism due to vitamin D deficiency 
x N = 4 moved abroad 
x N = 4 pregnant 
x N = 20 other reasons
69 patients did not wish to participate 
2 patients were excluded because of missing data 
225 patients were invited to participate
154 patients could be analyzed 
Figure 1
Flowchart of the study
Table 1: Patient characteristics
Total (n=154)
Age (years) 49.2 ± 1.0
Males 29 (18.8 %)
Females: Estrogen Replete / Deplete 79 (51.3 %) / 46 (29.9 %)
Age at diagnosis 36.6 ± 1.1
Histology 
 Papillary Thyroid Carcinoma (PTC) 107 (69 %)
 Follicular Thyroid Carcinoma 25 (16 %)
 Follicular variant PTC 21 (14 %)
 Hürthle cell Thyroid Carcinoma 1 (1 %)
Total Activity Radioiodine 8067 ± 699 MBq
Lymph Node Surgery 14 (9 %)
TNM Stage 
 T1-3 N0 M0 90 (63 %)
 T1-3 N1 M0 30 (21%)
 T4 or M1 n=143 23 (16 %)
Relapse DTC (all were cured after relapse) 20 (13 %)
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equilibrium proportions. The 92Ala allele had a frequency of 45%, which is similar 
to previous studies in Caucasians (33,31). The characteristics of the three genotype 
subgroups are given in Table 2. The three groups were comparable with respect to 
age, gender, estrogen state (including ages at menarche and menopause), and BMI. 
Table 2: Characteristicsw of patients by D2-Thr92Ala Genotype
Thr / Thr (60) Thr / Ala (66) Ala / Ala (28) P
Men (n) 13 11 5 0.8611
Women (n) Estrogen Replete 
/ Deplete
32 / 15 33 / 22 14 / 9 0.8941
Age (years) 47.2 ± 1.6 51.2 ± 1.7 48.3 ± 1.9 0.1481
Height (m) 1.72 ±0.01 1.70 ± 0.01 1.71 ± 0.02 0.3071
BMI (kg/m2) 25.6 ± 0.6 26.2 ± 0.4 25.8 ± 1.1 0.7731
Sports (hrs/week) 3.1 ± 1.1 5.0 ± 1.6 4.5 ± 2.3 0.6541
Smoking (n) 12 (9%) 7 (5%) 5 (1%) 0.0921
Menarche (age) 13.4 ± 0.2 13.1 ± 0.2 13.6 ± 0.3 0.3991
Menopause (age) 48.2 ± 1.5 47.7 ± 1.1 50.1 ± 1.5 0.4841
Follow-up duration (years) 13.1 ± 1.2 10.5 ± 1.0 11.3 ± 1.5 0.2411
Hypoparathyroidism (n) 5 (3%) 6 (4%) 2 (1%) 0.9521
Vertebral fractures (n) 1 (1%) 2 (1%) 1 (1%) 0.8321
HOMA (mmol*22.5/L) 1.75 ± 0.20 2.16 ± 0.21 1.86 ± 0.32 0.3611
Calcium (mmol/L) 2.39 ± 0.02 (59) 2.38 ± 0.01 2.39 ± 0.02 0.9431
25 OH vitD (nmol/L) 64.5 ± 3.9 (59) 60.4 ± 2.9 69.9 ± 4.8 0.2771
PTH (pmol/L) 4.88 ± 0.36 (58) 5.27 ± 0.43 (65) 6.19 ± 0.83 0.2501
TSH (mU/L)
0.051 (0.003-
4.620)
0.031 (0.003-
4.910)
0.051 (0.003-
6.830)
0.7531
Dose thyroxine (μg/kg) 2.09 ± 1.04 2.23 ± 0.87 2.19 ± 1.03 0.3981
Free T4 (pmol/L) 22.7 ± 0.1 22.4 ± 0.1 21.6 ± 0.2 0.5621
T3 (nmol/L) 1.49 ± 0.04 (54) 1.47 ± 0.05 (59) 1.40 ± 0.07 (23) 0.6241
T3/T4 ratio * 10 6.6 ± 0.2 (54) 6.7 ± 0.2 (59) 6.6 ± 0.4 (23) 0.9031
BMD femoral neck (g/cm2) 0.90 ± 0.02 0.84 ± 0.01 0.85 ± 0.03 0.028 /0.0152
BMD total hip (g/cm2) 0.97 ± 0.02 0.92 ± 0.02 0.92 ± 0.03 0.064 /0.0492
BMD lumbar spine (g/cm2) 1.08 ± 0.03 1.04 ± 0.02 1.07 ± 0.04 0.741 /0.0942
NTX / Creatinine * 1/1000 44.0 ± 4.1 56.5 ± 5.8 67.7 ± 10.6 0.008 /0.0022
BAP (ng/mL) 12.5 ± 0.5 13.5 ± 0.6 13.9 ± 0.7 0.063 /0.0852
P1NP (ng/mL) 40.0 ± 2.6 42.9 ± 3.4 50.9 ± 5.5 0.028 /0.0322
CTX (mg/mL) 0.28 ± 0.02 0.28 ± 0.02 # 0.37 ± 0.05 0.043 /0.0362
Values are presented as mean ± standard error (SE), median (range) or as numbers or proportions of 
patients. PTH= Parathyroid hormone, BAP= Bone Specifi c Alkaline Phosphatase, P1NP= Procollagen 
type 1 Aminoterminal Propeptide, CTX= C-crosslinking Terminal Telopeptide of Type I collagen, NTX/
Creatinine= Ratio of Urinary N-Telopeptide of Collagen Cross-links and Creatinine Concentration; 
1 = One-way ANOVA, 2 = general linear model, univariate with age, gender, estrogen state, BMI, Ca, 
lnPTH, 25-OHvitD, lnTSH and Free T4 as covariables, second value= patients with postoperative 
hypoparathyroidism left out.
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Physical activity and smoking habits did not differ either. Biochemical covariables for 
bone metabolism [ie, serum calcium, 25(OH)-vitamin D and PTH] were not different, 
as were serum FT4 and T3 levels, serum T3/T4 ratio, and TSH levels.
Because it has been documented that the D2-Thr92Ala polymorphism is associ-
ated with insulin resistance (28), we also compared insulin sensitivity by HOMA 
in the three genotypes, which again did not differ (p = 0.361). We also calculated 
whether HOMA was a signifi cant determinant of BMD and of biochemical param-
eters of skeletal metabolism (corrected for age, gender, estrogen state, and BMI). 
Univariate analyses revealed that p values for HOMA as an independent variable 
were, respectively, 0.912 for femoral neck BMD, 0.583 for lumbar vertebral BMD, 
0.826 for NTX/creatinine, 0.575 for BAP, 0.798 for P1NP, and 0.906 for CTX. HOMA 
therefore was not a determinant of BMD or bone turnover markers.
The relation between the three D2-Thr92Ala genotypes, BMD, and biochemical 
parameters of skeletal metabolism were studied by a stepwise univariate regression 
analysis. After correction for age, gender, estrogen status, and BMI, the following 
covariables were entered subsequently: serum levels of calcium, 25(OH)-vitamin D, 
lnPTH, FT4, and lnTSH. We found a signifi cant independent relationship between 
the Thr92Ala genotypes and femoral neck BMD (p = 0.022) (Table 2, Figure 2) with a 
6% lower BMD in homozygotes than in wild-type patients. This relationship was also 
present when total-hip BMD was measured. We also found independent relationships 
between the D2-Thr92Ala genotypes and biochemical parameters of skeletal me-
tabolism: P1NP (p = 0.028), CTX (p = 0.043), and NTX/creatinine (p = 0.008), which 
were higher in homozygotes than in wild-type patients. Data for analyses leaving out 
patients with postoperative hypoparathyroidism did not infl uence these results (Table 
2). The largest difference was observed for NTX/creatinine, which was 54% higher in 
homozygotes than in wild types.
Discussion
The main objective of this study was to investigate a potential role for the deiodinase 
D2 in bone metabolism in humans by studying the relationship between the D2-
Thr92Ala polymorphism, BMD, and bone turnover. The D2-Thr92Ala polymorphism 
is associated with a lower D2 Vmax and therefore may lead to decreased local avail-
ability of T3 (28), which, in turn, may affect skeletal metabolism. We studied this 
relationship in a human model of thyroidectomized patients cured from differentiated 
thyroid carcinoma receiving thyroid hormone substitution. The advantage of this 
model is that study subjects have more uniform FT4 levels, which fell between the 
25th and 75th percentiles for FT4 (19.5 and 24.9 pmol/L) in our group of patients.
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In support of the involvement of D2 in bone metabolism was the observation 
of a 6% decrease in femoral neck BMD and increased levels of P1NP (32%), CTX 
(27%), and NTX/creatinine (54%) in the Ala/Ala subgroup compared with wild-type 
subgroup. These effects were independent of factors known to infl uence BMD and 
bone metabolism, such as age, gender, BMI, estrogen state, PTH, and vitamin D. 
These effects were also independent of circulating levels of T3 and TSH and thus 
were indicative of an independent role of D2 in bone metabolism. We did not fi nd 
an association of the D2 polymorphism with lumbar spine BMD, possibly owing to 
a differential effect of the polymorphism on predominantly trabecular bone at the 
lumbar spine versus predominantly cortical bone at the femoral neck. Our data did 
not confi rm earlier observations of an association of the D2-Thr92Ala polymorphism 
with insulin sensitivity (28,29). This discrepancy may be explained by differences 
in the populations studied, with a low prevalence of obesity or insulin resistance 
in our subjects. Our data, however, are in keeping with the Framingham Offspring 
Study, which found no relation between the D2-Thr92Ala polymorphism and insulin 
resistance (31). We did not observe differences in height, indicating no difference 
in skeletal development among the three genotype subgroups. This is in line with 
A B
C D
Figure 2 
Relationships between D2 Thr92ALA genotypes and indicators of bone turnover. 
(A) Femoral neck BMD. 
(B) Ratio of urinary N-telopeptide of collagen cross-links and creatinine concentration.
(C) Procollagen type 1 amino-terminal propeptide (P1NP) levels. 
(D) Cross-linking terminal C-telopeptide of type I collagen. 
For levels of signifi cance, see text and Table 2.
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recent observations in C3H/HeJ D2-/- compound mutant mice with D1 defi ciency 
and deletion of D2, which were shown to maintain normal growth (26). This notion 
is supported by a recent study suggesting that D2 may not play a physiologic role in 
growth plate chondrocytes (27).
The observed effects of the D2-Thr92Ala polymorphism on femoral neck BMD 
are in line with the importance of local availability of T3 for bone formation. D2 
activity has been found on mature osteoblasts (34), which are the primary target cells 
for T3 regulatory effects on bone formation (1,2,10–12).
The effects of the D2-Thr92Ala polymorphism on bone turnover markers are not 
easy to explain. It is conventionally accepted that higher rather than lower circulating 
thyroid hormone levels result in higher bone turnover and decreased bone mass. 
However, the model we used is unique in the sense that circulating T3 levels were 
similar among the three D2 genotypes, allowing us to specifi cally study the conse-
quences of the polymorphism for local T3 availability in the bone microenvironment. 
Williams and colleagues (27) showed no D2 activity in osteoclasts. The effects of 
the polymorphism on the markers of bone degradation (NTX/creatinine and CTX) 
therefore may not be explained by direct effects on osteoclasts but are more likely to 
result from changes in the interaction between osteoblasts and osteoclasts, possibly 
by alterations in the RANK/RANKL/OPG signaling pathway, which potentially can be 
modulated by local T3 availability in the bone microenvironment. In the context of 
confl icting data on a functional role for TSH in skeletal development, our data, which 
were corrected for serum TSH levels, outline the importance of local T3 for bone me-
tabolism (13–17,35–38). Two recent papers by Bassett and colleagues (18,19), who 
studied mice with complete or haploinsuffi ciency of TRalpha and -beta, concluded 
that TRalpha regulates both skeletal development and adult bone maintenance.
Whereas a limitation of our study may be its relatively small size and its cross-
sectional design, one of its clear strengths is that all subjects were phenotyped for 
factors other than thyroid status known to modulate bone metabolism. This design 
enabled us to use regression models, including relevant covariables, the feasibility 
of which is diffi cult in large cohort studies. In addition, according to the power cal-
culation, the study had suffi cient power, which was confi rmed by a post hoc power 
analysis revealing that the power was 97% or higher for the dependent variables 
studied. A potential further limitation of our study is that thyroid hormone parameters 
measured at one point in time may not refl ect the overall thyroid status over time. 
To address this issue, we calculated the slope of all TSH measurements routinely 
obtained after initial therapy in every patient participating in the study to verify the 
stability over time. An average of 15 TSH measurements were obtained per patient, 
and the slope of TSH values was -0.0001 (range -0.004 to 0) mU/L per year, thus 
indicating stable TSH levels over time.
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In summary our data suggest that a decrease in local availability of T3 potentially 
owing to a D2 polymorphism may result in increased bone turnover and decreased 
bone mass at the predominantly cortical femoral neck. We believe that our study pro-
vides additional information on the role of D2 in bone metabolism and the functional 
consequences of the D2-Thr92Ala polymorphism, supporting a role for D2 in mature 
bone cells (27).
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Abstract
Background
Primary hypothyroidism affects bone metabolism. It is not clear whether this has to 
be attributed to decreased serum thyroid hormone levels per se or to increased TSH 
levels.
Objective
To document the effects of primary hypothyroidism on bone metabolism and to 
discriminate between effects mediated by decreased thyroid hormone levels versus 
those mediated by increased TSH levels.
Patients and methods
We studied the effects of recombinant human TSH (rhTSH) in 11 athyroid DTC patients 
on thyroxine substitution. In addition, we included 11 age-, gender- and BMI-matched 
athyroid patients previously treated for differentiated thyroid carcinoma (DTC), who 
were studied after 4 weeks of thyroxine withdrawal and during thyroxine replacement 
therapy. We measured plasma levels of PTH, 25-OH-vitamin D, procollagen type 
1 aminoterminal propeptide levels (P1NP), C-cross-linking terminal telopeptide of 
type I collagen (CTX), receptor activator for nuclear factor κ B ligand (RANKL) and 
osteoprotegerin (OPG).
Results
No differences were observed on parameters of bone turnover after rhTSH adminis-
tration. During thyroxine withdrawal, levels of C-cross-linking terminal telopeptide 
of type I collagen were signifi cantly lower, whereas levels of osteoprotegerin were 
signifi cantly higher compared to thyroxine replacement therapy.
Conclusion
Hypothyroidism results in decreased bone turnover. As rhTSH had no impact on 
bone turnover, it seems that low thyroid hormone levels instead of the increased TSH 
levels are responsible for the changes in bone turnover during hypothyroidism in DTC 
patients.
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Introduction
The effects of thyroid hormone on bone are established and the conventional view is 
that hyperthyroidism result in bone loss (1).
But the consequences of hypothyroidism on bone metabolism remain unclear 
(Table 1). Some studies document low bone turnover as evidenced by decreased 
markers of bone resorption and formation (2-5), whereas others report normal bone 
turnover (6-8). Most studies, however, included patients with Hashimoto thyroiditis, 
in whom the duration and the extend of hypothyroidism is not known (3-5,7). More-
over, it is not clear, given the recent suggestion that TSH may be a negative regulator 
of bone remodelling through direct effect on bone independent of thyroid hormone 
levels (9-11), if the effects of hypothyroidism must be attributed to increased TSH 
levels or decreased thyroid hormone levels. It has been reported that TSHR knockout 
and haploinsuffi cient mice with normal thyroid hormone levels have decreased bone 
mass, suggesting that TSH might directly infl uence bone remodelling (10,12,13). 
However, other studies question the role of TSH in bone metabolism (14,15).
Three studies in humans have investigated the effect of recombinant human TSH 
(rhTSH) on bone metabolism, but their results are inconclusive. They showed either 
no impact on bone turnover (16), increased markers of bone formation (17,18) or 
decreased markers of bone resorption (18). In hypothyroidism the relative importance 
of decreased thyroid hormone levels or increased TSH levels on bone remains thus 
to be established.
The present study was designed in an attempt to discriminate between potential 
effects mediated by decreased thyroid hormone levels from those mediated by in-
creased TSH levels in a human model in which the reciprocal relationship between 
thyroid hormone and TSH was interrupted. To this effect, we studied parameters of 
bone metabolism after parenteral administration of recombinant human TSH (rhTSH) 
resulting in exogenously increased TSH levels while preserving normal thyroid hor-
mone levels by uninterrupted thyroid hormone substitution in athyroid differentiated 
thyroid carcinoma (DTC) patients. We studied the same parameters in age-, gender- 
and BMI matched athyroid DTC patients during short-term thyroxine withdrawal, 
resulting in decreased thyroid hormone levels and endogenously increased TSH 
levels and after reestablishment of thyroid hormone substitution.
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Patients and Methods
Subjects
Patients were recruited from the outpatient clinic of the Department of Endocrinology 
& Metabolic Diseases of Leiden University Medical Center, which is a tertiary referral 
center for differentiated thyroid carcinoma (DTC). Patients included in the study had 
a diagnosis of DTC for which they had been treated with near-total thyroidectomy, 
followed by routine postoperative I-131 radioiodine ablation therapy. Only patients 
cured for DTC were included, documented by the absence of measurable serum 
thyroglobulin (Tg) levels during TSH stimulation as well as by negative total-body 
RaI scintigraphy. Patients with DTC planned for a TSH-stimulated diagnostic protocol 
were asked to participate in the study. High TSH levels were achieved either by 
recombinant human TSH stimulation or by 4 week withdrawal of thyroxine. Patients 
with diabetes mellitus, body mass index (BMI) >35 kg/m2 or other endocrine diseases 
were excluded. Patients who used any drugs known to infl uence bone turnover, such 
as bisphosphonates, corticosteroids or thiazide diuretics, were also excluded.
The local Ethics Committees of the Leiden University Medical Center approved 
the study, and written informed consent was obtained from all subjects.
Two groups matched for age, gender and BMI were studied. The fi rst group consisted 
of 11 athyroid DTC patients who received uninterrupted thyroxine replacement 
therapy and underwent a TSH stimulation test in the course of monitoring disease 
state by injections of rhTSH. This resulted in exogenously increased TSH levels with 
unchanged normal FT4 levels (rhTSH group). The second group also consisted of 11 
athyroid DTC patients with short-term thyroxine withdrawal resulting in decreased 
FT4 levels and endogenously increased TSH levels (thyroxine withdrawal group).
Study Design
Patients in the rhTSH group continued to receive thyroxine substitution and were 
evaluated prior to recombinant human TSH (Thyrogen, 0.9 mg) which was injected 
intramuscularly once daily for two consecutive days and patients were also evaluated 
1 and 3 days after the last injection of rhTSH.
Patients in the thyroxine withdrawal group were evaluated four weeks after 
withdrawal of thyroxine substitution and again 8 weeks after restoration of thyroxine 
replacement therapy.
All patients were assessed at 8.00 a.m. after a 12 hour fast. Height (meters [m]) 
and weight (kilograms [kg]) were measured and BMI (weight [kg]/lenght2 [m]) was 
calculated. Plasma samples were obtained for measurement of FT4, TSH, T3, PTH, 
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25-OH-vitamin D, procollagen type 1 aminoterminal propeptide levels (P1NP), 
C-cross-linking terminal telopeptide of type I collagen (CTX), receptor activator for 
nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG). Plasma samples were 
handled immediately and stored at –20o C in Sarstedt tubes.
Biochemical parameters
All plasma and serum samples were measured in one batch. Serum free thyroxine 
(FT4) and TSH were measured using an electrochemiluminescent immunoassay with 
a Modular Analytics E-170 system with an intra-assay CV of 1.6-2.2 % and 1.3-5.0 % 
respectively (Roche Diagnostics, Almere, The Netherlands). Serum T3 was measured 
using a fl uorescent polarisation immunoassay on an AxSYM system (Abbott, Abbott 
Park, IL, USA CV 2.5-9.0 %). Plasma Parathyroid Hormone (PTH) was measured by an 
immunoradiometric assay (Nichols Diagnostic Institutes, Wijchen, The Netherlands), 
calcium and alkaline phosphatase activity by colorimetry on a fully automated 
Modular P800 system (Roche, Almere, The Netherlands) and 25(OH) vitamin D 
by RIA (Incstar/DiaSorin, Stillwater, MN, USA). CTX and P1NP were measured by 
electrochemiluminescent immunoassays using a Modular Analytics E-170 system 
(Roche Diagnostics, Almere, The Netherlands). RANKL was measured using the ampli 
sRANKL human kit (Biomedica, Vienna, Austria), an enzyme linked immunoassay 
with a detection limit of 0.02 pmol/l (intra-assay CV 8-9%, interassay CV 3-6%). 
Osteoprotegerin was measured by ELISA (Meso Scale Discovery, Gaithersburg, Mary-
land, USA) with a detection limit of 5.9 pg/ml. In our hands, the range was 206 to 404 
pg/ml; CVs were 0.6-16.2%, with an average of 4.6%. All samples were measured in 
triplo in single batches for the levels of RANKL and osteoprotegerin.
Statistical Analyses
SPSS 15.0 for windows was used for statistical analyses (SPSS. Inc., Chicago, IL, 
USA). Values are expressed as mean ± SE. Data within subjects were analysed with 
the paired samples t-test or the ANOVA for repeated measures. Data between subjects 
were measured with the Mann-Whitney test. Differences were considered statistically 
signifi cant at P<0.05.
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Results
Patient demographic characteristics are shown in Table 2. Patients in the thyroxine 
withdrawal group and rhTSH group were well matched and there were no differences 
in age, gender, BMI, thyroxine dose or duration of follow-up between groups.
Eleven patients (4 male and 7 female patients) were included in the rhTSH group. 
Mean thyroxine dose at time of the evaluation was 200 ± 12 μg/day. TSH levels were 
signifi cantly increased without any changes in FT4 levels 1 and 3 days after rhTSH 
was administered (Table 3).
There were no differences in the levels of calcium, PTH, 25-OH-vitamin D, al-
kaline phosphatase activity, P1NP, CTX, OPG, RANKL and in the RANKL/OPG ratio 
between baseline and time points after rhTSH administration.
Eleven patients (4 male and 7 female patients) were included in the thyroxine 
withdrawal group. Mean thyroxine dose prior to withdrawal was 197 ± 13 μg/day. 
Four weeks after thyroxine withdrawal, TSH levels were signifi cantly increased at 
142.4 ± 10.4 mU/L (normal laboratory reference range 0.3-4.8 mU/L) and FT4 levels 
were signifi cantly decreased at 1.4 ± 0.2 pmol/L (normal laboratory reference range 
10-24 pmol/L). Eight weeks after restoration of thyroxine replacement therapy, six 
patients had TSH levels within the normal laboratory reference range and fi ve patients 
had suppressed TSH levels. 
There were no signifi cant differences in levels of calcium, PTH, 25-OH-vitamin 
D, alkaline phosphatase activity, P1NP, RANKL and the RANKL/OPG ratio between 
thyroxine withdrawal status and 8 weeks after reintroduction of thyroxine replace-
ment therapy (Table 3). Serum concentrations of CTX were signifi cantly lower and 
OPG levels signifi cantly higher during hypothyroidism compared to 8 weeks after 
reintroduction of thyroxine replacement therapy. There was no signifi cant difference 
between endogenously and exogenously increased TSH levels respectively obtained 4 
weeks after thyroxine withdrawal and 1 day after rhTSH-administration. As expected, 
Table 2: Patient characteristics
Thyroxine withdrawal-
study
(n=11)
rhTSH stimulation 
study
(n = 11)
P-value
Age (years) 45.5 ± 3.0 47.0 ± 2.8 0.65
Sex (m/f) 4 : 7 4 : 7 0.67
BMI (kg/m2) 28.1 ± 1.3 29.7 ± 2.6 0.75
Thyroxine dose (μg/day) 197 ± 13 200 ± 12 0.70
Duration of TSH suppression (years, (range)) 5.0 ± 2.1 (0.6-24.3) 6.7 ± 2.4 (1.2 -25.3) 0.33
Data are expressed as mean ± SE (range) or number of patients
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FT4 levels were signifi cantly decreased during thyroxine withdrawal compared to 
the normal levels attained by thyroxine substitution therapy 1 and 3 days after rhTSH 
administration. The differences in CTX levels and OPG levels were signifi cantly dif-
ferent between the thyroxine withdrawal group and rhTSH group. Calcium levels 
were signifi cant lower during hypothyroidism compared to rhTSH administration. 
There were no signifi cant differences observed in any other parameters measured 
between groups. 
Discussion
In this study, we have attempted to dissect the effects of increased TSH levels from 
those of decreased thyroid hormone levels on bone by studying athyroid DTC pa-
tients in which the relationship between thyroid hormone levels and TSH is disrupted. 
Our fi ndings suggest that acute changes in TSH in the presence of stable thyroid 
hormone levels obtained by rhTSH administration do not signifi cantly affect skeletal 
metabolism. The data from our second model suggest that hypothyroidism results in 
decreased bone turnover rather by decreased plasma thyroid hormone concentra-
tions than by increased TSH concentrations, because rhTSH did not impact on bone 
turnover in DTC patients. To our knowledge, this is the fi rst study comparing thyroxine 
withdrawal versus rhTSH-injection in age-, gender- and BMI matched DTC patients. 
It has been proposed that TSH may modulate bone remodelling independently of 
thyroid hormones through binding to the TSH receptor on osteoblasts and osteoclasts 
(10). However, other studies question these fi ndings. Bassett et al. reported that Pax -/- 
mice and hyt/hyt mice, two mouse models of congenital hypothyroidism in which the 
feedback between TSH and thyroid hormones was intact or disrupted, both displayed 
delayed ossifi cation, reduced cortical bone, trabecular bone remodelling defects and 
reduced bone mineralization, indicating that the effects of congenital hypothyroidism 
on bone are independent of TSH (14). Moreover, Bassett et al. showed that osteoblasts 
and osteoclasts express TSH-receptors, but TSH did not affect a cAMP response or 
the differentiation or function (14). We used the model of athyroid DTC patients in 
whom a rhTSH simulation test was performed in an attempt to discriminate between 
the effects of TSH and those of FT4 on bone metabolism. These patients have no 
endogenous thyroid hormone production and are therefore an excellent model to 
study the effects of TSH without interfering effects of changes in thyroid hormone 
concentrations. However, acute treatment with rhTSH did not affect bone turnover. 
This is in keeping with a study using the same model (16), but ad odds with two others 
studies (17,18). 
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Mazzioti et al. found signifi cantly increased levels of bone specifi c alkaline phos-
phatase with decreased levels of cross-linking terminal telopeptide of type I collagen 
in postmenopausal women after rhTSH administration (18). They found no changes 
in premenopausal women. Martini et al. found signifi cantly increased levels of P1NP 
and RANKL after rhTSH administration (17). These differences were only signifi cant 
in postmenopausal women for P1NP levels and in postmenopausal women and men 
for RANKL levels after stratifi cation for gender and menopausal state. We studied 
only 2 postmenopausal women. This might explain the differences in outcome. We 
found no differences in osteoprotegerin levels, which is consistent with previous 
studies (16-18) and in agreement with the fi nding that TSH regulates bone turnover 
by different mechanisms than OPG (10,14). 
Osteoprotegerin is a member of the TNF receptor superfamily. It inhibits osteo-
clastogenesis by interrupting the cell-to-cell interaction (19-21). Osteoprotegerin 
binds to RANKL (22), which is important for osteoclast differentiation. RANKL binds 
to its receptor, RANK, which is expressed on dendritic cells, T cells, osteoclast precur-
sors and mature osteoclasts (23,24). RANKL increases the survival of RANK positive 
T cells (23), promotes osteoclast differentiation (22,25-28), stimulates the activity 
of mature osteoclasts (26,29,30) and promotes survival of osteoclasts by preventing 
apoptosis. 
We also studied the effects of thyroxine replacement therapy after short-term hy-
pothyroidism due to thyroxine withdrawal in age-, gender and BMI matched athyroid 
DTC patients. Levels of C-cross linking terminal telopeptide of type 1 collagen were 
lower during hypothyroidism after thyroxine withdrawal compared to 8 weeks after 
restoration of thyroxine replacement therapy. This is consistent with most reports on 
hypothyroidism (2,3,31), although Sabancu et al. reported no differences in markers of 
bone turnover during hypothyroidism in a heterogeneous patient population includ-
ing patients with Hashimoto thyroiditis (7). A disadvantage of the inclusion of patients 
with Hashimoto thyroiditis may be that the duration and extent of hypothyroidism are 
not known. OPG levels were also signifi cant higher during hypothyroidism compared 
to thyroxine replacement therapy. This is consistent with previous studies (2-4) and 
strengthens our fi nding that thyroxine withdrawal decreases bone turnover. 
In summary, bone turnover is decreased during hypothyroidism after thyroxine 
withdrawal in DTC patients. We conclude that the low thyroid hormone levels in-
stead of the increased TSH levels are responsible for the decreased bone resorption 
during hypothyroidism in DTC patients. However, these results must be confi rmed in 
a wider population of men and pre-and postmenopausal women.
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Abstract
Background
Thyroid hormone has important effects on the cardiovascular system. The conse-
quences of episodes of acute hypothyroidism on cardiac function have been investi-
gated in only a few studies, and their results are inconclusive. Our objective was to 
investigate the effects of acute hypothyroidism on cardiac function in patients with 
iatrogenically induced subclinical hyperthyroidism after treatment for differentiated 
thyroid carcinoma.
Material and methods
Fourteen patients with a history of differentiated thyroid carcinoma on thyroid stimu-
lating hormone (TSH)-suppressive thyroxine replacement therapy were studied. We 
assessed cardiac function before, and 1 and 4 weeks after withdrawal of thyroxine 
substitution. We measured serum levels of free thyroxin, triiodothyronine and TSH 
and used a new sophisticated Doppler echocardiography technique, tissue Doppler 
imaging (TDI), to assess detailed and quantitative assessment of systolic and diastolic 
cardiac function. Echocardiographic parameters in patients were compared to con-
trols.
Results
Compared to controls, patients had higher left ventricular mass and wall thickness and 
decreased diastolic function during TSH-suppressive L-thyroxine substitution therapy. 
Thyroxine withdrawal resulted in a decrease in both early (E) and late (A) diastolic 
mitral infl ow velocities, without impact on E/A ratio. Using TDI, late diastolic velocity 
(A′) decreased without impact on E′/A′ ratio. Left ventricular dimensions, wall thick-
ness and mass did not change during thyroxine withdrawal.
Conclusions
Subclinical hyperthyroidism is accompanied by diastolic dysfunction. Subsequent 
acute hypothyroidism induces only subtle changes in diastolic function.
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Introduction
Thyroid hormone has profound effects on the cardiovascular system. Hyperthyroid-
ism induces cardiac arrhythmias, left ventricular (LV) hypertrophy and diastolic 
dysfunction, and enhances systolic function (1–3). Subclinical hyperthyroidism – i.e. 
suppressed thyroid-stimulating hormone (TSH) levels with normal free thyroxine (FT4) 
levels – is associated with increased heart rate and supraventricular arrhythmias, in-
cluding atrial fi brillation, increased LV mass (LVM) with a slightly enhanced systolic 
function, and diastolic dysfunction. Diastolic dysfunction is at least partly revers-
ible after restoration of euthyroidism and is associated with an increase in mortality 
(4–7). Conversely, hypothyroidism is associated with bradycardia, mild hypertension, 
increased peripheral cardiovascular resistance, heart failure (1,3,8,9), decreased 
cardiac output and diastolic dysfunction (1,3,10,11). Long-standing hypothyroidism 
can even result in asymmetrical septal hypertrophy (12) and pericardial effusion (6). 
Hypothyroidism is also associated with coronary artery disease, presumably because 
of associated hypercholesterolemia, hypertriglyceridemia and hypertension (1,3,13). 
Thyroxine substitution reverses most cardiovascular alterations associated with hypo-
thyroidism (3,6,9,14). 
Patients with differentiated thyroid carcinoma (DTC) are treated with total thy-
roidectomy and radioiodine ablative therapy, followed by long-term TSH-suppressive 
thyroxine replacement therapy (15–17). During the fi rst period after diagnosis, 
patients are regularly withdrawn from thyroxine for TSH-stimulated thyroglobulin 
measurements and diagnostic 185-megabecquerel iodine-131 scintigraphy. The con-
sequences of these episodes of acute hypothyroidism on cardiac function have been 
investigated in only a few studies up to now. However, the results of those studies 
have been inconclusive (18–27), varying from mainly decreased diastolic function 
(18,19,23,25,26), to mainly altered systolic function (21,24). In these studies, without 
control groups, these parameters were measured by different techniques (echocar-
diography, radionuclide imaging), without blinding the observers with regards to 
treatment modalities. 
Therefore, we performed a prospective study in a homogeneous group of athy-
reotic DTC patients to assess the impact of overt hypothyroidism induced by short-
term thyroxine withdrawal on cardiac function measured by a new sophisticated 
echocardiography technique: tissue Doppler imaging (TDI). This technique allows for 
detailed and quantitative assessment of cardiac parameters, including diastolic and 
systolic function (28,29). In addition, the researchers who collected and analyzed the 
echocardiographic data were blinded with regard to treatment modalities, and car-
diac parameters of the patients were also compared to a matched group of controls 
who have no cardiovascular co-morbidities. 
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Subjects and Methods
Subjects
Patients were recruited from the outpatient clinic of the Department of Endocrinology 
of the Leiden University Medical Center. The Department of Endocrinology is a tertiary 
referral center for DTC. Patients included were those who had been diagnosed with 
DTC, had received initial therapy consisting of total thyroidectomy and radioiodine 
ablative treatment, and were planned for TSH stimulated iodine-131 whole body scan-
ning for evaluation of the effect of prior radioiodine therapy or screening in case of posi-
tive thyroglobulin antibodies. The patients were on TSH-suppressive therapy, aiming at 
TSH levels below 0.1 mU/L (normal reference values for TSH 0.4–4.4 mU/L). No drugs 
known to infl uence cardiovascular parameters were allowed. None of the patients had 
hemodynamic instability, previous myocardial infarction, rheumatic fever, endocardi-
tis, diabetes mellitus, or connective tissue disease. The study was approved by the local 
ethics committee and written informed consent was obtained from all subjects.
Study design
Fifteen DTC patients undergoing TSH-stimulated iodine-131 whole body scanning for 
follow-up were prospectively asked to participate in this study. On the last day of thy-
roxine therapy, on day 7 and on day 28 after withdrawal, hormonal and biochemical 
parameters were measured and echocardiography was performed. At each visit patients 
came to the outpatient clinic after an overnight fast and blood was collected for the 
measurement of TSH, FT4, triiodothyronine (T3) and creatinine concentrations. Height 
(m), weight (kg), resting blood pressure (mmHg) and heart rate (beats per minute) were 
documented. An independent cardiologist performed echocardiography at each visit.
Echocardiography: data acquisition
Echocardiography was performed with the patients in the left lateral decubitus 
position using a commercially available system (Vingmed System Vivid 7, General 
Electric/Vingmed, Milwaukee, WI, USA). Images were obtained using a 3.5-MHz 
transducer, at a depth of 16 cm in the parasternal (long- and short-axis) and apical 
(2- and 4-chamber, long axis) views. Standard two-dimensional and colour Doppler 
data, triggered to the QRS complex, were saved in Cineloop format. A minimum of 
three consecutive beats were acquired from each view and the images were stored for 
offl ine analysis (EchoPac 6.0.1, General Electric/Vingmed Ultrasound). 
Left ventricular dimensions, fractional shortening and LV ejection fraction (LVEF) 
were measured from the M-mode recordings at the parasternal long-axis views (27). 
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LVM was calculated by the cube formula and using the correction formula proposed 
by Devereux et al. (31): 0.8 x {1.04[(LVEDD + PWT + IVST)3 – (LVEDD)3]} + 0.6, 
where, LVEDD is LV end-diastolic diameter, PWT is the posterior wall thickness, and 
IVST is interventricular septum thickness. LVM was corrected for body surface area to 
obtain LVM index (LVMI). LV hypertrophy was defi ned as LVMI > 120 g m² for men 
and > 116 g m² for women (31,32). Systolic function was evaluated by measurements 
of fractional shortening and LVEF (33). 
The following parameters of diastolic function were measured: diastolic transmi-
tral peak velocities (E and A wave) and the E/A ratio, the isovolumetric relaxation time 
and the deceleration time of the E-wave. In addition, left atrium anteroposterior diam-
eter was measured from the M-mode parasternal long-axis recordings. Quantitative 
diastolic data were derived from TDI data. For TDI data analysis, the digital Cineloops 
were analysed using commercial software (EchoPac 6.0.1, General Electric/Vingmed 
Ultrasound). The sample volume (4 mm3) was placed in the LV basal portions of the 
anterior, inferior, septal and lateral walls (using the 2- and 4-chamber images). The 
following parameters (mean values calculated from three consecutive beats) were 
derived: early diastolic velocity (E′) and late diastolic velocity (A’) and the E′/A′ ratio.
Baseline echocardiographic parameters from patients were compared to a control 
group consisting of 24 individuals matched for age, gender, body surface area and LVEF. 
The controls were selected from an echocardiographic database containing this informa-
tion and special care was taken to exclude those individuals with any cardiovascular co-
morbidity. Those individuals referred for echocardiographic evaluation of known valvular 
disease, murmur, congestive heart failure, or cardiac transplantation evaluation were ex-
cluded. Accordingly, the controls comprised of patients with curable breast cancer referred 
for examination of cardiac function before they undergo adjuvant chemotherapy, and of 
patients experiencing non-ischemic chest pain, palpitations or syncope without murmur. 
Acquisition of echocardiographic data was performed by one experienced observer, 
whereas data analysis was performed by a single independent observer, both blinded 
with regard to the study subgroups (patients and controls). Intra-observer reproducibility 
of quantitative M-mode measurements assessed by linear regression and Bland–Altman 
analysis showed an excellent agreement with high Pearson’s correlation coeffi cient (r2 
= 0.99) and small bias (0.1 ± 2.4 mm). Similarly, the intra-observer reproducibility of 
quantitative Doppler measurements was also excellent, with an r2 value of 0.99 and 
small bias of 0.8 ± 3.6, with no signifi cant trend for repeated measurements.
Assays
Serum FT4 concentration was measured with an IMx system (Abbott, Abbott Park, IL, 
USA) (intra-assay variability of 2.47–7.57% and interassay variability of 5.6–12.4% 
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at different levels). Serum TSH levels were determined with a Modular Analytics 
E-170 system (Roche Diagnostic Systems, Basel, Switzerland) (intra-assay variability 
of 0.88–10.66% and interassay variability of 0.91–12.05%). Serum T3 levels were 
measured by fl uorescent polarization immunoassay using an Axsym system (Abbott) 
(intra-assay variability of 0.15–0.37% and interassay variability of 6.5–19%).
Statistical analysis
SPSS for Windows, version 14.0 (SPSS Inc., Chicago, IL, USA), was used to perform 
data analysis. Data are expressed as mean ± standard deviation, unless mentioned 
otherwise. Outcomes of patients at the three visits were compared using analysis 
of variance for repeated measures, and post-hoc analysis if appropriate. Data from 
healthy controls were compared to data from the patients using Kruskal–Wallis non-
parametric tests. Differences were considered statistically signifi cant at P < 0.05.
Results
Patient characteristics
Patient characteristics are detailed in Table 1. Fifteen patients were included in this 
study. One patient was excluded from the analysis because follow-up data were not 
obtained. Accordingly, 14 patients completed this study (3 men and 11 women), with 
a mean age of 51.6 ± 14.5 years. Median duration of TSH suppression was 1 year 
(range 0.5–44.6 years). The dose of thyroxine replacement before withdrawal was 
162 ± 42 μg/ day. The control group consisted of 21 women and 3 men, with a mean 
age of 45.4 ± 8.5 years (P = 0.16 vs. patients).
Clinical and laboratory parameters
Thyroid hormone levels
Thyroid hormone levels are summarized in Table 2. At visit 1, serum FT4 concen-
trations were above the upper limit of the normal range (reference range, 10–24 
pmol/L), TSH levels (reference range, 0.4–4.8 mU/L) were below normal range, and 
T3 levels (reference range, 1.1–3.6 nmol/L) were within normal range. Seven days 
after thyroxine withdrawal, FT4 levels were already slightly below the lower limit of 
the reference values, and TSH levels had increased signifi cantly, whereas T3 levels 
were still within normal range. At visit 3, at the end of the study, all patients had 
elevated TSH levels and decreased FT4 and T3 levels (Table 2).
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Weight and body mass index
Weight and body mass index were signifi cantly different at visits 2 and 3 compared 
to visit 1, and were also different between visits 2 and 3 (Table 2). 
Table 1: Patient characteristics
Patients n=14
Age (years) mean ± SD (range) 51.6 ± 14.5 (24-69)
Sex (Male/Female) 3/11
Tumor stage
 T1 N0 M0 2
 T2 N0 M0 8
 T3 N0 M0 1
 T3 N1 M0 2
 T4 N1 M0 1
Histology tumor
 Papillary 7
 Papillary-follicular 4
 Follicular 2
 Follicular Hürthle 1
Duration TSH suppression (years) median (range) 1.0 (0.5-44.6)
Dose Levo-thyroxine (μg/day) mean ± SD 162.5 ± 41.6
Dose I-131 (MBq) median (range) 8381 (1800-20690)
MBq: megabequerel; SD: standard deviation; TSH: thyroid stimulating hormone 
Table 2: Weight, body mass index, blood pressure, heart rate and thyroid hormone parameters. 
Healthy 
controls
Visit 1
subclinical 
hyperthyroidism
Visit 2
7 days
withdrawal
Visit 3
28 days 
withdrawal
FT4 (pmol/l) (ref 10-24 pmol/l) NA 26.4 ± 3.1 9.6 ± 1.9 † 2.2 ± 1.3 †‡
T3 (nmol/l) (ref 1.1-3.6 nmol/l)) NA 1.5 ± 0.5 1.1 ± 0.2 * 0.6 ± 0.2 †‡
TSH (mU/l) (ref 0.4-4.8 mU/l) NA 0.3 ± 0.58 9.5 ± 15.5 * 105.2 ± 57.8 †‡
Weight (kg) 72.5 ± 11.0 78.9 ± 18.5 79.9 ± 18.5 * 81.6 ± 18.5 †‡
BMI (kg/m²) 24.9 ± 3.1 26.5 ± 6.1 26.9 ± 5.9 † 27.6 ± 6.0 †‡
Systolic blood pressure (mmHg) 124.8 ± 7.7 130.1 ± 23.2 130.2 ± 23.3 131.3 ± 20.1
Diastolic blood pressure (mmHg) 76.0 ± 6.9 81.7 ± 16.5 77.6 ± 12.9 85.5 ± 10.4 #§
Mean blood pressure (mmHg) 92.3 ± 6.3 97.8 ± 18.3 95.2 ± 15.4 100.8 ± 12.3
Heart rate (BPM) 70.4 ± 8.4 70.8 ± 8.0 65.2 ± 8.2 * 66.6 ± 6.7
Visit 2 refl ects euthyroid to hypothyroid state, visit 3 refl ects overt hypothyroidism. TSH= thyroid 
stimulating hormone, BMI= body mass index, BPM= beats per minute *= P< 0.05 compared to visit 1, 
†= P≤ 0.001 compared to visit 1, # = P< 0.05 compared to visit 2, ‡= P≤ 0.001 compared to visit 2, 
§= P≤ 0.05 compared to controls
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Blood pressure and heart rate
At baseline, six patients had hypertension, but only one patient was on antihyperten-
sive treatment. No differences were observed in systolic blood pressure and mean 
arterial pressure 7 and 28 days after l-thyroxine withdrawal. Diastolic blood pressure 
increased signifi cantly at visit 3 compared to visit 2. Heart rate was signifi cantly 
decreased at visit 2 (Table 2).
Echocardiography
LV dimensions and systolic function
At baseline, LVM, LVMI, IVST and PWT were signifi cantly higher in patients with 
subclinical hyperthyroidism as compared to control subjects. However, none of 
the patients met the criteria for LV hypertrophy (31). Echocardiography showed no 
signifi cant changes in M-mode measurements of LV dimensions and systolic function 
during acute withdrawal of thyroid hormone (Table 3). 
Diastolic function
Control subjects had signifi cantly higher mean values for E- and E′-wave as compared 
to patients at baseline. The E′/A′ ratio -was higher in controls when compared to the 
patients’ baseline values. The values for A- and A′-wave were signifi cantly lower in 
the patients at visit 3, 28 days after withdrawal, compared to visits 1 and 2. Baseline 
left atrium anteroposterior diameter was similar between patients and controls (Table 
4). Twenty-eight days after withdrawal, E-wave was signifi cantly lower compared to 
baseline. There were no changes in E/A ratio, E′/A′ ratio and left atrium anteroposte-
rior diameter during the study (Table 4). 
Table 3: Left ventricular dimensions and systolic function
Healthy 
controls
Visit 1
subclinical 
hyperthyroidism
Visit 2
7 days
withdrawal
Visit 3
28 days 
withdrawal
Left ventricular mass (g) 135.6 ± 27.2 157.8 ± 31.2 163.9 ± 32.4 * 168.6 ± 42.4 *
Left ventricular mass index (g/m²) 73.6 ± 9.3 81.6 ± 12.1 * 84.1 ± 12.2 * 85.2 ± 16.7 *
Inter-ventricular septum thickness (mm) 8.3 ± 1.0 w9.9 ± 1.3 * 9.3 ± 1.4 * 9.5 ± 1.5 *
Posterior wall thickness (mm) 8.2 ± 0.7 9.5 ± 1.9 * 9.4 ± 1.2 * 9.7 ± 1.5 *
Left ventricular end-diastolic diameter (mm) 48.5 ± 4.5 46.9 ± 5.3 49.4 ± 5.0 48.9 ± 5.0
Left ventricular end-systolic diameter (mm) 28.1 ± 4.1 28.7 ± 4.6 29.6 ± 3.5 29.1 ± 3.2
Fractional shortening (%) 38.2 ± 3.4 38.4 ± 7.4 39.8 ± 5.7 40.1 ± 5.8
Left ventricular ejection fraction (%) 68.0 ± 4.2 68.0 ± 8.8 70.4 ± 6.1 70.3 ± 6.7
Visit 2 refl ects euthyroid to hypothyroid state, visit 3 refl ects overt hypothyroidism. * P< 0.05 
compared to healthy controls
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Discussion
The current study aimed at investigating the effects of overt acute hypothyroidism in 
DTC patients on cardiac function. At baseline, when patients were subclinically hy-
perthyroid, patients had higher LV size and mass and decreased diastolic function as 
compared to controls. Thyroxine withdrawal resulted in an additional subtle decrease 
in both E- and A-wave velocities, without an impact on E/A ratio, indicating discrete 
unfavorable effects on diastolic function as assessed by echocardiography. In line 
with this observation, diastolic function, when more specifi cally analyzed by TDI, de-
creased. This was refl ected in decreased late diastolic velocity (A′) without impacting 
E′/A′ ratio. Overt hypothyroidism increased diastolic blood pressure signifi cantly, but 
had no effect on systolic blood pressure. Therefore, long-term subclinical hyperthy-
roidism is accompanied by diastolic dysfunction. Subsequent acute hypothyroidism 
induces subtle changes in diastolic function. 
The impact of acute hypothyroidism on cardiac function has been investigated 
in only a few studies. These studies were inconclusive and mainly showed decreased 
diastolic function (18,19,23–25) or decreased systolic function (21,24), measured by 
different techniques (conventional echocardiography and radionuclide imaging). In 
addition, none of these studies compared their outcomes to a control group without 
cardiovascular comorbidities or had their observers blinded with regards to treatment 
modalities. Moreover, none of these studies measured cardiac function using TDI, a 
new and sophisticated technique that permits quantifi cation of diastolic parameters 
which are independent of cardiac loading conditions (28,34,35). 
Table 4: Diastolic function
Controls Visit 1
subclinical 
hyperthyroidism
Visit 2
7 days
withdrawal
Visit 3
28 days 
withdrawal
E (cm/sec) 68.8 ± 10.7 57.0 ± 19.2 * 55.6 ± 15.6 * 46.6 ± 15.1 *‡
A (cm/sec) 54.6 ± 12.0 50.6 ± 11.7 50.9 ± 9.9 40.6 ± 11.6 *†‡
E/A ratio 1.3 ± 0.2 1.2 ± 0.2 1.1 ± 0.4 1.2 ± 0.5
E’ (cm/sec) -8.9 ± 1.6 -6.4 ± 2.6 * -6.4 ± 2.4 * -5.8 ± 1.6 *
A’ (cm/sec) -6.5 ± 1.6 -6.9 ± 1.4 -6.8 ± 1.7 -5.7 ± 1.7 *‡
E’/A’ ratio 1.4 ± 0.5 1.0 ± 0.5 * 1.1 ± 0.7 1.2 ± 0.6 *
AP diameter of the LA (cm) 38.2 ± 4.1 37.2 ± 4.6 36.9 ± 5.1 36.1 ± 5.2
Visit 2 refl ects euthyroid to hypothyroid state, visit 3 refl ects overt hypothyroidism. E= peak fl ow of 
early fi lling phase, A= peak fl ow in atrial fi lling phase, E’= peak fl ow of early fi lling phase measured 
by Tissue Doppler Imaging, A’= peak fl ow in atrial fi lling phase measured by Tissue Doppler Imaging, 
LA= left atrium. *= P< 0.05 compared to healthy controls, †= P< 0.05 compared to visit 1, ‡= P< 0.05 
compared to visit 2.
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Our study is in line with only one other study that reported no impact on cardiac 
function after thyroxine withdrawal (20). In that study, conventional echocardiog-
raphy without TDI was used and, in contrast to our study, the observers were not 
blinded with regards to treatment modalities. 
After thyroxine withdrawal, early and late diastolic velocity (E and A, respectively) 
decreased mildly, whereas the E/A ratio was not affected. In addition, mean values for 
E, A and E/A ratio were still within the normal range of reference values when patients 
suffered from overt hypothyroidism (36). These fi ndings imply that acute thyroxine 
withdrawal only minimally affects diastolic function. 
In the present study, only six patients had an E/A ratio slightly below 1 during 
overt hypothyroidism. This is probably due to impaired ventricular relaxation associ-
ated with a delay in the energy-dependent reuptake of calcium by the sacroplasmatic 
reticulum, which in turn is under thyroid hormone control (26). This thyroid hormone 
control of cardiac function is mediated mainly by T3 (3), which in our study de-
clined signifi cantly during thyroxine withdrawal. Although the fi ndings of the present 
study suggest minimal unfavorable cardiovascular effects of thyroxine withdrawal, 
the potential negative cardiovascular consequences of thyroxine withdrawal before 
diagnostic iodine-131 whole body scanning could be clinically relevant, especially 
in patients at cardiovascular risk (1,37,38). Therefore, recombinant TSH stimulation 
might be an attractive alternative in ‘low-risk thyroid carcinoma patients’ and/or high-
risk cardiovascular patients. 
At baseline, when patients had subclinical hyperthyroidism, echocardiography 
revealed decreased diastolic function. This is in line with a previous study in pa-
tients with exogenous subclinical hyperthyroidism (5). The clinical consequences of 
isolated diastolic dysfunction in subclinical hyperthyroidism are not entirely clear, 
but could be accompanied by increased morbidity and mortality when compared to 
isolated diastolic dysfunction in other conditions, especially in long-term subclinical 
hyperthyroidism (39). It has been suggested that diastolic dysfunction in subclini-
cal hyperthyroidism results from an increased LVM (40,41). In our study, however, 
no patient fulfi lled the criteria for LV hypertrophy, although there was a signifi cant 
elevation in LVM at baseline compared to controls. Therefore, biochemical effects 
of thyroid hormone on cardiac function instead of increased LVM are more likely 
involved in the induction of diastolic dysfunction (1). Nonetheless, additional studies 
with longer follow-up are needed to elucidate the effects on LV dimensions and mass. 
Systolic blood pressure did not change after thyroxine withdrawal, whereas 
diastolic blood pressure was higher at visit 3, when patients were overtly hypothyroid 
compared to visit 2, when patients were mildly hypothyroid. These fi ndings are in line 
with those of previous studies (3, 10, 19, 42, 43). The increase in diastolic blood pres-
sure in hypothyroidism is ascribed to increased peripheral vascular resistance (3, 43). 
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In conclusion, in the present study we demonstrated that long-term iatrogeni-
cally induced subclinical hyperthyroidism in patients with DTC induces diastolic 
dysfunction. Subsequently, overt acute hypothyroidism induces discrete decreases in 
diastolic parameters.
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Abstract
Objective
This study was performed to evaluate the impact of cured differentiated thyroid car-
cinoma (DTC) on quality of life. Previous studies on quality of life in patients with 
DTC were hampered by small patient numbers or limited quality-of-life parameters 
or were uncontrolled.
Design
This was a cross-sectional case-control study.
Method
We assessed quality of life in 153 cured DTC patients with a median duration of 
cure of 6.34 yr (range 0.3 – 41.8) and studied the contribution of disease-specifi c, 
biochemical, and social variables, focusing on the degree of TSH suppression. Four 
validated health-related questionnaires were used (Short Form-36, Multidimensional 
Fatigue Index-20, Hospital Anxiety and Depression Scale, and Somatoform Disorder 
Questionnaire), including multiple aspects of physical, psychological, and social 
functioning. Patients were compared with 113 controls selected by patients them-
selves (control group I) and 336 pooled age- and gender-matched controls from other 
Leiden quality-of-life studies (control group II).
Results
Patients had signifi cantly decreased quality of life in 11 of 16 subscales when com-
pared with control group I. In comparison with control group II, decreased scores in 
13 of 16 items were observed. An important independent predictor for quality of life 
was duration of cure. Quality-of-life parameters were not infl uenced by serum TSH 
levels both measured at the time of quality-of-life assessment and measured over time 
since initial therapy.
Conclusions
Patients cured for DTC have impaired quality of life, independently of TSH level. 
Quality-of-life parameters were inversely affected by duration of cure and conse-
quently may be restored after prolonged follow-up.
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Introduction
Well-differentiated thyroid carcinoma (DTC) is associated with an excellent medical 
prognosis, with 10-yr survival rates reaching 90–95% (1). After initial therapy, usually 
consisting of total thyroidectomy and radioiodine thyroid remnant ablation therapy, 
most patients used to be treated with high doses of L-thyroxine to suppress TSH levels 
(1). On the one hand, the excellent prognosis and moderate invasiveness of the initial 
therapy may implicate that quality of life in cured DTC patients may be relatively 
normal. On the other hand, TSH-suppressive T4 replacement therapy may lead to a 
decreased quality of life (2–4). Only a few studies have evaluated quality of life in 
cured DTC patients (5–9). These studies are limited by small patient numbers (6, 7), 
limited number of quality-of-life questionnaires (5, 9) or the absence of a healthy 
control group (5, 6, 8).
Studies that focussed on the relation between the level of TSH suppression and 
quality of life in DTC patients are inconclusive because of small patient numbers, selec-
tion of patients with symptoms of hyperthyroidism, or selection of patients with a long 
duration of cure (2, 10). Therefore, the aim of the present study was to assess quality of 
life in a large cohort of cured DTC patients and investigate the determinants of quality 
of life, including serum TSH levels. We used four validated, health-related question-
naires and included controls matched for age, gender, and socioeconomic status.
Patients and Methods
Patients
Cured DTC patients, 18–70 yr old, were recruited from the outpatient clinic of the 
Department of Endocrinology of the Leiden University Medical Center. Other medi-
cal conditions or drugs that could infl uence quality of life were not permitted. Initial 
therapy consisted of near-total thyroidectomy, followed by postoperative radioiodine 
ablation therapy with I-131. Cure after initial therapy was defi ned as the absence 
of I-131 accumulation at diagnostic 185 MBq scintigraphy, serum thyroglobulin 
concentrations less than 2 μg/liter after TSH stimulation in absence of thyroglobulin 
antibodies, and no other evidence of disease (11). Patients with tumor relapse were 
included only if they were subsequently cured. Initially, 157 DTC patients who met 
these criteria were asked to participate. Four validated questionnaires were sent to 
their homes together with a list of general questions about level of education, coun-
try of origin, and marital state. Four patients specifi cally wished not to participate. 
Each patient was also asked to provide a control person of comparable sex, age, and 
socioeconomic status (friend, neighbor, relative) (control group I). We received 153 
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completed questionnaires from patients and 113 questionnaires from controls. To 
exclude bias in the selection of control group I, we also compared the patients with 
a larger cohort of age-, gender-, and socioeconomic status-matched healthy controls 
(n = 336) obtained from other quality-of-life studies performed in our center (12–15) 
(indicated as control group II). The study protocol was approved by the Medical Eth-
ics Committee of the Leiden University Medical Center, and written consent was 
obtained from all patients.
Study parameters
Primary study parameters were the outcomes of the four health-related questionnaires 
and the contribution of patient characteristics (age, gender, educational level, marital 
status), disease-specifi c characteristics (initial tumor node metastasis stage, recurrent 
disease, duration of cure), treatment (extent of surgery, radioiodine therapy and additional 
treatments), and biochemical parameters (serum free T4, T3, and TSH levels) to quality of 
life. The infl uence of TSH on quality of life was investigated by both evaluation of serum 
TSH levels at time of the survey expressed as continuous variable or stratifi ed as pro-
foundly suppressed (<0.1 mU/liter), moderately suppressed (<0.4 mU/liter), and unsup-
pressed (<0.4 mU/liter) and summary TSH parameters over time since initial therapy for 
each patient. Summary TSH parameters over time were the mean, 25th, 50th, and 75th 
percentiles and the percentage of profoundly suppressed, suppressed, and unsuppressed 
TSH values from all available unstimulated TSH measurements since initial therapy.
Quality-of-life questionnaires
Short form-36 (SF-36)
The SF-36 questionnaire comprises 36 items and records general well-being during 
the previous 30 d (16), subdivided into six health concepts. Scores are expressed on 
a 0–100 scale, and higher scores are associated with a better quality of life.
Multidimensional Fatigue Index-20 (MFI-20)
The MFI-20 comprises 20 statements (fi ve dimensions) to assess fatigue, which are 
measured on a 5-point scale (17). Scores vary from 0 to 20; higher scores indicate 
greater fatigue.
Hospital Anxiety and Depression Scale (HADS)
The HADS consists of 14 items pertaining to anxiety and depression. Scores for the 
anxiety and depression subscale range from 0 to 21, and values for the total score 
range from 0 to 42. Higher scores indicate more anxiety or depression (18).
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Somatoform Disorders Questionnaire (SDQ)
All somatoform disorders mentioned in classifi cation Diagnostic and Statistical 
Manual of Mental Disorders, third edition, were comprised in this questionnaire (19). 
The total score varies from 0 to 51 for women and 0 to 55 for men. The total score 
expresses the extent of physical complaints that were present in the previous week.
Assays
Serum free T4 (FT4; normal range 10–24 pmol/liter) and TSH levels (normal range 
0.4–4.5 mU/liter) were measured by electrochemoluminescentic immunoassay using 
a Modular Analytics E-170 system (Roche, Almere, The Netherlands).
Statistical analysis
SPSS for Windows (version 12.0; SPSS Inc., Chicago, IL) was used to perform all 
analyses. Data are expressed as mean ± SD unless indicated otherwise. As de-
pendent variables, we calculated delta-scores between each patient and age- and 
gender-matched Leiden controls by subtracting age- and gender-specifi c means of 
the controls from patient scores for all questionnaire subscales. Stepwise univariate 
linear regression analysis was used to identify independent variables for quality of 
life. Differences were considered statistically signifi cant at P < 0.05. 
Results
One hundred fi fty-three patients (28 males, 125 females, aged 49 ± 13 yr, 127 pap-
illary and 27 follicular carcinomas) were analyzed. Tumor stages were T1–3M0 in 
131, T4 in 18 and M1 in four patients. Median duration of cure was 6.3 yr (range 
0.3–41.8). At the time of the survey, median TSH was 0.1 mU/liter (range 0.005–6.8) 
and FT4 was 22.4 ± 4 pmol/liter. An average of 15 unstimulated TSH measurements 
per patient was obtained since initial therapy. Summary parameters of TSH over time 
per patient were: mean 0.4mU/ liter (range 0.1–3.4) and median 0.05 mU/liter (range 
0.005 to 2.18); proportions of profoundly suppressed values: 58% (range 0–100) and 
moderately suppressed values: 80% (range 0–100%). The slope of TSH values was 
-0.0001 mU/yr (range -0.004 to 0.000 mU/yr), indicating that the TSH levels were 
reasonably stable. Mean dose of L-thyroxine was 183 ± 51 μg/d.
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Quality of life in DTC patients and controls
Quality-of-life scores in patients were signifi cantly reduced in 11 of the 16 items 
assessed when compared with control group I. According to the SF-36 question-
naire, patients had signifi cantly worse scores on social functioning and general health 
perception. All MFI-20 subscales and HADS subscales were affected in DTC patients. 
The SDQ total score was also signifi cantly worse than in control group I. Comparison 
of the patients with control group II (12–15) showed similar results: 13 of 16 quality-
of-life parameters differed signifi cantly between patients and controls (Table 1). 
Table 1: Quality of life in patients treated for DTC compared with controls selected by patients 
themselves (Control Group I) and age and gender matched controls from other Leiden quality of life 
studies (Control Group II) (12, 13, 14, 15). Data shown are mean ± SD
Questionnaire
Patients
(n=153)
Control 
group I
(n=113)
P value
(patients 
vs. control 
group I)
Control group 
II
(n=336)
P value
(patients vs.
control 
group II)
Age 49.10 48.08 0.522 49.99 0.496
M/F 28/125 19/94 0.754 67/269 0.672
SF-36
Physical functioning 83.70±21.02 88.27±16.78 0.052 87.77±17.14 0.040
Social functioning 81.09±24.90 87.39±20.01 0.037 88.06±19.28 0.007
Role limitations due to 
physical problems
75.35±40.04 81.42±34.36 0.194 83.38±32.43 0.035
Role limitations due to 
emotional problems
83.22±35.43 84.66±31.82 0.734 85.93±30.21 0.422
Bodily pain 82.74±21.70 84.78±18.93 0.426 85.17±19.24 0.216
General health perception 65.59±20.48 71.45±18.43 0.027 71.34±18.79 0.007
Change in health 52.15±18.37 55.18±18.19 0.185 54.77±18.64 0.105
MFI-20
General fatigue 11.03±4.72 8.11±3.35 <0.001 8.60±4.01 <0.001
Physical fatigue 9.95±4.93 6.65±2.64 <0.001 7.60±3.69 <0.001
Reduced activity 8.79±4.15 6.85±3.30 <0.001 7.18±3.57 <0.001
Reduced motivation 8.64±3.76 6.67±2.79 <0.001 7.26±3.53 <0.001
Mental fatigue 9.53±4.50 7.93±3.60 0.002 7.92±3.31 <0.001
HADS
Anxiety 5.69±3.95 4.14±3.15 <0.001 4.21±3.21 <0.001
Depression 3.61±3.08 2.37±2.52 <0.001 2.86±2.99 0.011
Total 9.30±6.30 6.51±4.92 <0.001 7.07±5.39 <0.001
SDQ
SDQ total 5.92±6.20 1.66±2.51 <0.001 1.65±2.50 <0.001
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Determinants of quality of life
Marital status, country of birth, initial tumor node metastasis stage, total activity of 
I-131, tumor recurrence, L-thyroxine dose, postsurgical hypoparathyroidism, and 
serum FT4 level did not affect any of the questionnaire items. TSH levels measured 
at the time of the assay (both continuous and stratifi ed) and summary TSH values 
over time appeared not to be a signifi cant independent predictor for quality of life. 
Post hoc power calculation revealed suffi cient power (all items > 0.9) to draw this 
conclusion. A longer duration of cure was correlated with better scores on SF-36 
social functioning (standardized β=0.21, P=0.030), role limitations due to physical 
problems (β=0.17, P=0.049), general health perception (β=0.32, P=0.001), MFI-20 
general fatigue (β=-0.17, P=0.035), physical fatigue (β=-0.24, P=0.003), and mental 
fatigue scores (β=-0.17, P=0.038). We calculated the duration of cure needed for 
the quality-of-life scores to reach the normal range of all healthy subjects (Figure 1). 
The 95% confi dence intervals of quality-of-life scores included only 0 (no difference 
between quality of life of patients and controls) after a relatively long duration of cure 
(~12–20 years for SF-36 and MFI-20, respectively).
Discussion
The purpose of this study was to evaluate quality of life in a large cohort of cured 
DTC patients using multiple quality-of-life parameters and a matched healthy control 
group. We found that quality-of-life scores assessed by the majority of subscales are 
reduced in patients previously treated for DTC, compared with controls. Although 
our observations are in line with other studies on quality of life in DTC patients (5–9), 
our study includes a higher number of patients, uses more quality-of-life question-
naires, and uses matched control groups. 
Longer duration of cure was associated with better scores on different quality-
of-life items. This fi nding is in line with studies by Dagan et al. (7) and Crevenna et 
al. (5), but this is the fi rst study to quantify the predicted duration of affected quality 
of life in relation to duration of cure. After a long duration of cure, approximately 
12–20 yr (MFI-20 and SF-36, respectively) the 95% confi dence intervals of 6 of the 
16 quality of life subscales included a normal score (Figure 1). 
In our study, quality of life was not infl uenced by TSH levels at the time of the 
survey and by TSH levels over time since initial therapy; although it can be objected 
that generic questionnaires were used. Other studies on the effects of subclinical 
hyperthyroidism on well being yielded inconclusive results. Most of these studies 
have been performed in patients with endogenous subclinical hyperthyroidism (3) 
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who cannot easily be compared with DTC patients or contained selected patients 
with DTC (2).
Comparison of DTC survivors to survivors of other cancer types is complicated 
because of the many differences between the several cancer types. A large study (20) 
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Figure 1 
Differences between age- and gender-matched controls and patients for the quality-of-life parameters 
plotted against duration of cure; linear regression line and 95% confi dence interval are shown 
(standardized Beta and signifi cance of linear regression analysis). The horizontal line represents the 
value for quality-of-life parameters where there is no difference between patients and the means of 
age- and gender-matched controls.
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revealed that DTC survivors had similar quality of life as patients with breast cancer, 
worse than survivors of melanoma or colorectal cancer, but better than hematological 
malignancies. Despite cure, excellent prognosis, and moderate aggressive treatment, 
DTC patients have an evident decrease in quality of life that may be restored only 
after years of follow-up. The fi ndings of our study have therefore implications for 
the approach of the cured DTC patients: attention for the psychological well-being 
of the patient and availability of professional support may be important aspects in 
follow-up.
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I. Introduction
Differentiated thyroid carcinoma (DTC) has a low incidence and a relative good prog-
nosis with a 10-year survival of approximately 90-95%. The incidence has increased 
during the last years and this trend appears to be continuing (1-4).
Despite the low incidence, many medical centers treat patients with thyroid car-
cinoma. This decentralized approach does not contribute to optimal treatment, since 
not all clinicians are fully familiar with the optimal treatment strategy. Moreover, 
DTC is a unique malignant disease in which fascinating biological phenomena, like 
the physiology of iodine transport, are present. This makes that general principles of 
clinical oncology cannot always be extrapolated to DTC. However, publications of 
consensus and guideline papers (5,6) have improved the implementation of uniform 
protocols for diagnosis, treatment and follow-up.
Regardless of these guidelines, still many uncertainties exist with respect to the 
optimal strategy for diagnosis, treatment and follow-up of DTC. An example of an 
unresolved diagnostic dilemma is that the diagnosis of DTC is still largely dependent 
on conventional histological staining procedures. Particularly the distinction between 
follicular adenoma (benign) and follicular thyroid carcinoma (malignant) is diffi cult 
to make. As a consequence, many patients will undergo surgery although they do not 
have DTC.
In this thesis, we tried to contribute to improve diagnostic markers for the distinc-
tion between benign and malignant thyroid disease. Furthermore, we performed a 
phase II trial with the tyrosine kinase inhibitor sorafenib in order to optimize treat-
ment for non-RaI avid metastatic DTC. In the other part of this thesis, we focused 
on the clinical consequences of initial therapy consisting of thyroidectomy and RaI 
ablative therapy. The subsequent treatment with TSH suppressive thyroxine replace-
ment therapy and regular withdrawal of thyroxine for TSH stimulated whole body 
scanning makes DTC patients an interesting model to study the metabolic effects of 
thyroid hormone on various organ systems and quality of life.
II. Diagnosis of differentiated thyroid carcinoma
Despite increasing standards of imaging techniques like FDG-PET and ultrasound, 
fi ne needle aspiration (FNA) is the procedure of choice in patients presenting with a 
thyroid nodule (5). However, the diagnosis of DTC and in particular the differentiation 
between follicular adenoma (FA), follicular thyroid carcinoma (FTC) and follicular 
variant of papillary thyroid carcinoma (FVPTC) is diffi cult to make on cytology. The 
consequence is that 70-80% of the patients with suspicious results from FNA, who 
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undergo surgery, have a benign tumor (5,7). The use of molecular markers (e.g. ga-
lectin-3, PAX8-PPARgamma, BRAF, RAS or RET/PTC), may be considered for patients 
with indeterminate cytology on FNA to help guide management (8-13). 
After hemithyroidectomy the microscopical distinction between benign and 
malignant neoplastic thyroid nodules by conventional histology remains diffi cult as 
these lesions may share overlapping histological characteristics. It is therefore impor-
tant to identify new markers to distinguish benign from malignant thyroid tumors. In 
recent years, several immunohistochemical markers have been studied to improve the 
differential diagnosis of thyroid lesions, using both candidate markers and unbiased 
approaches (14-19).
Differential expression of retinoic acid receptor (RAR) subtypes between benign 
and malignant thyroid tissues has been described; their diagnostic value has not been 
reported yet. In Chapter 2, we describe the diagnostic accuracy of RAR and retinoid X 
receptor (RXR) subtype protein expression for the differential diagnosis of thyroid neo-
plasms. We used a tissue array containing 93 benign thyroid tissues (normal thyroid, 
multinodular goiter, and FA) and 77 thyroid carcinomas (papillary thyroid carcinoma 
(PTC), FTC and FVPTC). Immunostaining was performed for RAR and RXR subtypes. 
Staining was analyzed semiquantitatively, based on receiver operating curve (ROC) 
analyses and using hierarchical cluster analysis. 
We found increased expression of cytoplasmic (c) RARalpha, cRARgamma, 
cRXRbeta and decreased expression of nuclear (n) RARbeta, nRARgamma, and 
nRXRalpha in thyroid carcinomas compared with benign tissues. We found three 
proteins expressed differently between FA and FTC and fi ve proteins differentially 
expressed between FA and FVPTC, with high diagnostic accuracies. Using cluster 
analysis, the combination of negative staining of membranous RXRbeta and positive 
staining for cRXRbeta had a high positive predictive value (98%) for malignant thyroid 
disease, whereas the combination of positive nRXRalpha and negative cRXRbeta 
staining had a high predictive value (91%) for benign thyroid lesions. 
We conclude that differences in RAR and RXR subtype protein expression may 
be valuable for the differential diagnosis of thyroid neoplasms. The results of this 
study and especially the value of cluster analysis have to be confi rmed in subsequent 
studies. 
Perspective
The fi ndings of chapter 2 have some limitations before they can be implemented in 
standard diagnostic strategies. Although we were able to distinguish between follicu-
lar lesions, the number of follicular lesions was relatively small. Therefore, additional 
studies should be performed with larger numbers of follicular lesions, also including 
histological subtypes of follicular lesions. Moreover, the fi ndings of our study and the 
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clinical usefulness of hierarchical cluster analysis have to be validated in subsequent 
studies and most importantly in cytological preparations. Also, other diffi cult-to-
classify thyroid neoplasms such as minimally invasive follicular carcinomas as well as 
FA subclasses should be included in subsequent studies. The biological mechanisms 
responsible for the differential expression of RAR and RXR between thyroid tissues 
also remain to be elucidated.
III. Novel treatment strategies for non-RaI avid metastatic disease
1. Sorafenib for RaI non-avid DTC
Distant metastases, usually in the bones and lungs, occur in approximately 10-15% 
of patients with differentiated thyroid carcinoma (DTC). The major problem in this 
category of patients is the dedifferentiation of thyroid cancer and with that the di-
minished or lost ability to accumulate RaI. Treatment options for patients with RaI 
refractory metastases of DTC are limited. Metastatic thyroid cancer that has become 
inoperable or refractory to radioiodine therapy is associated with a poor 10 year 
survival of 5-10%.
The extensive characterization in recent years of the molecular pathways involved 
in the pathogenesis of DTC has revealed potential targets for new therapies. The iden-
tifi cation of tyrosine kinase activated pathways in DTC together with the introduction 
of novel classes of tyrosine kinase inhibitors has provided new therapeutic perspec-
tives for patients with non-RaI avid DTC. In DTC, a relationship has been identifi ed 
between genetic alterations in the RET, RAS, RAF cascade and loss of NIS expression 
(21,22). Interestingly, in an in-vitro study, a multikinase inhibitor sunitinib was able 
to reinduce NIS expression in RET/PTC transformed thyroid cells (22). In addition, 
sunitinib also increased RaI uptake in FRTL-5 cells (23).
The anti-EGFR compound gefi tinib was not successful in 27 patients with DTC, 
medullary or anaplastic thyroid carcinoma (24). In a phase II study in 60 thyroid 
carcinoma patients with various histologies, the VEGFR inhibitor axitinib showed a 
partial response of 30% (25). Motesanib diphosphate, a multitarget kinase inhibitor 
induced a partial response in 14% of 93 DTC patients (median PFS 40 weeks) (28). 
Two studies have been published using sorafenib. Sorafenib (BAY 43-9006) is an 
inhibitor of RET, C-RAF, wild-type and mutant (V600E) BRAF, VEGFR1, -2, -3, Flt3, 
and c-KIT. In the fi rst study, including DTC, anaplastic and medullary thyroid carci-
noma patients, sorafenib induced a partial response in 23% (median PFS 79 weeks) 
(26). The second study included patients with DTC but also with anaplastic thyroid 
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carcinoma. As a result of that, the response rate was probably signifi cantly lower, 
11% (median PFS 4.5–16 weeks) (27). 
The mechanism behind the difference in response rate between the two mul-
tikinase inhibitors motesanib (14%) and sorafenib (23%) is probably based on the 
difference in IC50 for the tyrosine kinases which the compound inhibits. Motesanib 
has stronger inhibitory effects on VEGFR1 (IC50 2 nM), VEGFR2 (IC50 3 nM) and 
VEGFR3 (IC50nM), whereas sorafenib inhibits RET (IC 50 47nM), RET/PTC3 (IC50 
50nM) and BRAF (IC50 22 nM). However comparison of the results of phase II studies 
with different tyrosine kinase inhibitors in DTC is hampered by differences in patient 
categories (including histologies, tumor stages, sites of metastases, and tumor extent), 
study design, and analytical methods. 
We decided to study the effects of the multitarget tyrosine kinase inhibitor 
sorafenib on the reinduction of RaI uptake and tumor progression (Chapter 3). This 
was an open, single center, single arm, 26-week prospective phase II study with 
open-ended extension. We hypothesized that treatment with a multitarget tyrosine 
kinase inhibitor not only reduces tumor progression, but may also restore RaI uptake 
in non-RaI avid DTC. We treated 31 patients with progressive metastatic or locally 
advanced RaI refractory DTC with sorafenib 400 mg b.i.d. The primary endpoint was 
reinduction of RaI uptake at 26 weeks. Additional endpoints were the radiological 
response and the infl uence of bone metastases.
RaI therapy is the only available conventional therapy for patients with metastases 
of DTC. Hürthle cell carcinomas tend to respond less favorably to RaI, which is com-
patible with the fact that the most prevalent histology in our study was Hürthle cell 
metaplasia. The fact that 10/13 PTC harbored BRAFV600E mutations also illustrates 
the unfavorable prognostic characteristic of our patient group (29). 
At 26 weeks of sorafenib therapy, unfortunately no reinduction of RaI uptake at 
metastatic sites was observed. However, 19 patients (59%) had a clinical benefi cial 
response, eight of whom had a partial response (25%) and 11 had stable disease 
(34%). Seven patients had progressive disease (22%). The estimated median progres-
sion free survival was 58 weeks (95% confi dence interval, CI, 47–68). In general, 
thyroglobulin (Tg) response (both unstimulated and TSH stimulated) refl ected radio-
logical response. The median time of the nadir of Tg levels was 3 months. Responses 
were not infl uenced by histological subtype, mutational status or other variables. 
No unusual side effects were observed. Sorafenib was signifi cantly less effective in 
patients with bone metastases. 
Although a clear relation has been found in-vitro between genetic alterations 
in DTC and decreased NIS gene expression (20,21), multiple mechanisms may be 
involved in decreased NIS functionality, including impaired NIS membrane traffi ck-
ing (14,30), epigenetic changes in NIS and/or NIS promoter genes (31). Although 
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in-vitro studies have shown that multitarget tyrosine kinase inhibitors may lead to 
reinduction of RaI uptake (22,23), it may well be that these additional mechanisms 
have prevented a benefi cial effect of sorafenib on RaI uptake in our study.
Perspective
The results of our study are comparable with the results of previous studies. The 
results obtained with sorafenib in different studies, including our own, suggest that 
sorafenib is a successful and promising compound for metastatic DTC. However we 
found that patients with bone metastases respond less favorably and that diagnostic 
WBS did not reveal an effect of sorafenib on the reinduction of RaI uptake in these 
patients. Future phase III studies should confi rm the effi cacy of sorafenib for DTC. At 
the moment a large multicenter phase III study is being performed internationally and 
the decision whether sorafenib will become part of regular treatment for non-RaI avid 
thyroid carcinoma will depend on the results of this trial.
2. Tyrosine kinase therapy and thyroid hormone metabolism
Therapy with tyrosine kinase inhibitors is associated with thyroid dysfunction. Suni-
tinib has been associated with hypothyroidism in 14–85% of the patients (32-37) and 
in some patients it even induced hyperthyroidism (37-39). Both sunitinib induced 
hypothyroidism and hyperthyroidism may be caused by destructive thyroiditis, but 
other mechanisms, such as interference of sunitinib with thyroid peroxidase (37) or 
inhibition of thyroidal vascularization leading to thyroid atrophy (40,41), have been 
proposed. Decreased serum thyroid hormone levels during tyrosine kinase inhibitor 
therapy are also observed in athyreotic patients on thyroxin substitution after treat-
ment for thyroid carcinoma (26,28,42,43). Therefore, the mechanisms of hypothy-
roidism may include alterations in thyroid hormone metabolism as well. Stepwise 
deiodination is the major route of thyroid hormone degradation and is mediated 
by iodothyronine deiodinases (D1, D2, and D3) (44) and by hepatic conjugating 
enzymes (45).
In our study (Chapter 4), we assessed the relationship between treatment with the 
multitarget kinase inhibitor sorafenib and alterations in thyroid hormone parameters 
in athyreotic DTC patients. We hypothesized that sorafenib may infl uence thyroid 
hormone metabolism through the activities of iodothyronine deiodinases, which 
had not been studied in humans so far. The design included a prospective open, 
single-center, single-arm 26-week study. We measured serum thyroxine (T4), free 
T4, 3,5,3-triiodothyronine (T3), free T3, reverse T3 (rT3), and TSH concentrations 
at baseline and after 26 wk in 21 patients with progressive non-medullary thyroid 
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carcinoma treated with sorafenib. Ratios of T3/T4 and T3/rT3, which are independent 
of substrate availability and refl ect iodothyronine deiodination, were calculated. 
We found that a higher substitution dose of thyroxine was needed to maintain 
serum FT4 levels and T3 levels. Adjusted for levothyroxine dose per kilogram body 
weight, the FT4 and T3 levels decreased by 11% and 18%, respectively, whereas TSH 
levels increased. In addition, we found a clear decrease in serum T3/T4, T3/rT3, and 
T4/rT3 ratios. These ratios refl ect alterations in the peripheral metabolism of thyroid 
hormone, being positively infl uenced by deiodinases D1 and D2 and negatively by 
D3 (46).
The decreased T3/T4 and T3/rT3 ratios may be caused by a decrease in D1 and/
or D2 activity. However, this would be associated with a decreased rather than an 
increased metabolism of T4. Therefore, the decreased T3/T4 and T3/rT3 ratios are best 
explained by an increased D3 activity. It is unlikely that the increased D3 activity 
refl ects a state of non thyroidal illness because serum TSH increased during sorafenib, 
whereas in non thyroidal illness, decreased rather than increased TSH levels would 
be expected.
Although it can be hypothesized that decreased absorption of T4 could also have 
played a role, the interval between sorafenib and thyroxine intake was approximately 
12 hours. In addition, decreased T4 absorption would not affect T3/T4 and T3/rT3 
ratios. No changes in thyroxine binding globulin levels and the ratios between free 
and bound thyroid hormones were observed, ruling out effects of sorafenib on thyroid 
hormone binding proteins, which again, even if present, would not have affected the 
T3/rT3 ratio. It may be hypothesized that sorafenib may also infl uence conjugation 
of thyroid hormone with glucuronates and sulfates by hepatic microsomal enzymes. 
However, altered conjugation would not infl uence T3/rT3 ratios.
Clinical implications 
This study shows that, in addition to direct effects of tyrosine kinase inhibitors on the 
thyroid gland, enhanced peripheral metabolism of thyroid hormone, likely by activity 
of type 3 deiodinase, may contribute to hypothyroidism during therapy with these 
drugs. It is worthwhile to further elucidate the effects of sorafenib on D3 in in-vitro 
studies. Also, it is important to analyze thyroid hormone parameters regularly dur-
ing treatment with tyrosine kinase inhibitors. Well-being of patients can be seriously 
decreased in case of hypothyroidism, which can be easily treated with exogenous T4 
or in case of thyroidectomized patients, an increase in thyroxine dose.
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IV. Consequences of treatment of thyroid carcinoma
Patients with DTC who are treated with total thyroidectomy and radioiodine ablative 
therapy become completely dependent on exogenous thyroid replacement therapy. 
Because of the favorable effects on tumor recurrence, patients used to be treated 
with TSH suppressive doses of thyroxine for approximately 15 years. Whereas this 
long-term TSH suppression is associated with an overall better prognosis (46,47), this 
subclinical hyperthyroid state is also associated with deleterious effects on multiple 
organ systems and on well-being. For this reason, recent guidelines recommend 
initial TSH suppression below 0.1 mU/L for high risk and intermediate risk thyroid 
cancer, while maintenance of TSH at or slightly below the lower limit of normal 
(0.1-0.5 mU/L) is appropriate for low-risk patients. 
During follow-up, DTC patients used to be regularly withdrawn from thyroxine 
therapy to evaluate recurrence and disease state with TSH stimulated whole body 
scintigraphy and thyroglobulin measurement. This creates a state of controlled hypo-
thyroidism.
The long term subclinical hyperthyroidism combined with episodes of short-term 
hypothyroidism make DTC patients an interesting model to study the effects of thyroid 
hormone. Also, there is no interference by endogenous thyroid hormone, because 
patients are treated with total thyroidectomy. 
1. Insights in thyroid hormone metabolism
Peripheral thyroid metabolism is mainly regulated by the iodothyronine deiodinases 
D1, D2, and D3 (44,48). D1 converts T4 to T3, and is involved in serum T3 produc-
tion. In addition, it plays a role in the breakdown of rT3 (49,50). D2 catalyzes local T3 
production in various tissues (49,51,52). D2 in skeletal muscle may also contribute to 
plasma T3 production. D3 inactivates T3 and T4 and thus regulates the clearance of 
T3 and T4. It is thought that it contributes to thyroid hormone metabolism by protect-
ing tissues from excess thyroid hormone. The deiodinases adjust the thyroid hormone 
levels of individual tissues in response to various conditions.
Several polymorphisms in the deiodinases have been described of which some 
are associated with alterations of serum levels of TSH, T3 and T4 (53-57). Most studies 
investigate the consequences of the D2-Thr92Ala (rs225014) polymorphism. Patients 
treated for DTC are ideal to investigate thyroid hormone metabolism, because they 
have been treated with total thyroidectomy and radioiodine ablation therapy. Be-
cause of this treatment they have no intrinsic T3 production. Therefore T3 levels are 
dependent on production at the tissue level through deiodination of exogenous T4 by 
D1 and D2. The negative feedback regulation of pituitary TSH secretion by T3, which 
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in DTC patients is completely produced outside the thyroid, is mainly dependent on 
pituitary D2.
The D2-Thr92Ala polymorphism has been associated with decreased D2 activity 
in some in-vitro experiments (53), but not in others (54,57). So far no association 
between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has been 
observed in humans (49,53,54,57). However, in a recent study in athyroid patients, 
it was suggested that patients homozygous for the 92Ala allele need higher T4 doses 
to achieve TSH suppression (58). We therefore performed a study to reconfi rm these 
fi ndings (Chapter 5) in order to elucidate the association between the D2-Thr92Ala 
polymorphism, thyroid hormone levels and T4 dosage in patients treated for DTC and 
Hashimoto thyroiditis. We studied 154 patients with DTC treated with TSH suppres-
sive thyroid hormone replacement therapy for longer than 3 years and 141 patients 
with Hashimoto thyroiditis treated for at least 6 months with thyroxine. In all patients, 
serum levels of TSH, free T4, T3 and reverse T3 were measured and genotypes of the 
D2-Thr92Ala polymorphism were determined by Taqman assay. Univariate regression 
analysis was performed to determine the relation between T4 dosages and the D2-
Thr92Ala polymorphism corrected for age, gender, BMI and serum TSH levels.
Both in DTC patients and Hashimoto patients, no association was observed 
between serum thyroid hormone levels or T4 dosages in the presence of the D2-
Thr92Ala polymorphism. Categorization of DTC patients according to degree of 
TSH suppression did not change these results. We concluded that the D2-Thr92Ala 
polymorphism was not associated with thyroid hormone levels or T4 dose in patients 
treated for neither DTC nor for Hashimoto thyroiditis. 
Intraindividual variation in serum T4, T3 and TSH is narrow; however there is a 
considerable interindividual variability (59). A large body of evidence suggests that 
every individual has a unique thyroid function setpoint, compatible with a genetic 
infl uence on the regulation of the pituitary-thyroid axis (59-61). We hypothesized 
that polymorphisms in D1 and D2 could infl uence the setpoint of the hypothalamus-
pituitary-thyroid axis (Chapter 6).
We therefore performed a study on the effect of the following D1 and D2 
polymorphism on this axis: D1-C785T (rs11206244), D1-A1814G (rs12095080), 
D2-Thr92Ala (rs225014) and D2-ORFa-Gly3Asp (rs12885300). Effects of these poly-
morphisms on the setpoints were analyzed with regression analysis using a general 
mixed model with a unique series 1905 serum measurements of TSH and FT4 of 
151 patients treated and cured for DTC. These serum samples were collected as 
routine laboratory measurements during follow-up of the disease.
Our study demonstrates that thyroidectomised DTC patients on thyroxine sub-
stitution who are homozygous for the D2-ORFa-Gly3Asp polymorphism have an 
altered setpoint of the hypothalamus-pituitary-thyroid axis. The mixed model analysis 
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of the TSH/FT4 ratios is a precise approach to determine differences in individual 
setpoints. Our data suggest that the negative feedback of T4 on TSH is weaker in 
patients homozygous for the D2-ORFa-Gly3Asp than in wild-type and heterozygous 
subjects. We did not fi nd any other differences in pituitary-thyroid axis for the other 
polymorphisms.
Although we have found a clear difference in the setpoint of the hypothalamus-
pituitary-thyroid axis for the different D2-ORFa-Gly3Asp polymorphisms, there are 
some unknown factors that could have also infl uenced TSH/FT4 ratios. Unfortunately, 
because samples were collected as routine clinical follow-up, only TSH and FT4 lev-
els were available, hence T3 and rT3 are only measured at one time point. Therefore 
we are not able to speculate about the serum values of T3 and rT3, and with that not 
the complete metabolic cycle of thyroid hormones during the entire period of the 
sample collection. 
Our observations are in contrast with the fi ndings of Coppotelli et al. (62) who 
found an increased D2 activity of the D2-ORFa-GlyAsp polymorphism in an in-vitro 
study and with the results of the study by Peeters et al. (56), who found that healthy 
blood donors with a D2-ORFa-Gly3Asp mutation needed less T4 to produce local T3 
for the negative feedback action on the pituitary. These results were not confi rmed 
in a group of healthy elderly men (56). However their observations in healthy blood 
donors with intrinsic thyroid function cannot be easily compared to DTC patients on 
TSH-suppressive thyroxine therapy. 
Another factor could be that long term subclinical hyperthyroidism may result 
in downregulation of D1 and D2 and/or upregulation of D3 (48). However, we did 
not fi nd a signifi cant contribution of follow-up time and age at presentation to the 
observed effects of the D2-ORFa-Gly3Asp polymorphism on the setpoint of the 
hypothalamus-pituitary-thyroid axis. 
Perspective
In our study no association was found between the Thr92Ala polymorphism and 
thyroxine dose. However, not many studies have been performed on this subject and 
results are discordant. Future studies are necessary to elucidate any major clinical 
implication of the Thr92Ala polymorphism. 
In our second study we concluded that patients homozygous for the D2-ORFa-
Gly3Asp polymorphism have an altered setpoint of the hypothalamus-pituitary-thyroid 
axis. However, it is unknown what the clinical signifi cance of this altered setpoint 
will be. In the future, it would be interesting to investigate the proof of functionality of 
this D2 polymorphism and differences in biological variability in cell lines containing 
the different alleles of the D2-ORFa-Gly3Asp polymorphism. 
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2. Bone Metabolism
Although clinical observations suggest a clear involvement of thyroid hormone in 
bone metabolism, the molecular mechanisms by which thyroid hormone acts on 
bone are only partially uncovered so far. It is however an important subject since 
patients treated for thyroid carcinoma are treated with a TSH suppressive thyroxine 
dose during a long period of time. 
T3 promotes osteoblastic proliferation, differentiation and apoptosis, and by 
induction of IL-6, prostaglandins and RANKL, and probably also promotes osteoclast 
formation and activation. This suggests that osteoblasts are the primary target cells for 
T3 in the regulation of bone remodeling (63-68). A functional role of TSH on skeletal 
development and metabolism has also been proposed on the basis of data obtained 
in animal studies (69-71) and in humans (72). This was however disputed by data 
obtained in thyroid hormone receptor (TR) defi cient mice, which indicated that bone 
remodeling was predominantly mediated by T3 (64,72). It has also been reported 
recently in humans that there is a signifi cant association between BMD and serum 
thyroid hormone concentrations rather than TSH (73). 
Also the role of type 2 deiodinase (D2) in the human skeleton remains unclear. 
The D2 polymorphism Thr92Ala has been associated with lower TSH and lower 
enzymatic activity, which could result in lower local triiodothyronine (T3) availability 
in bone (53). We therefore performed a study to investigate a potential role for the 
deiodinase D2 in bone metabolism in humans by studying the relationship between 
the D2-Thr92Ala polymorphism, BMD, and bone turnover (Chapter 7). We studied 
this relationship in a human model of thyroidectomized patients cured from differ-
entiated thyroid carcinoma receiving thyroid hormone substitution. The advantage of 
this model is that study subjects have uniform FT4 levels.
BMD and bone turnover markers [bone-specifi c alkaline phosphatase (BAP), 
cross-linking terminal C-telopeptide of type I collagen (CTX), procollagen type 1 
aminoterminal propeptide (P1NP), and cross-linked N-telopeptide of type I collagen 
(NTX)] were measured. Sixty patients were wild type (Thr/Thr), 66 were heterozygous 
(Thr/Ala), and 28 were homozygous (Ala/Ala) for the D2 polymorphism. 
In support of the involvement of D2 in bone metabolism was the observation 
of a 6% decrease in femoral neck BMD and increased levels of P1NP (32%), CTX 
(27%), and NTX/creatinine (54%) in the Ala/Ala subgroup compared with wild-type 
subgroup. Furthermore, these increased levels of bone formation (P1NP) and indica-
tors of bone resorption (CTX and NTX) were independent of other determinants of 
bone metabolism, such as age, gender, BMI, estrogen status, calcium, vitamin D, PTH 
and most importantly independent of T3 and TSH. This may indicate a true effect of 
the D2-Thr92Ala polymorphism.
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The effect the D2-Thr92Ala polymorphism on bone turnover markers is not easy to 
explain. It is conventionally accepted that higher rather than lower circulating thyroid 
hormone levels result in higher bone turnover and decreased bone mass. However, 
the model we used is unique in the sense that circulating T3 levels were similar 
among the three D2 genotypes, allowing us to specifi cally study the consequences of 
the polymorphism for local T3 availability in the bone microenvironment. Williams 
and colleagues (74) showed D2 activity in mature osteoblasts, but not in osteoclasts. 
The effects of the polymorphism on the markers of bone degradation (NTX/creatinine 
and CTX) therefore may not be explained by direct effects on osteoclasts but are more 
likely to result from changes in the interaction between osteoblasts and osteoclasts, 
possibly by alterations in the RANK/RANKL/OPG signaling pathway, which poten-
tially can be modulated by local T3 availability in the bone microenvironment. 
In the context of confl icting data on the functional role for TSH rather than T3 
in skeletal metabolism, we performed a second study in order to dissect the effects 
of increased TSH levels from those of decreased thyroid hormone levels on bone 
(Chapter 8). We therefore studied the effects of recombinant human TSH (rhTSH) 
in 11 athyroid DTC patients on thyroxine substitution. In addition, we compared 
them with 11 age-, gender- and BMI-matched athyroid patients previously treated for 
differentiated thyroid carcinoma (DTC), who were studied after 4 weeks of thyroxine 
withdrawal and during thyroxine replacement therapy. We measured plasma levels of 
PTH, 25-OH-vitamin D, P1NP, CTX, RANKL and osteoprotegerin.
No differences were observed on parameters of bone turnover after rhTSH ad-
ministration. During thyroxine withdrawal, levels of CTX were signifi cantly lower, 
whereas levels of osteoprotegerin were signifi cantly higher compared to thyroxine 
replacement therapy, indicating decreased bone resorption. Our fi ndings suggest that 
acute changes in TSH in the presence of stable thyroid hormone levels obtained by 
rhTSH administration do not signifi cantly affect skeletal metabolism. Moreover, it 
can be suggested that hypothyroidism results in decreased bone turnover rather by 
decreased plasma thyroid hormone concentrations than by increased TSH concentra-
tions, because rhTSH had no impact on bone turnover in DTC patients. 
In summary our data suggest that a decrease in local availability of T3 potentially 
owing to a D2 polymorphism may result in increased bone turnover and decreased 
bone mass at the predominantly cortical femoral neck. We believe that our study 
provides additional information on the role of D2 in bone metabolism and the func-
tional consequences of the D2-Thr92Ala polymorphism, supporting a role for D2 in 
mature bone cells.
The data of the second study concluded that bone turnover is decreased dur-
ing hypothyroidism due to thyroxine withdrawal in DTC patients. As rhTSH had no 
impact on bone turnover, it can be suggested that low thyroid hormone levels instead 
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of the increased TSH levels are responsible for the decreased bone resorption dur-
ing hypothyroidism in DTC patients. We believe therefore that alterations in thyroid 
hormone levels are of more importance for bone turnover then TSH levels.1
Perspective
Although the observations of our studies suggest a clear involvement of thyroid hor-
mone in bone metabolism, the molecular mechanisms by which thyroid hormone 
acts on bone has not been completely discovered. It is an important subject though, 
in patients treated for thyroid carcinoma on a TSH suppressive thyroxine dose. 
These patients may be at risk for osteoporosis, which is however mainly reported in 
postmenopausal women. In these patients screening at baseline and during TSH sup-
pressive therapy is advised to allow timely intervention with bone protective agents. 
3. Cardiac function 
Thyroid hormone has profound effects on the cardiovascular system. Hyperthyroidism 
induces cardiac arrhythmias, left ventricular (LV) hypertrophy and diastolic dysfunc-
tion, and enhances systolic function (75-78). Subclinical hyperthyroidism, resulting 
from TSH suppressive thyroxine therapy, is associated with increased heart rate and 
supraventricular arrhythmias, increased LV mass (LVM) with a slightly enhanced 
systolic function, and diastolic dysfunction. Diastolic dysfunction is at least partly 
reversible after restoration of euthyroidism (78-80). Conversely, hypothyroidism is 
associated with bradycardia, hypertension, increased peripheral cardiovascular re-
sistance, heart failure (75,78,81), decreased cardiac output and diastolic dysfunc-
tion (75,77,81). Hypothyroidism is also associated with coronary artery disease, 
presumably because of associated hypercholesterolaemia, hypertriglyceridaemia and 
hypertension (75,77,82).
The consequences of episodes of acute hypothyroidism on cardiac function have 
been investigated in only a few studies, and their results are inconclusive (83-90). 
We therefore performed a study aimed at the investigation of the effects of overt 
hypothyroidism on cardiac function in patients with iatrogenically induced subclini-
cal hyperthyroidism after treatment for differentiated thyroid carcinoma (Chapter 9). 
Fourteen patients with a history of differentiated thyroid carcinoma on thyroid stimu-
lating hormone (TSH)-suppressive thyroxine replacement therapy were studied. We 
assessed cardiac function before, and 1 and 4 weeks after withdrawal of thyroxine 
substitution. We measured serum levels of free thyroxin, triiodothyronine and TSH 
and used a new sophisticated Doppler echocardiography technique, tissue Doppler 
imaging (TDI), to assess detailed and quantitative assessment of systolic and diastolic 
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cardiac function. Echocardiographic parameters in patients were compared to con-
trols without cardiac disease.
At baseline, when patients had subclinical hyperthyroidism, echocardiography 
revealed decreased diastolic function, higher LV size and LV mass. The clinical 
consequences of isolated diastolic dysfunction in subclinical hyperthyroidism are 
not entirely clear, but could be accompanied by increased morbidity and mortality, 
especially in long-term subclinical hyperthyroidism (74).
Thyroxine withdrawal resulted in an additional subtle decrease in both E- and 
A-wave velocities, without an impact on E/A ratio, indicating discrete unfavorable ef-
fects on diastolic function as assessed by echocardiography. When more specifi cally 
analyzed by TDI, diastolic function decreased, with a decrease in late diastolic veloc-
ity (A′) without impact on the E′/A′ ratio. Overt hypothyroidism increased diastolic 
blood pressure signifi cantly, but had no effect on systolic blood pressure. Therefore, 
long-term subclinical hyperthyroidism is accompanied by diastolic dysfunction. Sub-
sequent acute overt hypothyroidism induces subtle unfavorable changes in diastolic 
function.
Only six patients had an E/A ratio below 1 during overt hypothyroidism. This 
is probably due to impaired ventricular relaxation associated with a delay in the 
energy-dependent reuptake of calcium by the sacroplasmatic reticulum, which in 
turn is under thyroid hormone control. This thyroid hormone control of cardiac 
function is mediated mainly by T3, which in our study declined signifi cantly during 
thyroxine withdrawal (77).
Perspective
We demonstrated that long-term iatrogenically induced subclinical hyperthyroidism 
in patients with DTC induces diastolic dysfunction and increases LV mass and size. 
It is therefore not recommended to treat all patients with TSH suppressive thyroxine 
replacement unconditionally.
Acute overt hypothyroidism induced only minimal unfavorable cardiovascular 
effects, but signifi cantly increased diastolic blood pressure during thyroxine with-
drawal. The potential negative cardiovascular consequences of thyroxine withdrawal 
before diagnostic iodine-131 whole body scanning could be clinically relevant, 
especially in patients at cardiovascular risk. Therefore, recombinant TSH stimulation 
might be an attractive alternative in low-risk thyroid carcinoma patients and/or high-
risk cardiovascular patients.
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4. Quality of life
Quality of life may be affected in DTC patients by either the diagnosis of having a 
malignant disease, with the impact of the initial therapy, or by the consequences of 
TSH suppressive therapy. A few studies have investigated this subject, but results are 
inconclusive (91-95). For that reason, we studied quality of life in a large cohort of 
cured DTC patients. For this we used multiple quality of life questionnaires and com-
pared the results to those of a large group of healthy controls, who weren matched 
for age, gender and socioeconomic status (Chapter 10). Longer duration of cure was 
associated with better scores on different quality-of-life items. After a long duration of 
cure, approximately 12–20 yr, 6 of the 16 quality of life subscales were comparable 
with the quality of life of healthy controls. Our fi ndings indicate decreased quality of 
life in DTC patients, which may restore after a long period of follow-up.
The consequences of long duration of subclinical hyperthyroidism are less clear 
(78,91,92). Studies investigating this subject included selected groups of DTC pa-
tients or patients with endogenous subclinical hyperthyroidism in which duration 
and course of subclinical hyperthyroidism were not known. In our study, quality of 
life was not affected by alterations in TSH during the complete period of follow-up.
Perspective
Despite cure, excellent prognosis, and moderate aggressive treatment, DTC patients 
have an evident decrease in quality of life that may be restored only after years of 
follow-up. The fi ndings of our study have therefore implications for the approach of 
the cured DTC patients: attention for the psychological well-being of the patient and 
availability of professional support may be important aspects during follow-up.w
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I. Introductie
Gedifferentieerd schildkliercarcinoom is een aandoening met een lage incidentie 
van 1/100.000 personen per jaar en een relatief gunstige prognose met een 10-jaars 
overleving van 90-95%. De incidentie is de afgelopen decennia gestegen, en deze 
trend lijkt zich te continueren. De prevalentie is echter relatief hoog door de gunstige 
prognose als gevolg van een relatief langzaam groeiende tumor en een zeer effectieve 
initiële behandeling. Deze initiële behandeling bestaat uit totale thyreoïdectomie 
en ablatieve therapie met radioactief jodium (RaJ). De prognose wordt aanzienlijk 
slechter indien er metastasen op afstand bestaan. Deze metastasen ontstaan voorna-
melijk in longen en bot en kunnen door dedifferentiatie minder jodium opnemen en 
raken daardoor vaak ongevoelig voor RaJ therapie. RaJ therapie is de enige curatieve 
behandelingsoptie. Metastasen zijn niet onmiddellijk levensbedreigend, maar geven 
vaak wel aanzienlijke klachten en beperken daarmee de kwaliteit van leven. Helaas 
zijn in het geval van gemetastaseerde ziekte conventionele behandelingen als che-
motherapie en radiotherapie vaak weinig effectief.
Recent is veel onderzoek gedaan naar de pathogenese van schildkliercarcinoom, 
waarbij veel nieuwe inzichten zijn ontdekt in de genetische ontwikkeling van 
schildklierkanker. Hierbij zijn nieuwe potentiële aangrijpingspunten ontdekt voor de 
behandeling van gemetastaseerde ziekte die ongevoelig is geworden voor RaJ. Tyrosi-
nekinaseremmers, zoals sorafenib, zijn hierbij veelbelovende nieuwe medicamenten.
Ondanks de lage incidentie, wordt de behandeling van schildkliercarcinoom in 
verscheidene ziekenhuizen verricht. Deze gedecentraliseerde aanpak draagt waar-
schijnlijk niet bij aan een optimale behandeling. Wel dragen recente publicaties van 
artikelen met Europese en Amerikaanse richtlijnen voor de behandeling van schild-
kliercarcinoom bij aan de verbetering van de behandeling door de implementatie van 
uniforme behandelingsprotocollen en follow-up strategieën. Daarbij is schildklier-
carcinoom een bijzondere kankersoort met unieke biologische fenomenen zoals het 
bijvoorbeeld het jodiumtransport. Dit zorgt ervoor dat standaard oncologische be-
handelingen niet zomaar geëxtrapoleerd kunnen worden naar schildkliercarcinoom. 
Ongeacht deze richtlijnen, zijn er nog steeds onzekerheden en blijven er nog 
steeds verschillende opinies bestaan over de optimale strategie voor diagnose, be-
handeling en follow-up van schildkliercarcinoom. Een voorbeeld hiervan is dat de 
optimale strategie voor de diagnose van schildkliercarcinoom nog steeds afhankelijk 
is van conventionele histologische kleuringen. Hiermee is met name het onderscheid 
tussen folliculair adenoom (goedaardig) en folliculair carcinoom (kwaadaardig) 
moeilijk te maken.
Na de initiële behandeling voor schildkliercarcinoom zijn patiënten afhankelijk 
van de substitutie van schildklierhormoon door middel van thyroxine. Zij worden 
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ingesteld op een hoge dosering schildklierhormoon om het thyroid stimulerend 
hormoon (TSH) te onderdrukken. TSH wordt geproduceerd door de hypofyse en 
stimuleert normaal gesproken de schildklier tot het maken van schildklierhormoon. 
Het is echter ook een groeifactor voor schildkliercellen en dus kan de remming ervan 
de potentiële groei van eventuele achtergebleven tumorcellen onderdrukken. Met 
de onderdrukking van TSH ontstaat een status van milde hyperthyreoïdie. Dit kan 
gevolgen hebben voor de functie van multipele orgaansystemen en kan van invloed 
zijn op hartfunctie, botmetabolisme, glucosemetabolisme en de kwaliteit van leven. 
Tijdens de follow-up van schildkliercarcinoom werden patiënten met name in het 
begin van de therapie regelmatig onttrokken van schildklierhormoon teneinde een 
TSH gestimuleerde meting van thyroglobuline en RaJ scintigrafi e te bewerkstellin-
gen. Hiermee kan gecontroleerd worden of er nog ziekteactiviteit is, of dat er in de 
tussentijd metastasen zijn ontstaan. Gedurende een aantal weken ontstaat er dan 
een gecontroleerde status van hypothyreoïdie. Er wordt tegenwoordig echter steeds 
vaker gebruik gemaakt van recombinant humaan TSH (rhTSH), waarbij patiënten 
hun standaard dosis schildklierhormoon blijven gebruiken. Deze laatste methode 
heeft veel minder negatieve gevolgen voor de kwaliteit van leven en wordt inmiddels 
aanbevolen in de internationale richtlijnen. 
De behandeling met TSH supressieve dosering van schildklierhormoon en de 
gecontroleerde onttrekking van thyroxine substitutie vormen een uniek model om het 
effect van exogeen schildklierhormoon en schildklierhormoonovermaat en -defi ciën-
tie te onderzoeken op de verschillende orgaansystemen. 
In dit proefschrift wordt een aantal studies beschreven die kunnen bijdragen aan 
de verbetering van de diagnostiek en behandeling van schildkliercarcinoom. Ook 
hebben we studies verricht die meer inzicht geven in de lokale werking en beschik-
baarheid van schildklierhormoon. We hebben een studie verricht naar potentiële 
nieuwe markers die kunnen bijdragen aan de differentiatie tussen benigne en maligne 
schildklierweefsel. Daarnaast hebben we een fase II studie verricht naar het effect van 
de multitarget tyrosinekinaseremmer sorafenib, met het doel de behandeling van RaJ-
resistent schildkliercarcinoom te verbeteren. In de rest van dit proefschrift focussen we 
op de klinische consequenties van de behandeling van schildkliercarcinoom. Hierbij 
wordt gefocust op de effecten van exogene milde hyperthyreoïdie en gecontroleerde 
hypothyreoïdie op verschillende orgaansystemen alsmede op de kwaliteit van leven.
II. Diagnose van gedifferentieerd schildkliercarcinoom
Ondanks verbeterde beeldvormende technieken als 18-F fl uorodeoxyglucose-posi-
tron emission tomography (FDG-PET) en echografi e blijft fi jne naaldaspiratie (FNA) 
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de procedure van eerste keus bij patiënten die zich presenteren met een zwelling 
in de schildklier. Hiermee blijft de diagnose van schildkliercarcinoom en in het 
bijzonder de differentiatie tussen het benigne folliculair adenoom en maligne fol-
liculair carcinoom lastig. Als gevolg hiervan zal tussen de 70-80% van de patiënten 
met een verdachte FNA uitslag, een onnodige operatie ondergaan. Het gebruik van 
moleculaire markers als galectin-3, PAX8-PPARgamma, BRAF, RAS of RET/PTC kan 
bijdragen aan een verbeterde diagnostiek.
Ook na (hemi-)thyreoïdectomie kan het microscopische onderscheid tussen 
benigne en maligne schildklierzwellingen moeilijk te maken zijn met conventionele 
histologie, aangezien de verschillende laesies histologische karakteristieke kenmer-
ken kunnen delen. Het is daarom belangrijk nieuwe markers te ontwikkelen die dit 
onderscheid vergemakkelijken. In het verleden zijn verscheidene immunohistoche-
mische markers geïdentifi ceerd, maar geen van deze is succesvol geïmplementeerd 
in de routine diagnostiek.
Verschillen in de expressie van de retinoïdezuur receptor (RAR) subtypes zijn 
beschreven tussen benigne en maligne schildklierweefsels. De diagnostische waarde 
is echter nog niet eerder beschreven. In Hoofdstuk 2 van dit proefschrift beschrijven 
wij de diagnostische waarde van de expressie van de retinoïdezuur receptor (RAR) 
en de retinoïde X receptor (RXR) subtype eiwitexpressie voor de differentiatie tussen 
verschillende schildklierneoplasmata. Hiervoor gebruikten we een tissue microarray 
met 93 benigne schildklierweefsels (normaal schildklierweefsel, multinodulair struma 
en folliculair adenoom) en 77 schildkliercarcinomen (papillair schildkliercarcinoom 
(PTC), folliculair schildkliercarcinoom (FTC) en folliculaire variant van PTC (FVPTC)).
De immunohistochemische kleuring werd verricht voor verschillende RAR en 
RXR subtypes. De kleuringen werden semikwantitatief geanalyseerd met behulp van 
receiver operating curves (ROC-curves) en hiërarchische cluster analyse.
Wij vonden hiermee een verhoogde expressie van cytoplasma (c) RARalpha, 
cRARgamma, cRXRbeta en verminderde expressie van nucleaire (n) RARbeta, 
nRARgamma, en nRXRalpha in schildkliercarcinomen vergeleken met goedaardige 
weefsels. Drie eiwitten vertoonden signifi cant verschillende expressie tussen FA 
(goedaardig) en FTC (kwaadaardig). Tussen FA (goedaardig) en FVPTC (kwaadaardig) 
kwamen vijf eiwitten verschillend tot expressie. Met behulp van cluster analyse gaf 
de combinatie van een negatieve kleuring van membraneus RXRbeta en een positieve 
kleuring voor cRXRbeta en zeer hoge positief voorspellende waarde voor maligne 
schildklierziekte (98%). Terwijl de combinatie van een positieve kleuring van nR-
XRalpha en een negatieve kleuring van cRXRbeta een hoge positief voorspellende 
waarde had voor benigne schildklierlaesies (91%).
Uit deze studie kan geconcludeerd worden dat de verschillen in expressie van ei-
witten van RAR en RXR subtypes kunnen bijdragen aan de differentiaal diagnose van 
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schildklierzwellingen. De resultaten van deze studie, en dan met name de waarde 
van de clusteranalyse zal bevestigd moeten worden in andere studies.
Perspectief
De bevindingen van hoofdstuk 2 moeten eerst bevestigd worden voordat ze ge-
implementeerd kunnen worden in de standaard diagnostiek. Aanvullende studies 
zouden verricht moeten worden met grotere aantallen weefsels en dan voornamelijk 
met verschillende folliculaire weefsels. Bovendien moet het klinisch nut van de 
hiërarchische cluster analyse eerst gevalideerd worden, waarbij het gebruik van 
door FNA verkregen materiaal essentieel is. Ook moet het biologische mechanisme 
dat verantwoordelijk is voor de verschillen in eiwitexpressie van RAR en RXR in de 
verschillende schildklierweefsels nog opgehelderd worden.
III. Nieuwe behandelingsstrategieën voor gemetastaseerd 
schildklier-carcinoom dat ongevoelig is voor radioactief jodium 
(RaJ)
1. Sorafenib en de behandeling van RaJ-ongevoelig schildkliercarcinoom
Metastasen op afstand komen meestal voor in botten en longen en ontstaan in 10-15% 
van de patiënten met schildkliercarcinoom. Het grootste probleem in deze categorie 
van patiënten is dat als gevolg van dedifferentiatie van schildklierkankercellen, de RaJ 
opname afgenomen of afwezig is. RaJ is bij schildkliercarcinoom de enige curatieve 
behandelingsoptie. Andere behandelingsopties, zoals conventionele chemotherapie 
of radiotherapie hebben meestal maar beperkt effect. Gemetastaseerde ziekte is 
daarom ook geassocieerd met een slechte 10 jaars overleving van 5-10%
De laatste jaren is veel onderzoek verricht naar de moleculaire routes die be-
trokken zijn bij de pathogenese van gedifferentieerd schildkliercarcinoom. Dit heeft 
geleid tot de ontdekking van nieuwe aangrijpingspunten voor nieuwe therapieën. De 
identifi catie van tyrosinekinase geactiveerde routes en de ontwikkeling van nieuwe 
tyrosinekinaseremmers bieden nieuwe perspectieven voor de behandeling van 
schildkliercarcinoom dat ongevoelig is geworden voor RaJ. Daarnaast is er bij schild-
kliercarcinoom een relatie ontdekt tussen genetische veranderingen in de RET-RAS-
RAF-cascade, die betrokken is bij de maligne ontaarding en het verlies van expressie 
van de jodiumtransporter NIS. Een in-vitro studie met de multi-kinaseremmer sunitinib 
liet zelfs hernieuwde NIS expressie zien bij verschillende schildklierkankercellen.
Er zijn al enkele studies verricht met tyrosinekinaseremmers bij patiënten met 
schildkliercarcinoom. Hierbij was gefi tinib niet succesvol en axitinib wel succesvol 
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bij patiënten met verscheidene soorten schildkliercarcinoom. De multi-tyrosinekina-
seremmer motesanib (remt RET- PDGF –VEGFR-KIT) gaf een partiële respons bij 14% 
van de patiënten met gedifferentieerd schildkliercarcinoom. De multi-tyrosinekina-
seremmer sorafenib (remt RET, C-RAF, wild-type and mutant (V600E) BRAF, VEGFR1, 
-2, -3, Flt3, and c-KIT) gaf in twee studies een respons (partiële respons of stabiele 
ziekte) van respectievelijk 11% en 23%, waarbij in de eerste studie ook patiënten met 
het agressievere anaplastisch carcinoom waren geïncludeerd.
Het mechanisme achter het verschil in respons tussen de multi-kinaseremmers 
motesanib en sorafenib zou kunnen berusten op het verschil in IC50 voor de ty-
rosinekinases van de doeleiwitten die geremd worden. Motesanib heeft hierbij 
een sterkere remming op VEGFR1 (IC50 2 nM), VEGFR2 (IC50 3 nM) en VEGFR3 
(IC50nM), terwijl sorafenib remmend werkt op RET (IC 50 47nM), RET/PTC3 (IC50 
50nM) en BRAF (IC50 22 nM). Desondanks zijn de resultaten van de verschillende 
studies niet zomaar te vergelijken in verband met verschillen in patiëntcategorieën, 
soorten schildkliercarcinoom, studieontwerp en analytische methoden.
Wij hebben ervoor gekozen een studie te verrichten naar het effect van de multi- 
tyrosinekinaseremmer sorafenib op tumorprogressie, maar daarnaast ook naar het ef-
fect op de opname van RaJ (Hoofdstuk 3). Dit was een open, singlecenter, 26-weekse 
prospectieve fase II studie. De hypothese was dat behandeling met sorafenib niet 
alleen effect zou hebben op tumorprogressie, maar ook de RaJ opname zou kun-
nen herstellen bij patiënten met schildkliercarcinoom dat ongevoelig is voor RaJ. 
We behandelden daarvoor 31 patiënten met progressieve, gemetastaseerde of lokaal 
doorgroeiende ziekte. Zij kregen tweemaal daags 400 mg sorafenib. Het primaire 
eindpunt was hernieuwde RaJ opname. Additionele eindpunten waren radiologische 
respons van tumor of metastasen gemeten met CT scans.
Na 26 weken behandeling was er helaas geen nieuwe opname te zien van RaJ. 
Wel hadden 19 patiënten (59%) een klinisch gunstige respons, waarbij 8 (25%) een 
partiële respons hadden en 11 (34%) stabiele ziekte. Zeven patiënten (22%) hadden 
onder de behandeling progressie van hun ziekte. De mediane progressievrije overle-
ving was 58 weken (95% betrouwbaarheidsinterval 47-68 weken). De tumormarker 
thyroglobuline daalde gedurende de behandeling en kwam overeen met het kleiner 
worden van de tumorgrootte op de CT scans. De respons werd niet beïnvloed door 
histologisch carcinoomsubtype, mutatiestatus of andere variabelen. Behalve al 
bekende bijwerkingen van sorafenib deden zich geen andere bijwerkingen voor. 
Sorafenib bleek minder effectief bij patiënten met botmetastasen. Er is hiervoor geen 
duidelijke verklaring.
Dieke Hoftijzer BW.indd   203 23-02-11   15:19
204 Chapter 12
Perspectief
De resultaten van onze studie zijn vergelijkbaar met de resultaten van eerdere studies 
met sorafenib. De resultaten van alle studies lijken erop te wijzen dat sorafenib een 
succesvol en veelbelovend product is voor patiënten met gemetastaseerd of progressief 
schildkliercarcinoom. Helaas blijkt sorafenib minder effectief bij botmetastasen. Ook 
konden de in-vitro studies waarbij tyrosinekinaseremming de RaJ opname verbeterde 
niet bevestigd worden. Op dit moment wordt een grote multicenter fase III studie 
verricht naar de effectiviteit van sorafenib. Indien deze studie gunstige resultaten 
laat zien, zou sorafenib onderdeel kunnen worden van de standaard behandeling 
van schildkliercarcinoom dat ongevoelig is geworden voor RaJ. Het is mogelijk dat 
combinatiebehandeling met meerdere tyrosinekinaseremmers in de toekomst een 
nieuwe behandelingsstrategie gaat worden.
2. Tyrosinekinase remmende therapie en schildklierhormoon-metabolisme
Behandeling met tyrosinekinaseremmers is geassocieerd met schildklierdysfunctie. 
Sunitinib is geassocieerd met hypothyreoïdie bij 14-85% van de patiënten en bij en-
kele patiënten werd ook hyperthyreoïdie geobserveerd. Er zijn hiervoor verschillende 
hypothesen over het onderliggende mechanisme, zoals destructieve thyreoïditis, in-
terferentie met thyroid peroxidase of schildklieratrofi e als gevolg van vaatdestructie. 
Ook bij patiënten met status na thyreoïdectomie werden schildklierfunctiestoornissen 
waargenomen. Zodoende zou de remming van perifere conversie van schildklierhor-
moon het mechanisme achter de hypothyreoïdie kunnen zijn. Stapsgewijze deiodina-
tie is normaal gesproken de route van schildklierhormoondegradatie en deze wordt 
gemedieerd door iodothyronine deiodinases D1, D2 en D3 en leverenzymen.
D1 zet T4 om in T3, en draagt bij aan de serumproductie van T3. Daarnaast speelt 
het een rol in de afbraak van rT3. D2 katalyseert de lokale T3 productie in verschil-
lende weefsels. D2 in het skeletspierweefsel draagt mogelijk ook bij aan de serum T3 
productie. D3 inactiveert T3 en T4. Het beschermen van weefsels tegen een overmaat 
van schildklierhormoon is waarschijnlijk de belangrijkste rol van D3. De deiodinases 
passen het niveau van schildklierhormoon aan aan de behoefte van lokale weefsels 
en aan diverse condities.
Om het mechanisme achter de schildklierfunctiestoornissen bij het gebruik van 
tyrosinekinaseremmers te ontrafelen, hebben we een studie verricht bij schildklier-
kankerpatiënten die behandeld werden met sorafenib (Hoofdstuk 4). De hypothese 
was dat sorafenib het schildklierhormoonmetabolisme zou beïnvloeden via de ac-
tiviteit van iodothyronine deiodinases. Dit was niet eerder in mensen onderzocht. 
Hiervoor hebben we een prospectieve 26 weken durende studie verricht waarbij 
patiënten tweemaal daags 400 mg sorafenib kregen. Vervolgens werden de serum 
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thyroxine (T4), vrij T4, 3,5,3-triiodothyronine (T3), vrij T3, reverse T3 (rT3), en TSH 
concentraties gemeten op baseline en na 26 weken bij 21 patiënten met progres-
sief gedifferentieerd schildkliercarcinoom. Ook werden de ratios van T3/T4, T3/rT3 
en T4/rT3 berekend. Deze zijn namelijk afhankelijk van het substraataanbod en 
refl ecteren iodothyronine deiodinatie.
We vonden dat er een hogere dosis thyroxine nodig was om vrij T4 en T3 concen-
traties binnen de normaalwaarden te houden. Gecorrigeerd voor thyroxinedosis per 
kilogram lichaamsgewicht daalden de vrij T4 en T3 concentraties met 11% en 18%. 
Daarbij stegen de TSH concentraties. Daarnaast werden er duidelijke dalingen in de 
serum T3/T4, T3/rT3 en T4/rT3 ratios gevonden. Deze ratios refl ecteren veranderin-
gen in het perifere metabolisme van schildklierhormoon, dat positief beïnvloed wordt 
door D1 en D2 en negatief door D3. De daling van de T3/T4 en T3/rT3 ratios zou 
een gevolg kunnen zijn van een daling in D1 en/of D2 activiteit. Echter, dit zou ook 
geassocieerd kunnen zijn met een verlaagd metabolisme van T4, maar dit was juist 
verhoogd. Daarom zouden de verlaagde ratios het best verklaard kunnen worden 
door een verminderde activiteit van D3.
Klinische implicaties
De resultaten van onze studie tonen aan dat tyrosinekinaseremmers naast directe 
effecten op de schildklier, ook het perifere schildklierhormoonmetabolisme beïnvloe-
den. Dit is waarschijnlijk het gevolg van een verminderde activiteit van deiodinase 
type 3. Het zou van waarde zijn om deze theorie te testen met in-vitro studies. Daar-
naast is het van belang om tijdens de behandelingen met tyrosinekinaseremmers 
de schildklierfunctie regelmatig te testen en zonodig de dosering thyroxine aan te 
passen.
IV. Consequenties van de behandeling van schildkliercarcinoom
Patiënten met gedifferentieerd schildkliercarcinoom die behandeld zijn met totale 
thyreoïdectomie en radioactief jodium ablatietherapie worden volledig afhankelijk 
van de toediening van exogeen schildklierhormoon. Omdat TSH een groeifactor is 
voor schildklierkankercellen, werden de patiënten voorheen standaard behandeld 
met een TSH supressieve dosis thyroxine gedurende een periode van 15 jaar. Waar 
deze TSH supressieve dosis een gunstige invloed heeft op de prognose, heeft de zo 
verkregen milde hyperthyreoïdie een negatieve invloed op diverse orgaansystemen en 
op de kwaliteit van leven. Daarom wordt tegenwoordig in de internationale richtlij-
nen aanbevolen dat alleen patiënten met een hoog of intermediair risico schildklier-
carcinoom moeten worden gesubstitueerd tot een gesupprimeerde TSH concentratie 
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beneden 0.1 mU/L. Bij laagrisico patiënten wordt aanbevolen dat het TSH ingesteld 
wordt tussen 0.1-0.5 mU/L, net iets onder de normaalwaarde.
Gedurende de follow-up van schildkliercarcinoom werden patiënten voorheen 
regelmatig onttrokken van schildklierhormoon om de ziektestaat en ziekteprogressie 
te beoordelen door middel van TSH gestimuleerde thyroglubulinemeting en schild-
klierscintigrafi e. Dit creëert een staat van gecontroleerde, maar wel acute hypothyre-
oïdie. Tegenwoordig wordt steeds vaker gebruik gemaakt van recombinant humaan 
TSH tijdens follow-up, wat veel minder impact heeft op de kwaliteit van leven. De 
patiënten blijven dan namelijk hun gewone dosering schildklierhormoon gebruiken.
De afhankelijkheid van exogeen schildklierhormoon, de langdurige milde hyper-
thyreoïdie in combinatie met episodes van acute hypothyreoïdie maken schildklier-
carcinoompatiënten een interessant model om de effecten van schildklierhormoon 
op diverse orgaansystemen te onderzoeken.
1. Inzicht in het schildklierhormoonmetabolisme
Het perifere schildklierhormoonmetabolisme wordt onder andere gereguleerd door 
de iodothyronine deiodinases D1, D2 en D3. Er zijn verschillende polymorfi smen 
beschreven in D1 en D2, waarvan sommigen serumwaarden van TSH, T3 en T4 lijken 
te beïnvloeden. Patiënten behandeld voor schildkliercarcinoom zijn ideaal om het 
schildklierhormoonmetabolisme in te onderzoeken. De meeste studies focussen op 
het D2-Thr92Ala polymorfi sme.
Het D2-Thr92Ala polymorfi sme wordt geassocieerd met een verminderde D2 
activiteit in sommige in-vitro experimenten, maar in anderen juist weer niet. Er was 
voorheen nog geen associatie gevonden tussen het D2-Thr92Ala polymorfi sme en 
circulerende schildklierhormoonconcentraties bij mensen. Wel heeft een recente 
studie gesuggereerd dat patiënten die homozygoot zijn voor het Ala 92 allel in het 
deiodinase type 2 een hogere dosis thyroxine nodig hebben om het TSH te onder-
drukken. 
Om deze bevindingen (Hoofdstuk 5) te bevestigen hebben wij een studie uitge-
voerd om de associatie tussen het D2-Thr92Ala polymorfi sme, schildklierhormoon-
concentraties en de thyraxdosering te onderzoeken in patiënten behandeld voor 
schildkliercarcinoom en patiënten met Hashimoto thyreoïditis. Daarvoor hebben 
we 154 patiënten met gedifferentieerd schildkliercarcinoom en 141 patiënten met 
M.Hashimoto die allen behandeld werden met schildklierhormoonsubstitutie, onder-
zocht. Bij alle patiënten werden de serumconcentraties van TSH, vrij T4, T3 en reverse 
T3 gemeten. Ook werd het D2-Thr92Ala polymorfi sme bepaald. In beiden groepen 
patiënten werd geen verband gevonden tussen schildklierhormoonconcentraties, 
thyroxinedosering en de aanwezigheid van het D2-Thr92Ala polymorfi sme. 
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Wij hebben uit onze studie geconcludeerd dat de aanwezigheid van het D2-
Thr92Ala polymorfi sme niet geassocieerd is met serum schildklierhormoonspiegels 
bij patiënten die behandeld waren voor schildkliercarcinoom en Hashimoto thyre-
oïditis. 
De intra-individuele variatie in serum TSH, T3 en T4 is erg klein, terwijl de inter-
individuele variatie juist erg groot is. In verschillende studies wordt aangetoond dat 
elk individu een eigen uniek setpoint heeft van zijn of haar schildklierfunctie. Dit 
wordt beïnvloed door genetische verschillen in de regulatie van de hypothalamus-
hypofyse-schildklier as. Wij hebben onderzocht of polymorfi smen in D1 en D2 dit 
setpoint kunnen beïnvloeden.
We hebben daarom een studie uitgevoerd (Hoofdstuk 6) naar het effect van 
de volgende polymorfi smen: D1-C785T, D1-A184G, D2-Thr92Ala en D2-ORFa-
Gly3Asp. De effecten van deze polymorfi smen op het setpoint van de hypothalamus-
hypofyse-schildklier as werden onderzocht met behulp van een general mixed mo-
del. We gebruikten daarvoor 1905 bloedmonsters waar tegelijk FT4 en TSH bepaald 
waren tijdens routine follow-up van 151 patiënten behandeld voor en genezen van 
schildklierkanker. 
Onze studie laat zien dat patiënten behandeld voor schildkliercarcinoom ho-
mozygoot voor het D2-ORFa-Gly3Asp polymorfi sme een veranderd setpoint hebben 
van de hypothalamus-hypofyse-schildklier as. De negatieve feedback van T4 op TSH 
is zwakker in homozygote patiënten in vergelijking met wildtype en heterozygote 
patiënten. De andere polymorfi smen bleken het setpoint niet te beïnvloeden..
Hoewel we een duidelijk effect van het D2-ORFa-Gly3Asp polymorfi sme zagen 
op het setpoint van de hypothalamus-hypofyse-schildklier as, is het nog niet makke-
lijk om te bepalen wat de klinische consequentie hiervan is. Ook zijn er onbekende 
factoren die eventueel de TSH/FT4 ratio zouden kunnen beïnvloeden. Helaas hebben 
we geen informatie over T3 en rT3, omdat de bloedmonsters tijdens routine follow-
up zijn afgenomen en deze bepalingen niet standaard gedaan worden. We hebben 
daarom geen inzicht in de gehele cyclus van het schildklierhormoonmetabolisme. 
Ook verschilden onze resultaten van een eerdere studie bij gezonde vrijwilligers. 
Echter, het is ook niet duidelijk of onze patiënten zonder intrinsieke schildklierfunctie 
die afhankelijk zijn van een vaste dosis schildklierhormoon wel te vergelijken zijn 
met patiënten met een eigen schildklierhormoonproductie. Daarnaast zou het feit dat 
onze patiënten behandeld worden met een TSH onderdrukkende dosis schildklier-
hormoon, nog van invloed kunnen zijn op onze uitkomst. Het zou kunnen dat de 
langdurige subklinische hyperthyreoidie resulteert in downregulatie van D1 en D2 
en/of upregulatie van D3. Hier valt tegenin te brengen dat we geen effect zagen van 
de duur van de follow-up op het setpoint.
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In onze eerste studie werd geen verband gevonden tussen het D2-Thr92Ala poly-
morfi sme en thyroxine dosis. Tot op heden zijn hier nog maar weinig studies naar 
verricht en zijn de resultaten tegenstrijdig. Eventuele toekomstige studies zouden hier 
doorslag in kunnen geven, hoewel een grote klinische consequentie niet verwacht 
wordt.
Na het verrichten van onze tweede studie kunnen we concluderen dat patiënten 
homozygoot voor het D2-ORFa-Gly3Asp polymorfi sme een ander setpoint hebben 
voor hun hypothalamus-hypofyse-schildklier as. Het is echter ook niet duidelijk wat 
de klinische consequentie hiervan is. In de toekomst zou het interessant zijn om 
verschillen in biologisch werking van de verschillende polymorfi smes in cellijnen te 
testen.
2. Botmetabolisme
Klinische observaties suggereren een belangrijke bijdrage van schildklierhormoon 
aan het botmetabolisme, echter het moleculaire mechanisme is nog maar gedeeltelijk 
ontrafeld. Het is wel een belangrijk onderwerp, aangezien patiënten met schildklier-
carcinoom gedurende een lange periode behandeld worden met een TSH supressieve 
thyroxinedosering en dus langdurig milde hyperthyreoïdie hebben.
T3 stimuleert proliferatie, differentiatie en apoptose van osteoblasten. Dit 
suggereert dat osteoblasten het belangrijkste doel zijn van T3 in de regulatie van 
botmetabolisme. Echter, er is ook een functionele rol toebedeeld aan TSH bij de 
regulatie van botontwikkeling, dit op basis van resultaten uit dierexperimenten, maar 
ook uit experimenten bij mensen. Dit werd daarentegen weer betwist door resul-
taten van andere studies waarbij bij schildklierhormoonreceptor defi ciënte muizen 
ernstige skeletafwijkingen ontwikkelden, wat de suggestie wekt dat botremodelling 
voornamelijk gemedieerd wordt door T3. Ook werd in mensen al aangetoond dat er 
een signifi cante relatie is tussen schildklierhormoonconcentraties en botdichtheid, 
maar niet tussen TSH en botdichtheid.
 Ook de rol van het deiodinase type 2 bij de skeletontwikkeling is niet geheel 
opgehelderd. Het D2-Thr92Ala polymorfi sme is geassocieerd met een lagere TSH 
concentratie en een lagere enzymatische activiteit, wat zou kunnen leiden tot een 
lagere T3 beschikbaarheid op lokaal niveau. 
Om de rol van het deiodinase D2 bij botmetabolisme te onderzoeken hebben we 
een studie verricht naar de relatie tussen het D2-Thr92Ala polymorfi sme, botdicht-
heid en botturnover (Hoofdstuk 7). We hebben deze relatie onderzocht bij patiënten 
die behandeld waren met een totale thyreoïdectomie in verband met schildkliercar-
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cinoom en vervolgens behandeld werden met schildklierhormoon substitutie. Een 
voordeel van dit model is dat T4 en TSH serum spiegels vrij uniform zijn. 
De botdichtheid en markers van botmetabolisme [bot-specifi ek alkalisch fosfa-
tase (BAP), cross-linking terminal C-telopeptide van type I collageen (CTX), procol-
lageen type 1 aminoterminal propeptide (P1NP) en cross-linked N-telopeptide van 
type I collageen (NTX)] werden gemeten. Zestig patiënt hadden wildtype (Thr/Thr), 
66 waren heterozygoot (Thr/Ala), en 28 waren homozygote (Ala/Ala) dragers van het 
D2 polymorfi sme. 
In deze studie werd geobserveerd dat patiënten die homozygoot zijn voor het D2 
polymorfi sme (Ala/Ala) een 6% lagere botdichtheid hadden, gemeten bij het femur. 
Daarnaast waren er verhoogde concentraties van P1NP (32%), CTX (27%) en de NTX/
creatinine ratio (54%) in de Ala/Ala subgroep vergeleken met de wild-type subgroep. 
Tevens waren de verhoogde concentraties van botformatie (P1NP) en indicatoren van 
botresorptie (CTX en NTX) onafhankelijk van andere indicatoren die botmetabolisme 
kunnen beïnvloeden (leeftijd, geslacht, BMI, oestrogeenstatus, calcium, vitamine D, 
PTH), maar belangrijker nog, onafhankelijk van T3 en TSH. De verhoogde botre-
sorptie kan waarschijnlijk verklaard worden door veranderingen in interactie tussen 
osteoclasten en osteoblasten. Onze studie laat zien dat de relatie tussen de lokale T3 
beschikbaarheid en D2 activiteit complex is en niet volledig verklaard kan worden 
door traditioneel waargenomen directe effecten van T3 op bot. Waarschijnlijk zijn 
hier vele onbekende componenten van het micromillieu van het bot bij betrokken.
In een poging om onderscheid te maken tussen de effecten op bot gemedie-
erd door TSH of door schildklierhormoon, hebben we een tweede studie verricht 
(Hoofdstuk 8). Hiervoor hebben we 11 patiënten met gedifferentieerd schildklier-
carcinoom tijdens onttrekking van schildklierhormoon (hoge TSH concentratie, lage 
vrij T4 concentratie) vergeleken met 11 patiënten na toediening van recombinant 
TSH (hoge TSH concentratie, normale vrij T4 concentratie). De eerste groep hebben 
we vergeleken na 4 weken onttrekking van schildklierhormoon en acht weken na 
herstarten van schildklierhormoon. De patiënten van de twee groepen waren gelijk 
qua leeftijd, geslacht en BMI. Voor de bestudering van het botmetabolisme hebben 
we plasmaspiegels gemeten van PTH, 25-OH-vitamine D, P1NP, CTX, RANKL en 
osteoprotegerin.
Tijdens hypothyreoïdie werden er signifi cant lagere CTX spiegels en hogere 
osteoprotegerin concentraties gevonden, hetgeen wijst op verminderde botresorptie. 
Na injectie van recombinant TSH werden er geen verschillen gevonden in de bepa-
lingen van botmetabolisme. 
Onze bevindingen suggereren dat acute veranderingen van TSH bij stabiele 
schildklierhormoonspiegels geen signifi cant effect hebben op skeletmetabolisme. 
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Daarnaast laten onze resultaten zien dat hypothyreoïdie resulteert in verminderde 
botturnover door de lage vrij T4 spiegel en niet door de hoge TSH spiegel.
Concluderend suggereren onze data dat een vermindering in lokale T3 beschik-
baarheid als gevolg van polymorfi sme in het deiodinase type 2 leidt tot vermindering 
van botturnover en verminderde botmassa.
De tweede studie leert dat de botturnover is verminderd tijdens acute hypothy-
reoïdie, waarbij de belangrijkste bevinding lijkt te zijn dat het botmetabolisme meer 
afhankelijk is van T4 dan van TSH.
Perspectief
Hoewel de resultaten van onze studies een duidelijke relatie aantonen tussen schild-
klierhormoon en botmetabolisme, is het moleculaire mechanisme dat ten grondslag 
ligt aan deze relatie nog niet volledig opgehelderd. Het is wel een belangrijk on-
derwerp voor patiënten die langdurig behandeld worden met een TSH supressieve 
thyroxinedosering, aangezien zij mogelijk een verhoogd risico hebben op osteopo-
rose. Dit is echter voornamelijk geobserveerd bij postmenopausale vrouwen. Bij deze 
patiënten is screening op baseline en tijdige interventie met medicijnen noodzakelijk 
in geval van optredende osteoporose.
3. Hartfunctie
Schildklierhormoon heeft uitgesproken effecten op het cardiovasculaire systeem. 
Hyperthyreoïdie induceert cardiale ritmestoornissen, linker ventrikel hypertrofi e 
en diastolische dysfunctie, maar tast de systolische functie niet aan. Ook milde 
hyperthyreoïdie als gevolg van een TSH supressieve thyroxinedosis is geassocieerd 
met tachycardie en supraventriculaire ritmestoornissen, een vergrote linker ventrikel 
massa en diastolische dysfunctie. Deze diastolische dysfunctie is gedeeltelijk herstel-
baar na herstel van euthyreoidie. Hypothyreoïdie is daarentegen geassocieerd met 
bradycardie, hypertensie, een verhoogde perifere vasculaire weerstand, hartfalen, 
verminderde cardiale output en diastolische dysfunctie. Ook is hypothyreoïdie geas-
socieerd met coronarialijden, waarschijnlijk als gevolg van hypercholesterolaemie, 
hypertriglyceridemie en hypertensie.
De gevolgen van episodes van acute hypothyreoïdie op de hartfunctie zijn in 
slechts enkele studies onderzocht. De resultaten hiervan waren echter niet conclusief. 
Daarom hebben wij een studie verricht naar de effecten van acute hypothyreoïdie op de 
hartfunctie bij patiënten die behandeld zijn voor schildkliercarcinoom (Hoofdstuk 9).
Hiervoor werden 14 patiënten gerekruteerd die in het verleden behandeld waren 
voor schildkliercarcinoom en vervolgens gesuppleerd werden met een TSH supres-
sieve dosering schildklierhormoon. De hartfunctie werd beoordeeld voor, één week 
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na en vier weken na staken van schildklierhormoonsubstitutie. Voor de beoordeling 
van de hartfunctie werd een nieuwe geavanceerde echotechniek gebruikt, namelijk 
Tissue Doppler imaging (TDI). Hiermee kan een gedetailleerde en kwantitatieve me-
ting van de systolische en diastolische hartfunctie verricht worden. De echoresultaten 
werden vergeleken op de verschillende tijdstippen na staken van schildklierhormoon 
en werden daarnaast vergeleken met de resultaten van gezonde vrijwilligers met 
normale hartfunctie.
Op het eerste tijdstip, tijdens milde hyperthyreoïdie, liet echocardiografi e zien 
dat patiënten een verminderde diastolische functie en hogere linker ventrikelmassa 
hadden in vergelijking met gezonde controlepersonen. De klinische consequenties 
van geïsoleerde diastolische dysfunctie zijn bij milde hyperthyreoïdie niet geheel 
duidelijk, maar zou gepaard kunnen gaan met verhoogde morbiditeit en mortaliteit.
Onttrekking van schildklierhormoon resulteerde in een subtiele additionele da-
ling van de E wave (vroege diastolische instroomsnelheid over de mitralisklep, repre-
senteert de passieve vulling van de linker ventrikel) en A wave (late instroomsnelheid 
over de mitralisklep, representeert de actieve vulling van de linker ventrikel en dus 
de atriale systole), zonder impact op E/A ratio. Dit wijst op discrete onvoordelige 
effecten op de diastolische functie. Ook bij de evaluatie met TDI werd een subtiele 
vermindering gevonden van de diastolische functie. Daarnaast werd tijdens overte 
hypothyreoïdie een signifi cante stijging gevonden van de diastolische bloeddruk.
Uit onze studie kan geconcludeerd worden dat langdurige milde hyperthyreoïdie 
gepaard gaat met diastolische dysfunctie. Vervolgens zorgt acute overte hypothyreoï-
die voor een subtiele verslechtering van de diastolische functie.
Perspectief
In onze studie werd aangetoond dat langdurige iatrogene milde hyperthyreoïdie 
bij patiënten behandeld voor gedifferentieerd schildkliercarcinoom diastolische 
dysfunctie induceert. Daarnaast geeft subklinische hyperthyreoïdie een stijging van 
de linkerventrikelmassa. Hoewel de klinische consequenties voor de patiënt niet 
geheel duidelijk zijn, is het niet aanbevolen alle patiënten met schildkliercarcinoom 
onvoorwaardelijk in te stellen op TSH suppressie.
Acute hypothyreoïdie induceerde bij onze patiënten vervolgens minimale na-
delige effecten op de diastolische functie van het hart, met daarbij een duidelijke 
verhoging van de diastolische bloeddruk. De potentiële negatieve cardiovasculaire 
consequenties van thyroxineonttrekking voor een RaJ scan zouden klinisch relevant 
kunnen zijn met name bij patiënten die al een verhoogd cardiovasculair risico heb-
ben. Daarom is recombinant humaan TSH een aantrekkelijk alternatief.
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4. Kwaliteit van leven
De kwaliteit van leven kan veranderd zijn bij patiënten met gedifferentieerd schild-
kliercarcinoom, enerzijds doordat ze gediagnosticeerd zijn met een kwaadaardige 
ziekte met de bijbehorende initiële behandeling. Anderzijds zou de TSH supressieve 
behandeling en de eventuele onttrekking van schildklierhormoon tijdens follow-up 
ook de kwaliteit van leven kunnen beïnvloeden. Er zijn eerdere studies verschenen 
over kwaliteit van leven bij patiënten met schildkliercarcinoom, maar de resultaten 
hiervan zijn niet eenduidig. Daarom hebben wij de kwaliteit van leven onderzocht in 
een grote groep patiënten die genezen is van gedifferentieerd schildkliercarcinoom. 
We hebben hiervoor gebruik gemaakt van vier verschillende kwaliteit van leven 
vragenlijsten en hebben de uitkomsten van patiënten vergeleken met de uitkomsten 
van een groep vrijwilligers gematcht voor geslacht, leeftijd en socio-economische 
status (Hoofdstuk 10). 
Onze bevindingen lieten zien dat patiënten die genezen zijn van gedifferentieerd 
schildkliercarcinoom nog langdurig een verminderde kwaliteit van leven hebben. Dit 
kan echter wel herstellen na langdurige follow-up. Na langdurige genezing, circa 
12-20 jaar waren 6 van de 16 subschalen van kwaliteit van leven vergelijkbaar met 
gezonde controles. 
De gevolgen van langdurige milde hyperthyreoïdie op de kwaliteit van leven 
waren ook niet geheel duidelijk. Studies die dit onderwerp eerder onderzochten 
includeerden geselecteerde groepen patiënten met gedifferentieerd schildkliercarci-
noom of patiënten met endogene hyperthyreoïdie waarbij de duur en het beloop 
van schildklierhormoonschommelingen niet bekend zijn. In onze studie bleek dat de 
kwaliteit van leven niet beïnvloed werd door TSH spiegels. 
Perspectief
Ondanks genezing, een excellente prognose en een matig agressieve initiële be-
handeling is de kwaliteit van leven van patiënten met schildkliercarcinoom evident 
verminderd. De kwaliteit van leven kan uiteindelijk wel verbeteren na een lange 
periode van genezing. De bevindingen van deze studie hebben implicaties voor 
de aanpak van de behandeling van schildkliercarcinoompatiënten. Er moet naast 
medisch noodzakelijke ingrepen ook aandacht zijn voor de psychosociale gevolgen 
voor de patiënt en eventueel kan professionele ondersteuning aangeboden worden 
tijdens de follow-up.
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